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Abstract 
 
This thesis examines some early renal and neurological manifestations in Anderson 
Fabry disease (AFD). First, estimating glomerular filtration rate in AFD using serum 
creatinine (Cr) based equations was assessed in 106 AFD patients. The Modification in 
diet in renal disease (MDRD) and the Chronic kidney disease epidemiology 
collaboration (CKD-EPI) equations had the least bias and were the best methods of 
estimating glomerular filtration rates in AFD patients with chronic kidney disease 
(CKD) stage 1 to 3.  
The monitoring of renal involvement in AFD use methods which assess glomerular 
function predominantly though there is evidence of renal tubular damage and atrophy on 
renal biopsy. We investigated possible urine markers of renal tubular dysfunction in 
AFD and 2 other proteins detectable in urine which have been shown to be markers of 
renal scarring and inflammation. Urine β-hexosaminidase (β-hex) and Monocyte 
chemoattractant protein-1 (MCP-1) were elevated in AFD patients compared with 
control demonstrating evidence of renal tubular involvement and possible renal 
inflammation. 
Finally we investigated cardiac autonomic function, cardiac neuroendocrine function, 
sweat function and symptoms related to neuropathic and autonomic function in an AFD 
cohort. There was little evidence of sweat dysfunction, cardiac autonomic or cardiac 
neuroendocrine dysfunction, though there is significant evidence of neuropathic pain 
and autonomic symptoms. 
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1.1 Introduction 
 
Anderson – Fabry Disease (AFD) is an X-linked inherited lysosomal storage disease 
(Xq22.1) caused by a mutation in the gene encoding α-galactosidase A (α-Gal). AFD 
was first described independently in 1898 by Johannes Fabry in Germany and William 
Anderson in the UK, and characterised clinically by the presence of angiokeratomas, 
proteinuria, and lymphoedema
1, 2
. The gene encoding α-Gal has been isolated and 
sequenced
3, 4
 and to date there are more than 500 mutations reported in the GLA gene in 
the Human Gene Mutation Database (Cardiff, UK: 
http://www.hgmd.cf.ac.uk/ac/gene.php?gene=GLA). AFD has been termed an orphan 
disease due to its low prevalence in the general population. Orphan diseases are diseases 
that are rare enough that there are no commercial incentives for research and the 
development of effective therapies to be carried out, without separate government 
legislation. In the United States, the Orphan Drug Act (1983) defines an orphan disease 
as a disease or condition considered to affect fewer than 200,000 individuals in the 
United States or has a prevalence of < 7.5 per 10,000 Americans
5
. In Europe, an orphan 
disease has been defined by the European Committee for Orphan Medicinal Products as 
a life-threatening or very serious disease affecting not more than 5 per 10,000 
Europeans
6
. With these legislations enzyme replacement therapy (ERT) has been 
developed and approved to manage AFD individuals. Both agalsidase alfa (Replagal®, 
Shire Human Genetic Therapies Inc.), and agalsidase beta (Fabrazyme®, Genzyme 
Corp.), have been approved by the European Committee for Orphan Medicinal Products 
but due to orphan drug laws in the United States, only Fabrazyme has FDA approval. 
ERT has been available for more than a decade and has improved morbidity in AFD. 
ERT has been shown to stabilise and reduce the rate of decline of renal function
7-15
, 
reduce left ventricular hypertrophy
8, 16-18
, improve pain and peripheral neuropathy
8, 19-23
, 
improve quality of life
8, 21, 24
 and reduce abdominal pain
25, 26
. The improvement in 
cardiac and renal manifestations may ultimately decrease mortality in this orphan 
disease. Therefore the use of ERT and the potential efficacy of the treatment has 
increased awareness of the importance of diagnosing unrecognised AFD patients to 
ensure their optimal management.  
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1.2 Pathogenesis 
 
The primary disease process is the pathological accumulation of neutral 
glycosphingolipids in lysosomes, predominantly globotriaosylceramide (GB3), due to a 
deficiency of the lysosomal enzyme hydrolase α-Gal, which catalyses the hydrolytic 
cleavage of the terminal galactose from GB3. Glycosphingolipids are the most abundant 
and diverse class of glycolipids in humans. They contain carbohydrate residues attached 
by glycosidic linkage to the C-1 hydroxyl group of a ceramide lipid moiety. The 
ceramide lipid moiety consists of a long-chain amino alcohol (sphingosine) in amide 
linkage to a fatty acid. The four principal classes of glycosphingolipids are the 
cerebrosides, sulfatides, globosides and gangliosides. A globoside is a type of 
glycosphingolipid with more than one sugar as the side chain, while a cerebroside has 
only one sugar as the side chain. Gangliosides are glycosphingolipids with one or more 
sialic acids linked on the sugar chain and sulfatides contain a sulphuric ester group. Fig 
1.1 demonstrates the chemical structure of GB3 and Fig 1.2 illustrates the metabolic 
pathway of glycosphingolipid degradation and the defect in this metabolic pathway first 
described by Brady et al in 1967
27
 resulting in AFD. The accumulation of GB3 occurs 
in multiple organs throughout the body most clinically significant in the cardiovascular, 
renal and neurological systems.  
 
 
 
 
Fig 1.1. Chemical structure of globotriaosylceramide (GB3) and site of action of α-galactosidase A (α-
Gal). 
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Fig 1.2. A schematic drawing of the possible enzyme defects in the catabolic pathways of sphingolipids. 
Names of glycosphingolipids (black), enzymes (green italic) and diseases caused by enzyme deficiency 
(red). Adapted from Chapter 41 Genetic Disorders of Glycan Degradation, Essentials of Glycobiology
28
. 
 
α-GAL is encoded by the GLA gene on the long arm of the X-chromosome and is 
synthesized on the endoplasmic reticulum (ER) bound ribosomes as a precursor form 
(429 amino acid residues). The enzyme is translocated into the lumen of the ER by the 
addition of N-linked oligosaccharides. The oligosaccharides are then trimmed in the ER, 
and the enzyme is transferred to the Golgi apparatus, where further modification of 
sugar chains and the addition of mannose 6-phosphate residues occur, and then 
transported to endosomes and subsequently lysosomes where it exerts its function as a 
mature form consisting of 398 residues. 
In AFD, mutations in the GLA gene results in the loss of enzyme activity. The level of 
residual enzyme activity is determined by the type of mutation and the part of the gene 
affected. Usually non-functional, or a complete lack of the genetic product is caused by 
mutations affecting the active site of the enzyme
29
. Missense mutations on the other 
hand may result in a considerable loss of metabolic activity but still retain some residual 
activity enough to ameliorate clinical manifestations. These mutations are usually 
distant from the active site and result in small structural changes of the mutant enzyme. 
The mutant enzyme is post-translationally inactivated and rapidly degraded, but has 
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some appropriate residual activity which leads to milder clinical manifestations
30
. 
Mutations distant from the active site that adversely affects the folded state of the 
molecule, reduces the enzyme stability and this decreases the amount of active enzyme 
transported to the lysosome
31
. 
 
 
1.3 Clinical Manifestations 
 
The initial description of AFD was of angiokeratomas, lymphoedema and proteinuria. 
With increasing awareness and diagnosis of this disease, it has been well documented 
that AFD patients also have cardiac, renal, cerebrovascular, neurological, 
gastrointestinal, ophthalmologic and auditory involvement. Ramaswami et al 
highlighted the main signs and symptoms in children, as neurological, gastrointestinal, 
ophthalmologic, auditory and skin involvement
32
. As AFD patients increase in age 
renal, cardiac and cerebrovascular involvement become more clinically relevant. Table 
1.1 summarises the predominant signs and symptoms with age. Quality of life is 
impaired in AFD patients
33
 and life expectancy reduced by approximately 20 years in 
males and 15 years in females
34-37
. 
It is well documented that AFD females (heterozygotes) can be as affected as males 
(homozygotes) despite being an X-linked inherited disorder. AFD females develop left 
ventricular hypertrophy, renal dysfunction, stroke, acroparaethesia, auditory 
involvement, skin involvement and gastrointestinal symptoms but usually at a older 
age
35, 38-44
. Dobyns et al
45
 classified AFD females having a high penetrance (70%) but 
low severity (4%). The heterogeneity of disease manifestation in females depends on 
the degree to which the normal X-chromosome is inactivated
46-48
. This process whereby 
one copy of the X-chromosome is randomly inactivated in all cells of the female 
embryo is called lyonisation and partly explains heterogeneity in females. Another 
reason for phenotypic heterogeneity in females is the cross-correction mechanism or 
metabolic cooperation
49
. Lysosomal enzymes freely enter and leave lysosomes and are 
transferred from one cell to another via mannose-6-phosphate mediated endocytosis. 
This “sharing” of enzyme helps to correct for lack of enzyme in deficient cells. In AFD 
females, if the amount of active enzyme secreted is insufficient or not adequately taken 
up by cells, there might be reduced cross correction. The decreasing efficiency of this 
process through the years, could explain why females get more symptomatic with age
50
. 
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Childhood and adolescence (≤16- years) 
• Acroparaethesia/ Pain Crisis – chronic or episodic, burning sensation in the 
palms of hands or soles of feet, exacerbated by temperature changes, fever, 
stress, physical exercise and alcohol 
• Angiokeratomas (Fig 1.2) – small, raised, dark red spots, develop slowly, 
found on the buttocks, genitalia, inner thighs, back and oral cavity 
• Ophthalmologic abnormalities -  cornea verticillata (whorl-shaped opacity), 
posterior subcapsular cataracts, torturous vascular lesions in the retina and 
conjunctiva 
• Sensorineural hearing loss 
• Hypohidrosis or Hyperhidrosis 
• History of non specific bowel disturbances 
• History of lethargy and tiredness 
Early adulthood (17 – 30 years) 
• More extensive angiokeratomas 
• Proteinuria, lipiduria, haematuria 
• Oedema 
• Fever 
• Hypohidrosis or anhidrosis 
• Heat sensitivity 
• Diarrhoea, abdominal pain 
Later adulthood (age > 30 years) 
• Prominence of acroparaethesia less prominent 
 Heart disease – left and right ventricular hypertrophy, heart valve 
abnormalities and conduction disturbances 
• Impaired renal function – including end stage renal failure needing renal 
replacement therapy with dialysis or renal transplantation 
 Stroke or transient ischaemic attacks 
 
Table 1.1. Summary of major signs and symptoms in AFD based on different age groups. There is an 
accumulation of symptoms from childhood to adulthood, with progressive end organ damage but 
acroparaethesia becomes a less prominent feature. 
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Fig 1.3. Angiokeratomas in the groin and male genitalia. 
 
The prediction of organ involvement and progression in AFD is complicated by firstly 
the large number of different mutations described
51
 in a small population, secondly the 
large phenotypic heterogeneity associated with the same mutation, both among patients 
in related and unrelated families
52
; and thirdly the difficulty that clinical features of 
AFD are frequently features of more prevalent diseases in the general population. 
Residual enzyme activity in affected individuals result in a delayed onset or less severe 
presentation of disease
53-55
 and in females can range from normal to absent activity. 
Patients with the “cardiac variant” present usually in the 5th to 8th decades of life with 
left ventricular hypertrophy, arrhythmias, and/or cardiomyopathy
56-58
 and with the 
“renal variant” present typically after the age of 50 years with proteinuria and later onset 
end stage renal failure
59, 60
. More recently Hughes et al developed a prognostic score, 
the Fabry International Prognostic Index, to demonstrate that it is possible to 
differentiate groups of patients with different outcome probabilities
61
. In terms of renal 
decline, Warnock et al showed that AFD patients with more significant proteinuria  had 
a greater rate in decline in  glomerular filtration rate
62
. 
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1.4 Diagnosis of AFD 
 
Diagnostic methods are based on measuring plasma and leukocyte α-Gal activity and 
DNA mutation analysis. Once an index case is found, pedigree analysis and these 
methods are used to diagnose affected relatives. Classically affected hemizygotes have 
very low or undetectable enzymatic activity, but some heterozygotes, e.g. the N215S 
mutation may have residual enzyme activity in plasma and/ or leucocytes close to the 
normal range. In affected females enzymatic activity may range from low levels 
comparable to male, up to levels in the normal range. This means that heterozygote 
females, who may or may not be symptomatic, could have normal enzyme activity and 
be misdiagnosed if DNA mutation analysis is not performed. Therefore in heterozygotes 
enzymatic analysis alone may lead to misdiagnosis and DNA mutation analysis is 
essential. Fig 1.3 outlines a useful diagnostic algorithm. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 1.4. Diagnostic algorithm in AFD. 
Screening 
Program 
Plasma and Leucocyte 
Enzyme Activity 
Clinical Suspicion 
or Family history 
Normal Activity 
Proceed if index of suspicion is high 
 
DNA Mutation 
analysis 
Low Activity 
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1.5 Prevalence of AFD 
 
The prevalence of AFD has been reported at 1 in 117 000
63
 (Australia), 1 in 468 000
64
 
(Netherlands) and 1 in 833 000
65
 (Portugal), but the true prevalence maybe higher as 
highlighted by Italian and Taiwanese newborn screening studies. In the Italian study the 
incidence of α-Gal deficiency was 1 in 3100 (newborn Italian males) and if only known 
disease causing mutations were included the incidence was 1 in 4600
66
. In the 
Taiwanese screening study the incidence of α-Gal mutations were approximately 1 in 
1250 newborn males and 1 in 40000 newborn females. The screening of high risk 
populations have shown an increased prevalence; 1 in 86
59
 (chronic haemodialysis 
Japanese males), 1 in 621
60
 (Austrian dialysis patients), 1 in 26
67
 (German young adults 
with cryptogenic stroke) and 1 in 26
58
 (males with hypertrophic cardiomyopathy). A 
recent systematic review by Linthorst et al of all screening studies for AFD in high risk 
groups showed a prevalence of 0.33% male dialysis patients, 0.1% female dialysis 
patients and at least 1% for patients with left ventricular hypertrophy
68
. Prevalence 
screening studies may inadvertently have falsely higher prevalence due to 
polymorphisms in particular D313Y
69
. In these polymorphisms, in vitro testing due to 
an artificial substrate shows low enzyme activity but further studies demonstrated 
normal in vivo activity. 
Due to increased prevalence of AFD in high risk populations and the beneficial effects 
of ERT, strategies for recognising and diagnosing AFD are important. 
 
 
1.6 Management of AFD 
 
1.6.1 Multidisciplinary Approach 
As AFD can present in so many varied ways and multiple organ involvement is usual, it 
is desirable that patients are treated by a multidisciplinary team with interested medical 
professionals from a number of different specialities. In the United Kingdom, the 
National Specialist Commissioning team has designated six centres to provide 
diagnosis, assessment and treatment of lysosomal storage diseases. Other key areas of 
provision of care would include genetic counselling and supportive care. 
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1.6.2 Enzyme replacement therapy (ERT) in AFD 
 
Two preparations of α-galactosidase A have been tested and been approved for use; 
agalsidase alfa (Replagal®, Shire Human Genetic Therapies Inc.)
19
 in Europe,  and 
agalsidase beta (Fabrazyme®, Genzyme Corp)
24
 in the USA and Europe (Table 1.2). 
Both these glycoproteins are identical but are produced in different cell lines, resulting 
in different glycosylation at the N-linked carbohydrate attachment sites. Replagal 
contains a greater amount of complex carbohydrate while Fabrazyme contains a higher 
fraction of sialylated and phosphorylated carbohydrate
70
. 
The clinical goals of ERT are to reduce symptoms and complications of GB3 deposition 
in the lysosomes of major organs, and where disease is already evident, stabilisation and 
possibly reversal of disease process. Clearance of microvascular endothelial deposits of 
GB3 from the kidneys, heart, and skin have been claimed
16, 19, 24, 71
 and various studies 
and clinical trials have shown clinical benefit including improved neuropathic pain and 
peripheral neuropathy
8, 19-23
, retarded or reduced progression of renal disease
7-15, 19
, 
reduction in left ventricular mass or hypertrophy
8, 16-18
, improved quality of life
8, 21, 24
 
and reduced abdominal pain
25, 26
. 
For agalsidase alfa, an analysis of 201 AFD patients (with CKD stage 2 or 3) in the 
Fabry outcome survey (FOS), who had been on treatment for up to 4.7 years, showed 
that the decline in estimated glomerular filtration rate (GFR) is halted when compared 
to the year before start of ERT
12
. Similarly ERT stabilised renal function in AFD 
patients with CKD stage 2 or 3
8
. Another single centre prospective open-label treatment 
trial of 25 adult male AFD patients initially in a 6 month randomized placebo-controlled 
study and subsequent open-label extension study, showed patients with CKD stage 1 
and 2 had stable estimated GFR and in those with CKD stage 3, the slope of decline in 
GFR was reduced compared with historical controls
11
. For agalsidase beta, a double-
blind, randomised, placebo-controlled phase III study, involving 58 AFD patients, 
median serum Cr and eGFR remained stable at up to 54 months
10
. 
ERT has been shown to be safe although infusion related reactions with fevers, chills, 
rigors, headaches, rhinitis and nausea can be easily treated with premedication 
(paracetamol, antihistamines and steroids) or by slowing the infusion rate. AFD patients 
develop antibodies toward both preparations of ERT, and the IgG antibodies produced 
when treated with either product are cross-reactive
72
. IgG antibodies were shown to 
reduce enzymatic activity in vitro and AFD patients who were IgG negative had 
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significantly decreased urinary GB3 compared with IgG positive AFD patients at 6 
months of treatment, but with stable renal function
72
 and the presence of IgG antibodies 
to ERT did not seem to affect clinical course or result in withdrawal of treatment
11
. 
Another multicenter 20 week phase 3 double blind, randomised and placebo controlled 
study and subsequent open-label extension study of 58 AFD patients, demonstrated 
approximately 90% of treated patients developed IgG antibodies with median time to 
seroconversion of 6 weeks and did not affect long-term efficacy of ERT
15
.  
Currently in the UK, agalsidase alfa, Replagal is licensed at a dose of 0.2mg/kg every 2 
weeks and agalsidase beta, Fabrazyme is licensed at a dose of 1 mg/kg every 2 weeks 
(Table 1.2 summarises the administration, dosage and origin of agalsidase alfa and 
beta). There is only one study known comparing agalsidase alfa and agalsidase beta 
showing no difference in clinical end points with either preparation, but this study only 
had 34 patients enrolled with follow up of 24 months and agalsidase beta used at a 
lower dose than licensed for (0.2mg/kg compared to licensed dose of 1mg/kg)
73
. In the 
Canadian Fabry Disease Initiative study on of the aims is to determine the difference 
between efficacy of the two different enzyme preparations, unfortunately due to 
worldwide shortages in Fabrazyme this objective is not been able to be demonstrated 
currently. 
 
 Agalsidase alfa, Replagal 
 
Agalsidase beta, Fabrazyme 
Dose 0.2mg/kg every 2 weeks 
 
1.0mg/kg every 2 weeks 
Origin Human fibroblast cell line 
 
Chinese hamster ovary cell line 
Intravenous 
Administration 
In 100mls Saline over 40mins In 500mls Saline over 4 hours 
reducing to 90mins if tolerated 
 
Table 1.2. Summary of available ERT 
 
In the UK administration of ERT is conducted in a hospital environment and if no 
infusion reactions occur, it is usual for ERT to be administered in a local environment 
(home, work place, GP surgery, day hospital etc.). Administration by a home care team 
or patients themselves have been shown to be safe
11, 74
. The duties of the home care 
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team include intravenous cannulation, phlebotomy, drug delivery and preparation, as 
well as educating patients on drug administration and trouble-shooting home therapy 
problems.  
The question of the effect of ERT in patients with end stage renal failure is not fully 
understood. It does not reverse end stage renal failure, but ERT in dialysis patients 
improves quality of life, appears to decrease progression of AFD cardiomyopathy and 
has been shown to be safe
75
. Others have reported favourable cutaneous, 
gastrointestinal, neurological and psychiatric response in dialysis dependent AFD 
patients
76
. A study of 10 AFD patients on haemodialysis showed there was no reduction 
in enzymatic activity with the administration of ERT during haemodialysis
77
. 
Current evidence shows there is probably is some benefit in ERT improving morbidity 
in AFD patients but long term data is needed to see if ERT would improve mortality.  
 
 
1.7 Conclusion 
 
AFD is a rare disease with multisystem involvement. Current therapies reduce 
morbidity but treatment is expensive, and timing of the initiation of this treatment is 
difficult to be precise with. In this thesis I hope to examine methods of identifying 
organ involvement at an earlier stage which maybe subclinical, to ensure that the future 
impairment of these organs could be prevented with appropriate early intervention. 
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Chapter 2. Assessment of glomerular filtration rate in 
AFD 
 
 
2.1 Introduction 
2.2 Rationale for study 
2.3 Aims 
2.4 Materials and methods  
2.5 Results 
2.6 Discussion 
2.7 Limitations 
2.8 Conclusions 
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2.1 Introduction 
 
Proteinuria was one of the characteristics noted in AFD when first described in 1898 
independently by two dermatologists, Johannes Fabry in Germany, and William 
Anderson in London, UK. This showed evidence of renal involvement in AFD from the 
onset of its description. Significant proteinuria is defined as ≥ 300mg/L of total protein 
in a 24 hour urine collection. Spot urine samples are now more reliable than 24 hour 
urine collections for estimating proteinuria. Two separate early morning urine samples, 
spaced by 1 to 2 weeks are needed to confirm significant proteinuria. Urine 
protein:creatinine ratio (UPCR) of ≥ 45 mg/mmol and urine albumin:creatinine ratio 
(UACR) of ≥ 2.5mg/mmol in males and ≥ 3.5 mg/mmol in females is significant78. 
Microalbuminuria refers to albumin excretion above the normal range but below the 
level of detection by tests for total urine protein. Increased excretion of albumin is a 
more sensitive marker than proteinuria for CKD in diabetes, glomerular diseases and 
hypertension.  
 
2.1.1 Renal involvement in AFD 
Renal involvement is usually apparent by the age of 30 years in affected males
34, 
79-81
, but in females there is more heterogeneity. Females may have no apparent 
renal disease to severe renal dysfunction requiring renal replacement therapy 
(dialysis or renal transplantation)
35, 82-85
. 
Branton et al in 2002
55
 showed in a review of 105 male hemizygotes that all 
those who survived other complications of AFD developed end stage renal 
disease [defined as need for dialysis or renal transplantation or an estimated 
glomerular filtration rate (eGFR) less than or equal to 12 ml/min] by 55 years of 
age. Seventy-eight of the 105 (74%) male hemizygotes had proteinuria and/or 
chronic renal insufficiency [defined as sustained serum Cr more than or equal to 
1.5mg/dL or 132.6µmol/L] by a median age 42 years. Fifty percent of patients 
developed proteinuria by age 35 years and a hundred percent by age 52 years. 
Two large registries have reported the prevalence of renal involvement in AFD. 
Mehta et al in 2009
86
 described data from the FOS in which 59% of 699 males 
(mean age 32.6 years) and 38% of 754 females (mean age 38.5 years) had renal 
symptoms and/or signs; also, 13% of males and 1% of females had reached end 
stage renal disease requiring renal replacement therapy. Wilcox et al in 2008
42
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from the Fabry Registry showed that 64% of males and 39% of females had 
significant proteinuria (≥300mg/24 hours), and 14% of males and 2% of females 
had reached end stage renal disease (mean ages 38.2 and 39.2 years 
respectively). In children and adolescents the predominant renal symptoms are 
proteinuria
32, 87
 and occasional microscopic haematuria
32
, but the prevalence of 
renal symptoms is generally low and other clinical manifestations of AFD are 
more apparent in this age group. 
Current guidelines
88
 for the initiation ERT for renal complications of AFD are:  
i) GFR < 80ml/min/1.73m2; 
ii) Proteinuria > 300mg/24 hour;  
iii) Microalbuminuria with evidence of GB3 deposition on renal biopsy.  
These are guidelines are based on expert consensus. Different measures of GFR 
will alter the patients who are initiated on ERT based on the above guidelines, as 
measures of GFR could be over or under estimated depending on test used. 
 
2.1.2 Advantages and disadvantages of GFR measurements using serum creatinine 
 
2.1.2.1  Serum creatinine 
In muscle metabolism, Cr is synthesized endogenously from creatine and 
creatine phosphate at a fairly constant rate. Cr production and excretion varies 
among individuals especially children
89
, the elderly
90
, by ethnicity and sex, 
obesity
91
, during pregnancy
92,93
, and in severely ill patients with low muscle 
mass and poor nutritional status. Under conditions of normal renal function, Cr 
is excreted by glomerular filtration, and a small amount is actively secreted by 
the renal tubules. Cr clearance determinants are performed for the diagnosis and 
monitoring of renal function. In renal dysfunction, the serum Cr rises. Therefore, 
Cr levels have been used to estimate the GFR by a variety of methods. With a 
declining GFR, active tubular secretion of Cr plays a more significant role in Cr 
excretion from the body
94
. Serum Cr can be in the normal range even with GFR 
less than 60ml/min/1.73m
2
, as there needs to be a marked decrease in 
functioning nephron mass, before the serum Cr is elevated. In severe renal 
impairment, extra-renal elimination of Cr may occur in the small bowel, where 
bacterial overgrowth causes degradation of up to two thirds of total daily Cr 
excretion
95
. Assays of Cr are technically difficult, hampered by interferences up 
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to 20% by oxidoreductive compounds and can be reduced by the enzymatic 
assay method
96
. Differences in specificity in different assays can make it 
difficult to compare values from different laboratories. Interference may also 
arise from certain medications (Flucytosine and some cephalosporins) or from 
ketones e.g. in diabetic ketoacidosis (increases serum Cr).  
 
2.1.2.2  24 hour urine creatinine clearance (24h U Cr Cl) 
Timed urine collections have been used to circumvent the problem of varied Cr 
production but not tubular secretion of Cr which can be doubled with declining 
GFR. Drugs such as cimetidine and trimethoprim can decrease tubular secretion 
of Cr so drugs administered during timed urine collections need to be identified. 
Also the result depends on accurately timed and complete urine collections, 
which can be difficult for some patients. 
 
2.1.2.3     Equations estimating GFR based on serum creatinine 
 
Cockcroft – Gault (CG)97 equation 
The CG equation was first derived in 1976 and based on 249 patients aged 
between 18 – 92 years, so as to predict Cr clearance using serum Cr and 
factoring in age, sex and weight. This formula was not normalised to body 
surface area (BSA) and was based on an outdated laboratory assay (Jaffe). 
 
Modification in Diet in Renal Disease (MDRD)
98
 equation 
The MDRD equation was based originally on 1628 non-diabetic patients with 
CKD and it factored in age, sex, ethnicity, serum Cr, albumin and urea. Later a 
simplified 4 variable equation using age, sex, ethnicity and serum Cr was 
introduced for clinical use
99
. It is still unsuitable for healthy individuals and for 
GFRs above 60ml/min/1.73m
2
 where the MDRD underestimates GFR. In GFRs 
below 20ml/min/1.73m
2
 or in individuals with nephrotic range proteinuria it 
overestimates. In non-caucasian populations it is inaccurate but there is a 
correction for African-Americans (multiple eGFR of the MDRD equation by 
1.2). The MDRD equation also has not been validated in acute renal failure. 
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Mayo Quadratic
100
 equation 
The Mayo quadratic equation was developed to improve estimates of GFR in 
healthy individuals, as well as in CKD, using serum Cr, age and sex. In 
developing this equation 320 subjects with CKD and 580 normal subjects were 
used, but the elderly and ethnic African-Americans were under-represented.  
 
Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI)
101
 equation 
The CKD-EPI equation was recently developed to better estimate GFR in 
normal individuals with GFR more than 60ml/min/1.73m
2
. It included different 
ethnic groups, the elderly, and diabetics. The development of the equation used 
data from 8254 individuals and validation based on 3896 individuals. This 
formula has 8 different equations, depending on sex, serum Cr and ethnic group. 
Compared with MDRD it has less bias and increased accuracy in estimating 
higher GFR. However limitations are similar to the MDRD equation because of 
the small numbers of ethnic and elderly subjects. 
 
2.1.3 Advantages and disadvantages of exogenous GFR markers 
 
2.1.3.1  Radio-labelled or unlabelled polysaccharides 
Inulin (MW 5.2kDa) is a polymer of fructose, is freely filtered at the glomerulus, 
and is neither reabsorbed nor secreted by renal tubules. It is also metabolically 
inert and cleared only by the kidney. These characteristics make it the gold 
standard for the estimation of GFR
102
. Using inulin clearance to measure GFR is 
expensive, involves time-consuming, labour intensive chemical analysis and has 
limited availability. It involves continuous administration of the intravenous 
marker to maintain plasma levels and once steady state has been achieved, 
plasma and timed urine collections (ideally via bladder catheterisation) is 
needed, therefore making it unsuitable for routine clinical use but used in a 
research setting. 
 
2.1.3.2  Radio-labelled or unlabelled chelates 
 Cr
51
 EDTA, Tc
99m
 DTPA and Gd-DTPA GFR measurements are simpler to use 
than inulin clearance. Single intravenous bolus injection of a radio-labelled 
filtered marker is injected with a serum/plasma measurement of the marker at a 
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fixed time (usually 4 hours later) post-injection. Accuracy of the test could be 
increased with an increased number of serum/plasma measurements. 
Disadvantages are the complicated measures required to handle, store and 
dispose of radio-labelled waste. Skilled personnel are needed and some radiation 
is administered though in very small non-toxic amounts. Radio-labelled chelates 
are unsuitable in pregnant women and children.  
 
2.1.3.3  Urographic contrast media (radio-labelled or non-labelled) 
Urographic contrast media (Iothalamate/
131
Iothalamate or Iohexol) used as a 
GFR marker may have the added advantage of diagnostic imaging, such as 
urography, angiography or CT. Iohexol is readily available as a safe non-ionic 
low osmolar contrast agent. It is not secreted, metabolised or reabsorbed by the 
kidney and is eliminated exclusively without metabolism by the kidneys and has 
been increasingly been used as a GFR marker in adults and children. The only 
contraindication is an allergy to iodine and cautioned in severe asthma/eczema. 
 
2.1.4 Current Studies of GFR measurement comparisons in AFD 
 
Kleinert et al in 2005
103
 retrospectively reviewed previous published studies and 
concluded that the MDRD equation overestimates GFR in AFD patients with 
normal or near normal serum Cr levels. In their cohort of 8 patients, using the 
MDRD formula, overestimated GFR in 5 patients and underestimated GFR in 3 
patients when compared with 
51
Cr EDTA radioisotope GFR studies. 
Aakre et al in 2009
104
 concluded in their cohort of 21 patients that the MDRD 
and CG equations overestimate GFR compared with ioxehol clearance in their 
male AFD patients with CKD stages 1-2 and in male AFD patients with a lower 
normal body mass index (BMI). 
More recently Rombach et al
105
 compared Cr, Cystatin C and beta-trace protein 
based GFR equations in 36 AFD patients on ERT and concluded that the Stevens 
equation (Cystatin C and Cr based equation) best most closely approximated the 
measured GFR based on 
125
Iothalomate urinary clearance. 
Unfortunately, studies to date comparing different methods of estimated GFRs in 
AFD patients have been small. 
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2.2   Rationale for study 
 
A raised serum Cr alone is insufficient to diagnose renal involvement in AFD patients 
with GFR ≤ 80ml/min/1.73m2. Our clinical practice needs to ensure that AFD patients 
with normal serum Cr, but reduced GFR are detected and managed because studies have 
shown that earlier treatment of AFD reduces the rate of decline in GFR
9-12, 14, 55, 106
. 
The gold standard test for measuring GFR in a research setting is inulin clearance and in 
a clinical setting radioisotope GFR estimates or iohexol clearance. These methods may 
not be available in some centres that manage AFD patients. Other methods of 
estimating GFR have their problems with under or overestimation of GFR, urine 
collection inaccuracies and reliability of test assays and when factoring in age, sex and 
BMI/BSA. Using a retrospective review of our single centre experience I wanted to 
determine the best method for estimating GFR in AFD and for monitoring progression 
of renal involvement. 
 
 
2.3 Aims 
 
i) To document the most appropriate method of measuring GFR in AFD in a 
clinical setting. 
ii) To determine which method of measuring GFR over or under estimated GFR in 
AFD 
iii) To determine what proportion of patients might be inappropriately treated with 
or deprived of ERT. 
 
 
2.4 Materials and methods 
 
Patients who were diagnosed and/or followed in the Lysosomal storage disorders unit 
(Royal Free Hospital) from January 2004 until April 2008 were reviewed. Patients 
included in our analysis were ≥ 18 years of age and had a known mutation in the GLA 
gene encoding α-galactosidase A. Data from investigations carried out within a month 
of each patient's routine isotopic GFR estimate by single point 
51
Cr-EDTA radionuclide 
study (iGFR) were collected. Patients were excluded if they did not have a 24h U Cr Cl 
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and serum Cr measurement within 1 month of their iGFR estimate. Only single paired 
measurements from individual AFD patients were used. The data collected and analysed 
are summarised in Table 2.1. Serum Cr was determined by the enzymatic Jaffé
107
 
method, using a Roche automated clinical chemistry analyser. Table 2.2 summarises the 
equations used to calculate BSA, and eGFR by different formulae. If BSA correction is 
not already included in an eGFR formula, they were corrected for BSA using the 
Mosteller formula
108
.  
In analysing the data, iGFR estimates were presumed to be the most accurate measure 
of the true GFR
109-113
 and all eGFRs were compared with the corresponding iGFR. 
Demographic data were represented as mean (M), standard deviation of mean (SD), and 
range. The Mann-Whitney U test was used for statistical analysis of the demographic 
data in Table 2.1, unless otherwise stated. The mean and SD were calculated and shown 
graphically for all CKD stages, and subdivided into CKD stages 1, 2 and 3, according to 
the method of estimating GFR; statistical analysis was by the Wilcoxon matched pairs 
test. 
Bland-Altman plots
114
 were used to analyse the agreement between iGFR and the 
different methods of calculating eGFR. These plots show the mean difference between 
iGFR and eGFR method depicted, 95% limit of agreement (mean difference of iGFR 
and eGFR method depicted ± 1.96SD), bias and Spearman’s rank correlation coefficient 
between the absolute differences and the average.  
The percentage of eGFR within ±30% of the iGFR (P30) and the number and percentage 
of missed or early treated patients were calculated when the eGFR was used instead of 
the iGFR to decide when to start ERT. Missed patients were defined as patients who 
received ERT on the basis of an iGFR < 80ml/min/1.73m
2
, but who had a matched 
eGFR of ≥ 80ml/min/1.73m2 (false negative), and early treated patients were those who 
had an iGFR of ≥ 80ml/min/1.73m2, but had a matched eGFR of < 80ml/min/1.73m2 
(false positive). 
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Characteristics Males (n=45) Females (n=61) p values 
 Mean SD Range Mean SD Range  
Mean Age, years 44.70 ± 13.57 20 - 75 45.57 ± 14.96 18 – 80 NS 
On Enzyme Replacement Therapy, n [%] 43 [95.56%]   38 [62.30%]   p < 0.0001 (Fishers exact test) 
Height, m 1.77 ± 0.05 1.64 – 1.89 1.60 ± 0.06 1.50 – 1.73 p < 0.0001 
Weight, kg 77.91 ± 15.43 51.0 – 123.8 66.35 ± 10.93 42.3 – 86.9 p = 0.0002 
Body Surface Area, m
2 1.95 ± 0.20 1.58 – 2.45 1.71 ± 0.16 1.34 – 2.03 p < 0.0001 
Body Mass Index, kg/m
2 24.9 ± 4.8 16.7 – 40.9 25.9 ± 4.0 17.6 – 34.1 NS 
Serum Creatinine, µmol/L 89.60 ± 21.45 63 - 187 72.38 ± 13.54 47 – 123 p < 0.0001 
iGFR, ml/min/1.73m
2 84.11 ± 21.53 33.0 – 122.0 92.05 ± 23.24 39.0 – 150.0 NS (p = 0.0890) 
MDRD eGFR, ml/min/1.73m
2 90.42 ± 21.11 37.1- 132.5 84.59 ± 18.37 40.7 – 130.4 NS (p = 0.1004) 
Cockcroft Gault eGFR, ml/min/1.73m
2 93.27 ± 22.91 45.0 – 138.6 93.96 ± 22.76 38.7 – 138.4 NS 
24h U Cr Cl, ml/min/1.73m
2 92.33 ± 35.24 40.2 – 193.0 93.55 ± 24.39 34.9 – 160.8 NS 
Mayo Quadratic eGFR, ml/min/1.73m
2 113.2 ± 25.49 38.3 – 145.0 102.1 ± 15.63 50.9 – 126.6 p = 0.0004 
CKD-EPI eGFR, ml/min/1.73m
2
 92.32 ± 21.27 37.9 – 125.1 89.47 ± 19.86 38.4 – 123.7 NS 
24 hour Urine Protein, g/24 hour 0.25 ± 0.28 0.00 – 0.99 0.18 ± 0.25 0.05 – 1.50 p = 0.0271 
Spot Urine Protein: Creatinine Ratio, 
mg/mmol 
19.54 ± 36.30 1.49 – 174.5 22.94 ± 32.83 0.01 – 143.9 NS 
Spot Urine Albumin: Creatinine Ratio, 
mg/mmol 
17.63 ± 29.17 0.31 – 119.2 9.13 ± 20.08 0.25 – 109.4 p = 0.0327 
 
Table 2.1. Demographic and patient characteristic data (p values calculated by Mann-Whitney U test unless stated). 
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Investigation Formula 
Body Surface Area [m
2
]
 
 =                   {[Height(cm) x Weight(kg)]/3600}
1/2
 
24 hour Urine Creatinine Clearance 
[ml/min/1.73m
2
]             
=                     Urine Cr (µmol/L) x 24 hour Urine Volume (ml) x 1.73 
                                    serum Cr (µmol/L) x 24 x 60 x BSA (m
2
) 
MDRD eGFR [ml/min/1.73m
2
] 
 
=                     [serum Cr (µmol/L)/88.4]
-1.154
 x 186 x Age (years)
-0.203
 x 1.21(if black) x 0.742 (if female)  
Cockcroft Gault eGFR [ml/min/1.73m
2
]                        =                    [140 – Age (years) x Weight(kg)] x 0.85 (if female) x 1.73 
                      serum Cr (µmol) x 0.8136 x BSA 
Mayo Quadratic eGFR [ml/min/1.73m
2
] 
 
=     exp {1.911 + 5.249/serum Cr [mg/dL] – 2.114/(serum Cr [mg/dL])2 – 0.00686 x Age – 0.205 (if female)}. 
                                                                                          (If serum Cr < 0.8mg/dL use 0.8mg/dL for serum Cr)         
CKD-EPI 
 
 
 
 
 
 
 
 
 
(Note S Cr denotes serum Cr) 
Race and Sex Serum Cr (µmol/L) Equation 
Black   
Female ≤ 62 
> 62 
eGFR [ml/min/1.73m
2
] = 166 x (S Cr/0.7)
-0.329
 x (0.993)
Age
 
eGFR [ml/min/1.73m
2
] = 166 x (S Cr/0.7)
-1.209
 x (0.993)
Age
 
Male ≤ 80 
>80 
eGFR [ml/min/1.73m
2
] = 163 x (S Cr/0.9)
-0.411
 x (0.993)
Age
 
eGFR [ml/min/1.73m
2
] = 163 x (S Cr/0.9)
-1.209
 x (0.993)
Age
 
White or Other   
Female ≤ 62 
> 62 
eGFR [ml/min/1.73m
2
] = 144 x (S Cr/0.7)
-0.329
 x (0.993)
Age
 
eGFR [ml/min/1.73m
2
] = 144 x (S Cr/0.7)
-1.209
 x (0.993)
Age
 
Male ≤ 80 
>80 
eGFR [ml/min/1.73m
2
] = 141 x (S Cr/0.9)
-0.411
 x (0.993)
Age
 
eGFR [ml/min/1.73m
2
] = 141 x (S Cr/0.9)
-1.209
 x (0.993)
Age
 
 
Table 2.2. Formulae used for calculating body surface area (BSA) and estimated glomerular filtration rate (eGFR) 
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2.5 Results 
 
One hundred and thirty five AFD patients were reviewed: 5 patients were excluded as 
they were less than 18 years of age at the time of iGFR and 24 were excluded because 
matched investigations were not completed within 1 month of an iGFR measurement; 
106 individual AFD patient investigations were included in this analysis. There were 
more females (61) than males (45), with no significant differences in age and BMI. Men 
had a significantly higher BSA, serum Cr, 24-hour urine protein excretion and 
microalbuminuria. A larger proportion of males compared to females were on ERT 
(95.56% vs 62.30%). All 106 patients included in this study were Caucasian. 
 
All CKD stages (Figure 2.1 and Table 2.3) 
Comparing eGFRs, there were significant differences between the CG equation, 24h U 
Cr Cl, and Mayo Quadratic equation when compared with iGFR; all 3 overestimated 
GFR in AFD patients when compared with iGFR. The mean differences between iGFR 
and eGFR of CG, 24h U Cr Cl, and Mayo Quadratic were 5.0±16.2, -4.4±21.8 and -
18.1±17.7 ml/min/1.73m
2
, respectively. The Mayo Quadratic equation gave the greatest 
mean difference, while the MDRD and CKD-EPI eGFR were not significantly different 
from iGFR. When analysed according to sex, in males all methods of eGFR calculation 
overestimated GFR compared with iGFR (-6.3 to -29.1 ml/min/1.73m2), but in females 
only the Mayo Quadratic equation overestimated eGFR (-10.1±15.7 ml/min/1.73m
2
), 
and the MDRD significantly underestimated eGFR (7.5±17.5 ml/min/1.73m
2
). 
 
CKD stage 1 (Figure 2.2, Table 2.3) 
According to the iGFR in CKD stage 1, the MDRD equation underestimated eGFR in 
males and females (8.7±16.8 ml/min/1.73m
2
) and underestimated eGFR in females only 
(13.4±18.0 ml/min/1.73m
2
), but not in males only (0.3±10.3 ml/min/1.73m
2
). The Mayo 
Quadratic equation significantly overestimated eGFR in all CKD stage 1 patients (-
11.2±17.0 ml/min/1.73m
2
), but sub-analysis by sex showed significant overestimation 
in males (-26.1±9.1 ml/min/1.73m
2
), although not in females (-2.9±14.5 
ml/min/1.73m
2
). The CKD-EPI equation significantly underestimated eGFR only in 
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females (6.6±15.9 ml/min/1.73m
2
). There was no significant difference in CG estimates 
of eGFR and 24h U Cr Cl compared with iGFR in CKD stage 1.  
 
CKD stage 2 (Figure 2.3, Table 2.3) 
In CKD stage 2, CG, MDRD, Mayo Quadratic and CKD-EPI equations all 
overestimated eGFR; only 24hr U Cr Cl was similar to iGFR. Sub-analysis by sex 
revealed that the eGFR overestimates were predominantly in males (-10.4 to -32.8 
ml/min/1.73m
2
) and in females only the Mayo Quadratic equation overestimated eGFR 
(-16.6±9.9 ml/min/1.73m
2
). 
 
CKD stage 3 (Figure 2.4, Table 2.3) 
In CKD stage 3, all equations and 24h U Cr Cl overestimated GFR compared with 
iGFR, from a mean difference of -9.5 ml/min/1.73m
2
 for 24h U Cr Cl to -27.0 
ml/min/1.73m
2
 for the Mayo Quadratic equation. Sub-analysis by sex, showed that in 
females there was no significant difference between eGFR measurements and iGFR, 
except for the Mayo Quadratic equation, which significantly overestimated eGFR (-
27.8±16.2 ml/min/1.73m
2
); however, all equation-based methods of calculating eGFR, 
but not 24h U Cr Cl, overestimated eGFR in males. 
 
Agreement between iGFR and eGFR (Figure 2.5 and Table 2.4) 
Using Bland-Altman plots the Mayo Quadratic equation has the most bias in over-
estimating eGFR (-18.14) and the MDRD and CKD-EPI equations having the least bias 
(+1.62 and +2.00, respectively). The CKD-EPI had the highest P30 value at 93.4%, 
followed by the CG and the MDRD equations. The Mayo Quadratic equation had the 
lowest P30 value at 64.2%. If divided by GFR <60ml/min/1.73m
2 
(CKD stage 3), the 
CKD-EPI equation performed the best with a  P30 of 83.3% and the Mayo Quadratic 
equation the worst with a P30 value of 16.7%. 
 
Treatment accuracy (Tables 2.5 and 2.6) 
Based on a GFR estimate and criterion for treatment of < 80ml/min/1.73m
2
, 16 males 
and 16 females would have received ERT, if treated according to iGFR values. 
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Comparing the matched eGFRs with the corresponding iGFRs, the Mayo Quadratic 
equation gave the highest number of ‘missed’ (untreated) patients (20), while the 
MDRD, 24h U Cr Cl, and CKD-EPI estimates each resulted in 8 ‘missed’ patients. 
Conversely, 29 males and 45 females would not be treated on the basis of their iGFRs 
only. Compared with the corresponding iGFR, the MDRD (16 patients) and CKD-EPI 
(18 patients) eGFRs would have resulted in the greatest number of ‘early treated’ 
patients. 
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Fig 2.1. Comparison of iGFR, MDRD equation, CG equation, 24h U Cr Cl, Mayo Quadratic 
equation and CKD-EPI equation in AFD males and females for all stages of CKD. Wilcoxon 
matched pairs test used for statistical analysis. 
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Fig 2.2 Comparison of iGFR, MDRD equation, CG equation, 24h U Cr Cl, Mayo quadratic 
equation and CKD-EPI equation in AFD males and females for CKD stage 1. Wilcoxon matched 
pairs test used for statistical analysis. 
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Fig 2.3. Comparison of iGFR, MDRD equation, CG equation, 24h U Cr Cl, Mayo quadratic 
equation and CKD-EPI equation in AFD males and females for CKD stage 2. Wilcoxon matched 
pairs test used for statistical analysis. 
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Fig 2.4. Comparison of iGFR, MDRD equation, CG equation, 24h u Cr Cl, Mayo quadratic 
equation and CKD-EPI equation in AFD males and females for CKD stage 3. Wilcoxon matched 
pairs test used for statistical analysis. 
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(a) All (n = 106) 
Investigation, ml/min/1.73m
2
 All Stages CKD 1 CKD 2 CKD3 
 M SD M SD M SD M SD 
MDRD eGFR 1.6 ±17.4 8.7 ±16.8 -3.7 ±15.8 -11.8 ±9.8 
Cockcroft Gault eGFR -5.0 ±16.2 -1.7 ±17.4 -6.4 ±14.3 -14.6 ±13.5 
24 hour Urine Creatinine Clearance -4.4 ±21.8 -2.4 ±25.9 -5.4 ±17.8 -9.5 ±11.8 
Mayo Quadratic eGFR -18.1 ±17.7 -11.2 ±17.0 -24.5 ±15.8 -27.0 ±15.6 
CKD-EPI eGFR -2.0 ±15.3 6.5 ±15.3 -5.8 ±14.9 -12.3 ±11.6 
 
(b) Males (n = 45) 
Investigation, ml/min/1.73m
2
 All Stages CKD 1 CKD 2 CKD3 
 M SD M SD M SD M SD 
MDRD eGFR -6.3 ±13.8 0.3 ±10.3 -10.4 ±15.6 -13.6 ±8.2 
Cockcroft Gault eGFR -9.2 ±13.5 -5.2 ±13.3 -11.2 ±13.5 -14.9 ±13.1 
24 hour Urine Creatinine Clearance -8.2 ±27.1 -10.6 ±36.3 -6.9 ±20.6 -4.9 ±6.9 
Mayo Quadratic GFR -29.1 ±14.0 -26.1 ±9.1 -32.8 ±16.7 -26.1 ±16.5 
CKD-EPI eGFR -8.2 ±12.5 -2.7 ±8.4 -11.9 ±14.7 -13.5 ±9.7 
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(c) Females (n = 61) 
Investigation, ml/min/1.73m
2
 All Stages CKD 1 CKD 2 CKD3 
 M SD M SD M SD M SD 
MDRD eGFR 7.5 ±17.5 13.4 ±18.0 2.8 ±13.2 -10.0 ±11.7 
Cockcroft Gault eGFR -1.9 ±17.4 0.2 ±19.2 -1.9 ±13.9 -14.2 ±15.0 
24 hour Urine Creatinine Clearance -1.5 ±16.5 2.2 ±16.7 -3.9 ±15.2 -14.1 ±14.5 
Mayo Quadratic eGFR -10.1 ±15.7 -2.9 ±14.5 -16.6 ±9.9 -27.8 ±16.2 
CKD-EPI eGFR 2.6 ±15.6 6.6 ±15.9 -0.1 ±13.0 -11.1 ±14.0 
 
Table 2.3. Mean of differences between matched investigations eGFR compared with iGFR, negative values indicate overestimation, and positive values 
underestimation of GFR. (a) All, (b) Males and (c) Females. 
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24 hour Urine Cr Cl
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Mayo Quadratic Equation
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CKD EPI
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Fig. 2.5. Bland Altman plots of iGFR (gold standard) compared with different methods of eGFR. 
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P30, % All patients < 60 ml/min/1.73m
2
 ≥ 60 ml/min/1.73m2 
MDRD 88.7% 66.7% 91.5% 
Cockcroft Gault 92.5% 50% 97.9% 
24h U Cr Cl 83%% 58.3% 86.2%% 
Mayo Quadratic 64.2% 16.7% 70.3% 
CKD-EPI 93.4% 83.3% 94.7% 
 
Table 2.4. Percentage of matched eGFR within 30% of iGFR (P30). 
 
 
 iGFR  MDRD  Cockcroft Gault 24h U Cr Cl Mayo Quadratic CKD-EPI 
ml/min/1.73m
2
 M F M F M F M F M F M F 
≥ 80 29 
(64.4%) 
45 
(73.8%) 
32 
(71.1%) 
35 
(42.6%) 
35 
(77.8%) 
46 
(75.4%) 
26 
(57.8%) 
42 
(68.9%) 
39 
(86.7%) 
56 
(91.8%) 
35 
(77.8%) 
43 
(70.5%) 
< 80 16 
(35.6%) 
16 
(26.2%) 
13 
(28.9%) 
26 
(57.4%) 
10 
(22.2%) 
15 
(24.6%) 
19 
(42.2%) 
19 
(31.1%) 
6   
(13.3%) 
5 
(8.2%)  
10 
(22.2%) 
18 
(29.5%) 
 
Table 2.5. Classification of those who meet criteria for ERT based on different measures of GFR; numbers (%) 
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 MDRD Cockcroft Gault 24h U Cr Cl Mayo Quadratic CKD-EPI 
Missed Females 
 
3 (18.8%) 7 (43.8%) 4 (25.0%) 12 (75.0%) 5 (31.3%) 
Early treated Females 
 
14 (31.0%) 6 (13.3%) 8 (17.8%) 1 (2.2%) 7 (15.6%) 
Missed Males 
 
5 (31.3%) 7 (43.8%) 4 (25%) 8 (50.0%) 3 (18.8%) 
Early treated Males 
 
2 (6.9%) 1 (3.4%) 7 (24.1%) 2 (6.9%) 11 (37.9%) 
 
Table 2.6. Summary of missed or early treated patients if using other GFR estimates compared with iGFR; numbers (%).  
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2.6 Discussion 
 
In view of the low prevalence, it is difficult to obtain large numbers of AFD patients for 
study. With increasing awareness and increasing diagnosis of the “late-onset” 
phenotype from screening studies
66, 68
, there is need to understand the disease process 
and effectiveness of current therapies in managing AFD. An increasing number of AFD 
patients are diagnosed at an earlier age due to family screening and before the onset of 
clinically apparent end-organ damage. Genetic polymorphisms should caution us in 
diagnosing AFD without evidence of organ involvement. Renal involvement is one 
facet of disease-related progression that needs to be monitored closely; if there are signs 
a renal dysfunction, ERT should be introduced early to prevent or slow the progression 
to end stage renal failure. 
GFR measurements vary in method and accuracy, and from centre to centre, which 
could lead to premature or delayed initiation of ERT. The present study is the largest to 
assess the accuracy of different eGFR methods used to monitor renal function in AFD 
patients. The study population had more females than males, but there were no 
significant differences between age and BMI. AFD males had a higher BSA and serum 
Cr than females and as affected males have earlier and more severe organ involvement, 
more males than females were on ERT. Males had more proteinuria and 
microalbuminuria compared with females, as reported in the FOS
86
 and Fabry registry
42
. 
There were no significant difference between males and females using iGFR or eGFR, 
except for the Mayo Quadratic equation, where the mean eGFR was higher in males 
than females. As with any study involving AFD, numbers are limited. In our study this 
was true for CKD stage 3 (according to iGFR), for which we had only 12 patients and 
our study population did not include patients in CKD stages 4 and 5. 
The MDRD equation has been validated for GFRs < 60ml/min/1.73m
2
, but current 
guidelines for starting ERT in AFD use a value of < 80ml/min/1.73m
2
. The majority of 
our study patients were in CKD stages 1 and 2. In this study, the MDRD formula, when 
compared with iGFR, showed no significant difference overall, but when divided by 
sex, it overestimated eGFR in males and underestimated it in females. Sub-dividing by 
stage of CKD, the MDRD eGFR underestimated eGFR in CKD stage 1 and 
overestimated it in CKD stages 2 and 3. This shift from underestimation to 
overestimation is more apparent when sub-divided by sex: in males there was no 
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difference in CKD stage 1, but a significant overestimation in CKD stages 2 and 3, and 
in females there was an underestimation in CKD stage 1, but no difference in CKD 
stages 2 and 3. The MDRD equation had the least bias compared with iGFR, and 
approximately 90% of eGFRs were within 30% of their corresponding iGFRs. Also, 
males with CKD stages 2 and 3 had an overestimate of eGFR, suggesting more 
significant renal disease than evident from their MDRD-based eGFR. However, in 
females we must be careful that underestimation of eGFR by MDRD in stage 1 CKD 
may lead to initiation of ERT too early.  
The CG equation overestimated eGFR more in those with poorer renal function (CKD 
stages 2 and 3), which was more apparent in males than females. Using this equation 
could potentially result in a significant number of patients being excluded from ERT. 
Thus, it is not recommended for monitoring renal function in AFD. 
24h U Cr Cl overestimated of GFR in all patients, although when subdivided by CKD 
stage, this was only significant in CKD Stage 3. Compared with the other methods, only 
83% of 24h U Cr Cl eGFRs were within 30% of iGFRs. 24h u Cr Cl had the largest 
standard deviation of the mean, most notable in males with CKD stage 1. This could 
reflect incomplete or inaccurately timed urine collections, a common problem, and a 
disadvantage using 24h U Cr Cl to estimate GFR. Therefore it is not recommended for 
monitoring renal function in AFD patients. 
However, the Mayo Quadratic equation was the least reliable when compared with 
iGFR; it significantly overestimated GFR in all categories of eGFR, except for females 
with CKD stage 1. Only 64.2 % of eGFRs were within 30% of their corresponding 
iGFRs. Using this equation there would be the highest number of ‘missed’ patients for 
ERT, and it is not recommended for use in AFD patients. 
The CKD-EPI equation is probably the best non-invasive method of calculating eGFR 
in all stages of CKD, including CKD stage 1, as there were no significant differences 
when compared with iGFR. However, there was significant underestimation of eGFR in 
females in CKD stage 1, similar to the MDRD equation, although not as large a 
difference. It also significantly overestimated eGFR in males with CKD stages 2 and 3, 
but had the highest percentage of eGFRs within 30% of their corresponding iGFRs. 
Therefore the CKD-EPI equation would be our recommended method for calculating 
eGFR in AFD patients. 
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In a clinical setting, because of the small numbers of AFD patients, and the need for 
early treatment to prevent progression of disease, simple methods for the reliable 
detection, assessment, and monitoring of organ involvement needs to be easily 
available. The best methods of estimating GFR in a clinical setting would be isotopic 
GFR measurements, but they are not available in all hospitals and they are unsuited to 
regular monitoring, because of the risks of repeated radiation exposure and cost. Iohexol 
has been increasingly used in research and clinical practice as another measure of GFR 
but is more invasive and expensive than standard eGFR calculations. An easier and cost 
efficient method of estimating GFR is needed, since the majority of patients are now 
diagnosed and monitored through screening, or family tracing, when early renal 
involvement may not be evident
115
 and most patients have normal renal function or 
CKD stages 1 and 2. ERT is expensive and life-long, but it can potentially slow disease 
progression and prevent the development of renal failure, if started early enough
7
. 
Still the most widely used measure of renal function is serum Cr with all its limitations. 
Cr production and excretion varies among individuals especially by ethnicity, sex, age, 
in obesity
91
, during pregnancy
93
, and in severely ill patients with low muscle mass and 
poor nutritional status. Under conditions of normal renal function, Cr is excreted by 
glomerular filtration, and a small amount is actively secreted by the renal tubules. With 
a declining GFR, active tubular secretion of Cr plays a more significant role in Cr 
excretion from the body
94
. In severe renal impairment, extra-renal elimination of Cr 
may occur in the small bowel, where bacterial overgrowth causes degradation of up to 
two thirds of total daily Cr excretion
95
. Assays of Cr are technically difficult, hampered 
by interferences up to 20% by oxidoreductive compounds and can be reduced by the 
enzymatic assay method
96
. Differences in specificity in different assays can make it 
difficult to compare values from different laboratories. Therefore serum Cr is a poor 
measure of renal dysfunction in early kidney injury. 
Equations have been developed to estimate GFR more accurately based on serum Cr to 
improve stratification of CKD, but the widely used MDRD equation has not been 
validated in CKD stages 1 and 2
99
, and the new CKD-EPI equation may be more 
reliable in CKD stages 1 and 2
101
.  
A review of previously published studies
103
 concluded that the MDRD equation 
overestimated GFR in AFD patients with normal or near normal serum Cr levels. 
Another study
104
 with a cohort of 21 patients, the MDRD and CG equations 
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overestimated GFR compared with ioxehol clearance in male AFD patients with CKD 
stages 1-2 and lower normal BMI. The present study shows that the CKD-EPI equation 
in AFD patients is the best method for calculating eGFR, especially in CKD stages 1 
and 2, followed by the MDRD equation. More recently, Rombach et al
105
 recommended 
the use of the Stevens equation (based on serum Cystatin C concentration and serum Cr) 
in AFD; however, serum Cystatin C assays are not widely available in routine clinical 
practice and this recommendation was based on a small study population (n=36). 
Currently in the UK, most pathology laboratories report eGFR based on the MDRD 
equation. Changing this current practice to incorporate the CKD-EPI equations in all 
biochemistry laboratories, would be time consuming and increase costs. Unless the 
CKD-EPI equation was to be used for monitoring all renal diseases or renal 
dysfunction, streamlining current pathology systems to monitor AFD would not be cost 
efficient. But as we have shown, the CKD-EPI equation is a fairly simple to calculate, 
individual clinicians involved in the management of AFD patients could calculate this 
with basic databases and spreadsheets, and therefore not need wholesale changes to 
pathology departments reporting systems.  
Currently there are two large international registries for AFD patients; the Fabry 
Registry and the FOS. Incorporating the CKD-EPI equation in these registries, would 
provide a more accurate monitoring of renal function of AFD patients. This could be 
done on retrospective and prospective data, thus providing more longitudinal data and 
larger numbers to determine the accuracy of the CKD-EPI equation compared to the 
MDRD eGFR, radioisotopic GFRs or iohexol GFRs. 
 
 
2.7 Limitations 
 
As with any study involving AFD, small numbers will always be a limitation. This is 
especially true for CKD stage 3, where we had only 12 patients (based on iGFR). We 
also had no patients in CKD Stage 4 and 5 and we cannot comment on the reliability of 
eGFR in AFD for these stages of CKD. 
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2.8 Conclusions 
 
In a clinical setting in which GFR may be the only criterion for determining the 
initiation of ERT, eGFR based on the CKD-EPI or MDRD equations may still not be 
sufficient and an exogenous marker-based estimate of GFR is required. However, based 
on our findings, we would recommend the CKD-EPI equation as the best method for 
estimating GFR and for monitoring renal function in AFD patients. 
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3.1 Introduction 
 
Current methods of assessment and monitoring of renal involvement in AFD 
predominantly look at glomerular function, and evidence of non-glomerular renal 
involvement would need invasive tissue diagnosis based on renal biopsy. Renal biopsies 
although invasive have been used as the primary means of diagnosing AFD and in 
clinical trials to monitor efficacy of therapeutic interventions. Renal biopsies have also 
been used to ensure that there is no second pathology occurring in AFD patients with 
renal dysfunction such as diabetic nephropathy
116
, IgA nephropathy
117-122
, focal 
segmental glomerular sclerosis
123
, minimal change glomerulonephritis
124
, crescenteric 
glomerulonephritis
125, 126
 and systemic lupus erythematosus nephropathy
127-129
. 
 
 
3.2  Renal histopathology in AFD 
 
Renal histopathological changes in AFD has been described based on autopsies and 
renal biopsies, in male
130-133
 and female
130, 134
 patients. Characteristic renal pathological 
findings are vacuolisation of podocytes (Fig 3.1), tubular epithelial cells and vascular 
endothelial cells (GB3 deposition)
115, 116, 122, 135, 136
, mesangial expansion
115, 116, 135
, 
segmental and global glomerulosclerosis
115, 116, 122, 135, 137
, tubular atrophy
115, 116, 122, 135, 
137
, interstitial fibrosis
115, 116, 122, 135, 137
, vascular medial thickening and chronic 
inflammatory infiltrates. Females can be as affected as males
115, 116, 122
 and renal 
histopathological changes are present even with normal renal function and minimal or 
no proteinuria
115, 138
.  
Ultrastructural changes include inclusion bodies in the cytoplasm of all types of renal 
cells, characteristic onion skin or zebra appearance due to concentric lamellation (Fig 
3.2). These osmiophillic, myelinic bodies are found in tubular epithelial cells, all 
glomerular cells especially the podocytes, and in endothelial vascular cells
116, 135, 136, 139, 
140
. Other diseases that can mimic these pathological changes seen in AFD are silicon 
nephropathy
141
 and chloroquine induced phospholipidosis
142, 143
. Podocyte effacement is 
only apparent on electron microscopy when there is overt proteinuria
115, 116, 122
 
suggesting preservation of foot processes and slit diaphragms early on when proteinuria 
is absent.  
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Fig 3.1. Renal pathology in AFD from Alroy et al
135
. (A) Glomerulus showing extensive inclusion bodies 
of glycolipid in podocytes (arrowhead), and mild mesangial widening (PAS stain; magnification, _80). 
(B) Plastic embedded tissue showing in-site deposition of glycolipid in glomerular podocytes (arrowhead; 
toluidine blue stain; magnification, _80). (C) Plastic embedded renal tissue demonstrating glycolipid 
inclusion bodies in distal tubules (asterisk), with relative sparing of proximal tubules, and interstitial 
fibrosis (toluidine blue stain; magnification, _80). (D) Deposition of glycolipid in endothelial cells of 
peritubular capillaries (asterisk; toluidine blue stain; magnification, _200). (E) Urine showing vacuolated 
urinary epithelial cells (oval fat bodies) in a Fabry patient (Papanicolaou stain; magnification, _160). 
Figure modified with permission from Branton et al
55
. 
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Fig 3.2. Electron microscopy showing concentric lamellar inclusion bodies called Zebra bodies (Images 
courtesy of Jackie Lewin, Head Clinical scientist, EM Unit, UCL Medical School, Royal Free Campus). 
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Age has been shown to correlate with composite glomerular pathology scores but not 
tubulointerstial scores or glycolipid inclusions
55
. Glomerular pathology and 
tubulointerstial scores were also higher in patients with undetectable plasma α-Gal 
activity (<1%) but glycolipid scores were similar regardless of plasma α-Gal activity55. 
In males glomerular segmental or global sclerosis is the only significant pathological 
association with proteinuria in early AFD renal disease
115
. Tondel et al described renal 
lesions in children with normal GFR values but with slightly elevated urine albumin but 
could not correlate GB3 inclusion scores with age
138
. The International Study Group of 
Fabry Nephropathy also reported no relationship between light microscopy scoring 
system for renal lesions and renal fucntion
144
. More recently Najafian et al has shown in 
children (median age 12 years) the progressive accumulation of GB3 deposits in 
podocytes with normal GFR and absent or low-grade proteinuria. Using quantitative 
stereological electron microscopy methods, progressive accumulation of podocytes GB3 
inclusions can be correlated with increasing age
145
. The progressive accumulation of 
GB3 in podocytes is thought to be because podocytes are terminally differentiated and 
proliferate poorly in response to injury or loss
146
. 
 
 
3.3 Renal pathogenesis in AFD 
 
Ischaemic tissue damage
115, 135, 137
 from microvascular endothelial disease and/or 
necrosis of vascular smooth muscles and/or pericyte injury
147-149
 maybe the cause of 
these non-specific renal pathological findings. Injury from GB3 overloaded podocytes 
maybe another mechanism of glomerulosclerosis
135, 150
 and membranofibrillary deposits 
seen in cytoplasm
115, 116, 122
 are remnants of GB3 inclusions of dead cells. Mesangial cell 
necrosis
115
, direct toxic injury to tubular cells
135
 and glomerular proteinuria causing 
tubular injury as it passes down the lumen
151
 are thought to play roles in progressive 
renal dysfunction in AFD.  
 
 
3.4 Rationale for study 
 
i) Lipid laden distal tubular epithelial cells desquamate and can be detected in 
urinary sediment
152
 indicating possible renal tubular damage. These cells 
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containing glycosphingolipids (mainly GB3) in the urine are visualised as oval 
fat bodies with light microscopy and as maltese crosses when viewed by 
polarised light
136, 140
. 
ii) Currently non-invasive renal investigations in AFD and indications to start ERT 
do not account for renal tubular damage. 
iii) GB3 may be causing direct or indirect renal damage which eventually leads to 
renal scarring and fibrosis. 
iv) Serum Cr and estimation of GFR based on serum Cr may be insufficient to 
detect early renal dysfunction. 
 
 
3.5 Aims 
 
i) To investigate urine α-galactosidase A activity in AFD patients and healthy 
controls 
ii) To investigate if lysosomal enzymuria is an earlier marker of renal dysfunction 
or correlates with end organ damage in AFD 
iii) To determine if other markers of tubular dysfunction are an earlier marker of 
renal involvement in AFD 
iv) To determine if urine markers of renal fibrosis are elevated in AFD 
 
 
3.6 Hypothesis 
 
Urine biomarkers of glomerular or tubular dysfunction or renal fibrosis can be detected 
prior to clinically apparent renal disease. 
 
 
3.7 Rationale for urine proteins tested 
 
3.7.1 α-Galactosidase A 
Human α-Galactosidase A (α-Gal) is a lysosomal glycohydrolase that catalyzes 
the hydrolysis of terminal α-galactosyl residues from glycoproteins and 
glycolipids
153
. Human α-Gal is a homodimeric glycoprotein31 with a molecular 
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weight of 110 kDa. It is encoded by the GLA gene localised to the chromosomal 
region Xq22.1
3, 4, 154, 155
. Reduced or absent activity of this enzyme results in a 
X-linked lysosomal storage disorder called AFD
27, 153
. This leads to the 
accumulation of galactosylated substrates, primarily GB3. 
Christensen et al
156
 described the distribution of α-Gal in the normal kidney. In 
the renal cortex α-Gal is predominantly present in the proximal convoluted 
tubules, thick ascending limb of the Loop of Henle and in interstitial cells, and in 
the renal medulla present in the collecting ducts and thin limb of the loop of 
Henle. α-Gal was not demonstrated in the glomerular cells including podocytes, 
parietal epithelial cells of Bowman’s capsule and vascular endothelial cells. This 
was an unexpected finding as there is GB3 accumulation in these cell types in 
AFD patients, suggesting that there should be normal α-Gal activity and α-Gal 
present in these cell types in normal humans. The authors explained this finding 
a by saying that enzyme analysis may have been below the detection limit of 
their method used. The authors also showed increased urine α-GAL activity in 
AFD mice, after ERT infusions and concluded there was glomerular filtration of 
the recombinant enzyme
156
 but due to its relatively large molecular weight α-Gal 
is more likely to be secreted from lysosomes of tubular cells
157
. Immunolabelled 
recombinant enzyme accumulated in renal proximal tubules, interstitial cells and 
glomerular podocytes but not in renal vascular endothelial cells. 
To date there are few studies measuring urine α-GAL activity. Urine α-GAL 
activity has been shown to remain stable at 4˚C, 25˚C and 37˚C over a 4 hour 
period and at -70˚C over 1 month158. There is a trend in a decrease of the 
fractional excretion of α-GAL (non-significant) and a decrease in urine α-GAL 
activity in urine (significant) as age increases, but without any correlation to 
inulin clearance
159
 (gold standard for estimating true GFR). Also the fractional 
excretion of α-GAL decreases in pregnancy160 and in sickle cell patients161 . 
There is no difference in urine α-GAL activity in diabetics compared to non-
diabetics
162
 and between bladder cancer patients and matched controls
163
, but 
urine α-GAL activity increases in severely malnourished children164 and in 
preeclampsia
165
. 
In AFD there have been 3 reported studies of urine α-GAL. Berty et al measured 
fractional excretion of α-GAL in an AFD male with a functioning renal 
transplant in relation to induced acute acidosis and alkalosis
166
. Hamers et al 
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demonstrated that in AFD females, urine α-GAL activity was within the normal 
range
167
 while Kitigawa et al showed AFD males and females had significantly 
lower urine α-GAL activity than controls168. 
 
3.7.2  β-Hexominidase 
β-Hexominidase (β-Hex) is a 130 kDa lysosomal enzyme which hydrolyses the 
terminal non-reducing N-acetyl-D-hexosamine residues in N-acetyl-beta-D-
hexosaminides. It is also known as β-N-acetylhexosaminidase or N-acetyl-beta-
glucosaminidase (NAG). Functional β-Hex is dimeric in structure and made up 
of 3 isoenzymes with either α or β subunits. β-Hex A (α/β heterodimer) is able to 
cleave GM2 gangliosides, GA2 gangliosides, globosides, and hexosamine 
oligosaccharides and β-Hex B (β/β homodimer) is able to cleave all the above 
except for GM2 gangliosides. Deficiency of β-Hex A causes Tay-Sachs disease 
and deficiencies of both β-Hex A and B causes Sandhoff disease.  
β-Hex is present in tissues other than the kidney and is rapidly cleared by the 
liver as shown in rat experiments
169, 170. β-Hex is not normally filtered at the 
glomeruli (MW 130 kDa) and is secreted from lysosomes of tubular cells
171
. 
Immunohistochemistry has located β-Hex to the renal proximal tubules172. 
Urinary excretion of β-Hex is relatively constant with minimal diurnal 
changes
173, 174
, and is stable against changes of temperature and pH. In urine of 
healthy humans, β-Hex is present in similar amounts throughout adulthood173 
with isoenzyme A to isoenzyme B ratio of 4:1 (kidney) to 10:1(urine)
175
. The 
fractional excretion of β-Hex decreases in pregnancy160 and increases with 
age
159
, and this is related to either reduced tubular reabsorption or increased 
tubular secretion as changes were independent of glomerular filtration measured 
by inulin clearance. Increase in urinary β-Hex activity indicates damage to 
tubular cells or interstitial renal damage
171, 173, 176-178
 but can also reflect 
increased lysosomal activity without cellular damage.  
Urinary β-Hex activity has been used as a non-invasive, sensitive and reliable 
indicator of renal damage in a variety of conditions; vesicoureteric reflux
179
, 
diabetic nephropathy
180-182
, polycystic kidney disease
183
, Henoch-Schonlein 
purpura
184
, hypertensive nephropathy
185, 186
, pre-eclampsia
161, 165
, obstructive 
uropathy
187
, hypercalciuria
188
, nephrotoxic drugs related nephropathy
189-192
 and 
protein energy malnutrition
164
. 
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To our knowledge only two studies have investigated urine β-Hex in AFD 
patients. First was in an AFD male with a functioning renal transplant 
demonstrating changes in urinary lysosomal enzymuria with induced acid – base 
changes
166
 and by Rietra et al, showing that urine β-Hex:α-Gal ratios are raised 
in AFD males and females
193
. 
 
3.7.3  Chitotriosidase 
Chitotriosidase is a 39-50 kDa hydrolase and member of a family of 
glycosylhydrolases called chitinases and has the capability to hydrolyse chitin. It 
is mainly expressed by activated macrophages
194
 and neutrophils
195
. This 
macrophage derived enzyme had been discovered to be grossly elevated in 
untreated patients with Gaucher’s disease196 and modestly increased in other 
inherited lysosomal storage disorders, especially sphingolipidoses such as 
Niemann Pick
197
 GM1-gangliosidosis and Krabbe’s disease198, 199. Its level 
decreases with successful ERT
200
. It is therefore a very useful biomarker for 
Gaucher’s disease201, 202 and measurement of chitotriosidase activity is a reliable 
and easy way of monitoring therapy. Increased chitotriosidase activity has been 
observed in serum of patients with atherosclerosis
203-205, β-thalassaemia206 and 
acute Plasmodium falciparum malaria
207
. More recently chitotriosidase has been 
thought to be important during immunological response and inflammatory 
processes
208-213
. 
Urinary chitotriosidase is elevated in Gaucher patients and corrects with 
treatment
214
 and elevated in neonates with fungal and bacterial infection 
reflecting phagocyte activity
215
. In AFD two studies have shown that plasma 
chitotriosidase levels are elevated in male hemizygotes but not females, and in 
male hemizygotes elevated plasma chitotriosidase levels reduce with ERT
216, 217
. 
 
3.7.4 Retinol binding protein 
Retinol binding protein (RBP) is a 21kDa plasma protein of the lipocalin 
superfamily first described by Kanai et al in 1968
218
. RBP is synthesized in the 
liver and requires the binding of retinol to trigger its secretion
219
. In the plasma 
RBP binds to the larger protein transthyretin with a resulting molecular mass of 
80 kDa preventing loss of RBP by glomerular filtration
220
. Unbound RBP is 
filtered at the glomeruli, reabsorbed in the proximal tubules after binding to 
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megalin
221
 where it is catabolised
220
. RBP production is relatively constant, and 
the protein is very stable across whole range of urinary pH
222
. RBP serves as an 
important molecule in regulation and mobilisation of vitamin A from the liver to 
cell surfaces. 
Plasma levels of RBP are reduced in liver disease
223, 224
, inadequate dietary 
vitamin A intake
225-228
 and inflammation
229, 230
, and plasma RBP is increased in 
CKD
223, 224, 231-234
. Urine RBP levels are increased in  renal insufficiency
231, 232, 
235
 and has been shown to be a urinary marker of tubular dysfunction
231, 236-238
. 
More specifically it is increased in tubulo-interstitial nephropathy
239
, in heart 
transplant patients which predicted increased risk of renal failure over 5 years 
follow up
240
 and in renal transplants which predicted graft dysfunction 
241, 242
.  
More recently plasma RBP levels have been reported to be elevated in insulin 
resistant subjects and in subjects with obesity and/or type 2 diabetes
243-245
 due to 
upregulation of RBP in adipocytes
243
 but may more likely be related to impaired 
glomerular filtration manifested as decreased GFR
234, 246, 247
 or 
microalbuminuria
248
 rather than type 2 diabetes. 
To our knowledge in the AFD population, only 1 author has shown an increase 
in urine RBP by western blotting method (2 out 12 AFD patients)
156
. 
 
3.7.5 Transforming growth factor-β1 
Transforming growth factor-β1 (TGF-β1) is a 25kDa, disulfide-linked, non-
glycosylated homodimer, secreted by most cell types, generally in a latent form, 
requiring activation before exerting biological effect. It is an important 
endogenous mediator of growth, maintenance and repair processes in the 
developing of the embryo, neonate and adult. Major activities are to inhibit the 
proliferation of most cells but can stimulate the growth of some mesenchymal 
cells, exert immunosuppressive effects and enhance the formation of 
extracellular matrix.  
Increased levels of TGF-β1 has been described in animal models of renal 
disease, especially associated with renal scarring
249-251
. TGF-β1 is the principal 
mediator of diabetic renal complications and is important in the development of 
hypertrophy and accumulation of extracellular matrix
252, 253
. Neutralising TGF-
β1 has been to shown to reduce renal scarring and diminish the loss of renal 
function
254-256
. 
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Urinary TGF-β1 levels were shown to be raised in patients with diabetes257-263, 
focal glomerular sclerosis
264, 265
, IgA nephropathy
261, 265
, systemic lupus 
erythematosus
261
, membranous nephropathy
266
 and crescenteric 
glomerulonephritis
267
. Sato et al also showed urinary TGF-β1 was higher in 
patients with increased mesangial expansion and higher HbA1c, but did not 
correlate with serum TGF-β1, serum Cr or tubular proteinuria259. This probably 
reflects increased urinary TGF-β1 was due to increased production in the kidney 
of TGF-β1 rather than increased filtration or reduced tubular reabsorption. 
Higher urinary TGF-β1 levels have be shown by other authors to be associated 
with mesangial proliferation
261, 265
. In IgA nephropathy high urinary TGF-β1 
levels reduced after treatment with steroid therapy
268
 and higher baseline urinary 
TGF-β1 in crescenteric glomerulonephritis was associated with a poorer renal 
outcome
267
. Therefore urinary TGF-β1 levels may be a means of predicting or 
monitoring treatment response. 
 
3.7.6 Monocyte chemotactic protein 1 
Monocyte chemotactic protein 1 (MCP-1/CCL2) is a 13kDa
269
, potent monocyte 
attractant, also known as monocyte chemotactic and activating factor (MCAF), 
and is a member of the CC subgroup of chemokine superfamily
270
. MCP-1 is 
produced by many cell types including epithelial, endothelial, smooth muscle, 
fibroblasts, astrocytes, monocytes and microglia cells
271-273
, however the major 
source of MCP-1 are monocytes and macrophages
274, 275
. MCP-1 is thought to be 
an important player in the inflammatory processes. Blocking MCP-1 can 
suppress models of endotoxaemia, delayed-type sensitivity reactions, and 
inflammatory arthritis, and overexpression enhances the recruitment of 
monocytes and lymphocytes in vivo
276-279
. Elevated MCP-1 levels in human 
have been associated with sepsis
280, Crohn’s disease281, lupus nephritis282, 
amyotrophic lateral sclerosis
283
, multiple sclerosis
284
, rheumatoid arthritis
285
 and 
artherosclerosis
286
. It is also upregulated in several cancers including gastric 
carcinoma
287
, oesophageal squamous cell carcinoma
288
, malignant glioma
289
 and 
ovarian
290
, bladder
291
 and breast cancers
292
. 
In the kidney, MCP-1 is produced by a variety of mesenchymal cells including 
glomerular cells
293-295
. MCP-1 has the potential to drive the process of renal 
fibrosis indirectly by macrophage recruitment and also via direct induction of 
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fibrotic response in glomerular mesangial cells
296
. Over expression of MCP-1 
has been found in various proteinuric conditions, such as diabetic, hypertensive 
and membranous nephropathies
297-299
. Urinary MCP-1 has been shown to be 
significantly higher in lupus nephritis
300-304
, diabetic nephropathy
305-310
, IgA 
nephropathy
307, 311, 312
, inflammatory glomerulopathies
313
, acute renal allograft 
rejection
314, 315
, urolithiasis
316, 317
, renal vasculitis
318, 319
 and crescenteric 
glomuerulonephritis
320
. 
 
 
3.8 Materials and methods 
 
Patients were recruited from the lysosomal storage disorders unit at the Royal Free 
Hospital from Nov 2006 till Feb 2009. Study was approved by the NHS Research Ethics 
Committee (REC reference 07/Q0501/81). Patients recruited had to give informed and 
signed consent and have a documented mutation in the α-Galactosidase A gene. 
Controls were recruited from healthy volunteers working at the Royal Free Hospital 
Haematology department. They provided random morning urine samples only. 
 
3.8.1 Sample collection and storage 
Two approximately 10-15 ml random morning urine samples were collected. 
The first sample was analysed by the pathology department of the Royal Free 
Hospital for urine albumin, urine protein and urine Cr as part of the patients’ 
routine clinical assessment. The second sample was aliquoted into 1ml 
containers and frozen at -80˚C and stored for future analysis of various urine 
proteins. When analysis was ready to be carried out, 1ml aliquots were defrosted 
at room temperature and analysed within 1 hour. Samples were not refrozen and 
stored again once defrosted. 
 
3.8.2 Urine protein analysis 
 The following urine proteins analysed were carried out by me at the 
haematology research laboratory at the Royal Free hospital. 
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3.8.2.1 α-Galactosidase A (α-Gal) 
 
Principle
321, 322
: 
   4-methylumbelliferyl-α-D-galactopyranoside 
       
α-Galactosidase A at Acid pH 4.8 
 
4-methylumbelliferone (4MU) + Galactose 
 
Adding an alkaline buffer stops the enzyme reaction and causes 4-
methylumbelliferone (4MU) to fluorescence at different wavelength from the 
unhydrolysed substrate. α-Galactosidase A contributes 95% of total activity in 
leucocytes and α-Galactosidase B may contribute significantly to total α-
galactosidase activity in other cells and is inhibited by N-acetyl-D-
galactosamine. A relatively large sample is needed as there is decreased 
fluorescence due to quenching especially in haemolysed or jaundiced samples 
and increased fluorescence due to presence of other fluorescence material e.g. 
drugs. This is corrected by use of Substrate blank, Standard and Standard Blank. 
 
Reagents: 
1. Buffer: 0.5M acetate pH 4.8 
Solution X - Prepare a 0.5M solution in distilled water of sodium acetate.  
Solution Y - Prepare a 0.5M solution in distilled water of glacial acetic acid 
Mix 56.6ml of Solution X and 43.4ml of Solution Y to give 0.5M acetate pH 
4.8. 
2. Substrate: 4-methylumbelliferyl-α-D-galactopyranoside 250mg (MWt 
338) Sigma Aldrich. 
Solution A - Dissolve 250mg substrate in 74ml of 0.5M acetate buffer by 
warming to 80
o
C (which can be stored indefinitely at -20
o
C but will need 
warming to dissolve when removed from the freezer). Store in 11.3ml 
aliquots. 
3. Inhibitor: N-acetyl-D-galactosamine 500mg (MWt 221.2) Sigma 
Aldrich. 
4. Substrate+Inhibitor: 
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Solution B is the substrate/inhibitor working solution. Dissolve 500mg of 
inhibitor in 11.3ml of substrate solution A (Can be stored at -20
o
C 
indefinitely but will need warming to dissolve when removed from the 
freezer).  
5. Standard: 4-methylumbelliferone (MWt 176) Sigma Aldrich. 
Stock standard solution - Dissolve 176mg in 1ml methanol then make up to 
1 litre with distilled water 
Working standard - Dilute 100μl stock standard solution in 19.9ml distilled 
water to give 1nmol per 200ul.  
Both stock and working solutions are stable indefinitely when stored at -
20
o
C. 
6. Stopping Reagent: 1M glycine buffer pH 10.4. 
Solution C - Dissolve 75g glycine and 58g sodium chloride in 1 litre of 
distilled water. 
Solution D - 1M sodium hydroxide solution. 
Add 55.7ml of solution C to 44.3ml solution D to give 1M glycine buffer pH 
10.4. 
 
Methodology: 
A 24 well microtitre plate is divided into 4 rows of 5 wells as in Fig 3.3. Each 
plate can test 4 different samples. Into the 4
th
 and 5
th
 wells (samples in duplicate) 
of each row, pipette 100μl sample urine and 100ul solution B (substrate + 
inhibitor solution) and mix well. Into the 3
rd
 well (Substrate Blank) pipette 100μl 
solution B. Incubate the microtitre plate at 37
o
C for 2 hours. Add 1.0ml stopping 
reagent into wells 3, 4 and 5 and mix. Add 100μl sample urine to well 1 
(Standard), well 2 (Standard Blank) and well 3 (Substrate Blank). Pipette 200μl 
working standard and 0.9ml stopping reagent into well 1. Pippette 200μl distilled 
water and 0.9ml stopping reagent into well 2. Mix well. The total volume of 
each well is 1.2ml. Fluorescence is read using a flurometer from Fluostar 
Galaxy, BMG Lab Technologies, using an excitation wavelength of 360nm and 
emission wavelength 460nm. 
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           1  2  3  4  5 
Empty Standard 1 Standard 
Blank 1 
Substrate 
Blank 1 
S1 S1 
Empty 
 
Standard 2 Standard 
Blank 2 
Substrate 
Blank 2 
S2 S2 
Empty 
 
Standard 3 Standard 
Blank 3 
Substrate 
Blank 3 
S3 S3 
Empty 
 
Standard 4 Standard 
Blank 4 
Substrate 
Blank 4 
S4 S4 
Fig 3.3. Schematic layout of 24 well microtitre plate for α-Gal analysis. 
 
Calculating activity: 
For each sample, Standard – Standard blank = fluorescence of 1nmol 4MU. 
Average the test reading for duplicate of samples = T  
Standard = St 
Standard Blank = StB 
Substrate Blank for each sample = SB 
 
Activity of α-Galactosidase A 
  (T – SB)  60  1000 
= -------- x --- x ----  (nmol/hr/ml urine) 
(St – StB)  120  100 
[2 hr correction] [conversion to per ml urine] 
 
If the sample has to be diluted multiply the reading by the dilution factor before 
subtracting the blank reading. These sample values are then standardised for 
urine Cr. 
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3.8.2.2 β-Hexosaminidase (β-Hex) 
 
Principle
323, 324
: 
   4-methylumbelliferyl-N-acetyl-β-D-glucosaminide 
       
β-N-acetylhexosaminidase at Acid pH 4.6 
 
4-methylumbelliferone (4MU) + N-acetyl-D-hexosamine 
 
Adding an alkaline buffer stops the enzyme reaction and causes 4-
methylumbelliferone (4MU) to fluorescence at different wavelength from the 
unhydrolysed substrate. A relatively large sample is needed as there is decreased 
fluorescence due to quenching especially in haemolysed or jaundiced samples 
and increased fluorescence due to presence of other fluorescence material e.g. 
drugs. This is corrected by use of Substrate blank, Standard and Standard Blank. 
 
Reagents: 
1. Buffer: 0.1M Citrate Phosphate Buffer (McIlvaine Solution) pH 4.5 
Prepare a 0.1M solution in distilled water of Citric Acid (Solution X). 
Prepare a 0.1M solution in distilled water of Na2HPO4.2H2O (Solution Y). 
Mix 55ml of solution X and 45 ml of solution Y to give 0.1M Citrate 
Phosphate Buffer pH 4.2.  
2. Substrate: 0.1mM 4-Methylumbelliferyl N-acetyl-β-D-glucosaminide 
(MWt 379.4) Sigma Aldrich 
Dissolve 3.8mg substrate in 100 ml in 0.1M Citrate Phosphate Buffer 
(McIlvaine Solution) pH 4.5 by warming to 80
o
C. Store at -20
o
C in 5ml 
aliquots. 
3. Standard: 4-methylumbelliferone (MWt 176) Sigma Aldrich. 
Stock standard solution - Dissolve 176mg in 1ml methanol then make up to 
1 litre with distilled water 
Working standard - Dilute 100μl stock standard solution in 19.9ml distilled 
water to give 1nmol per 200μl.  
Both stock and working solutions are stable indefinitely when stored at -
20
o
C. 
70 | P a g e  
 
4. Stopping Reagent: 1M glycine buffer pH 10.4. 
Solution C - Dissolve 75g glycine and 58g sodium chloride in 1 litre of 
distilled water. 
Solution D - 1M sodium hydroxide solution. 
Add 55.7ml of solution C to 44.3ml solution D to give 1M glycine buffer 
pH 10.4. 
 
Methodology: 
A 24 well microtitre plate is divided into 4 rows of 5 wells as in Fig 3.4. Each 
plate can test 4 different samples. Into the 4
th
 and 5
th
 wells (samples in duplicate) 
of each row, pipette 100μl sample urine and 100μl substrate solution and mix 
well. Into the 3
rd
 well (Substrate Blank) pipette 100μl substrate solution only. 
Incubate microtitre plate at 37
o
C for 15 minutes. Add 1.0ml stopping reagent 
into wells 3, 4 and 5 and mix. Add 100μl sample urine to well 1 (Standard), well 
2 (Standard Blank) and well 3 (Substrate Blank). Pipette 200μl working standard 
and 0.9ml stopping reagent into well 1. Pipette 200μl distilled water and 0.9ml 
stopping reagent into well 2. Mix well. Total volume of each well is 1.2ml. 
Fluorescence is read using a flurometer from Fluostar Galaxy, BMG Lab 
Technologies, using an excitation wavelength of 360nm and emission 
wavelength 460nm. 
 
           1  2  3  4  5 
Empty Standard 1 Standard 
Blank 1 
Substrate 
Blank 1 
S1 S1 
Empty 
 
Standard 2 Standard 
Blank 2 
Substrate 
Blank 2 
S2 S2 
Empty 
 
Standard 3 Standard 
Blank 3 
Substrate 
Blank 3 
S3 S3 
Empty 
 
Standard 4 Standard 
Blank 4 
Substrate 
Blank 4 
S4 S4 
Fig 3.4. Schematic layout of 24 well microtitre plate for β-Hex analysis 
 
Calculating activity: 
 For each sample, Standard – Standard blank = fluorescence of 1nmol 4-MU. 
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Average the test reading for duplicate of samples = T  
Standard = St 
Standard Blank = StB 
Substrate Blank for each sample = SB 
 
Activity of β-Hexosaminidase 
  (T – SB)  60  1000 
= -------- x --- x ----  (nmol/hr/ml urine) 
(St – StB)  15  100 
[15 mins correction] [conversion to per ml urine] 
 
If the sample has to be diluted multiply the reading by the dilution factor before 
subtracting the blank reading. These sample values are then standardised for 
urine Cr. 
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3.8.2.3 Chitotriosidase 
 
Principle
196
: 
   4-methylumbelliferyl-β-D-N,Ni,Nii-triacetylchitotriose 
       
Chitotriosidase at pH 5.2 
 
4-methylumbelliferone (4MU) + Chitotrioside 
 
Adding an alkaline buffer stops the enzyme reaction and causes 4-
methylumbelliferone (4MU) to fluorescence at different wavelength from the 
unhydrolysed substrate. 
 
Reagents: 
1. Buffer: McIlvaine Citrate Phosphate Buffer 0.15M pH 5.2 
Prepare a 0.1M solution in distilled water of Citric Acid (Solution X). 
Prepare a 0.2M solution in distilled water of Na2HPO4.2H2O (Solution Y). 
Mix 46.8ml of solution X and 53.1 ml of solution Y to give 0.15M Citrate 
Phosphate Buffer pH 5.2.  
2. Substrate: 4-methylumbelliferyl-chitotrioside 1mg (MWt 786) Sigma 
Aldrich. 
 Dissolve 1mg of substrate in 57.8ml of 0.15M citrate phosphate buffer pH 
5.2 (M
c
Ilvaine buffer) by warming to 80
o
C. Store at -20
o
C in 5ml aliquots. 
3. Standard: 4-methylumbelliferone (MWt 176) Sigma Aldrich. 
 Dissolve 176mg in 1 litre of distilled water by warming to 80
o
C – stock 
standard solution. Dilute 100μl stock standard solution in 19.9ml distilled 
water to give working standard – 1nmol per 200μl. Both stock and working 
solutions are stable indefinitely when stored at -20
o
C.  
4. Stopping Reagent: 1M glycine buffer pH 10.4. 
Solution C - Dissolve 75g glycine and 58g sodium chloride in 1 litre of 
distilled water. 
Solution D - 1M sodium hydroxide solution. 
Add 55.7ml of solution C to 44.3ml solution D to give 1M glycine buffer 
pH 10.4. 
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Methodology: 
A 24 well microtitre plate is divided into 4 rows of 6 wells as in Fig 3.5. Each 
plate can test 4 different samples. In the 3
rd
 and 4
th
 wells add 5μl deionised water 
with 100μl substrate. In the 5th and 6th wells add 5μl sample with 100μl 
substrate. Incubate microtitre plate at 37
o
C for 1 hour. Add 1.0ml stopping 
reagent into wells 3, 4, 5 and 6. In the 1
st
 and 2
nd
 wells add 200μl of standard and 
0.9ml of stopping reagent. Fluorescence is read using a flurometer from Fluostar 
Galaxy, BMG Lab Technologies, using an excitation wavelength of 360nm and 
emission wavelength 460nm. 
 
         1  2  3  4  5  6 
Standard 1 Standard 1 Substrate 
Blank 1 
Substrate 
Blank 1 
S1 S1 
Standard 2 
 
Standard 2 Substrate 
Blank 2 
Substrate 
Blank 2 
S2 S2 
Standard 3 
 
Standard 3 Substrate 
Blank 3 
Substrate 
Blank 3 
S3 S3 
Standard 4 
 
Standard 4 Substrate 
Blank 4 
Substrate 
Blank 4 
S4 S4 
Fig 3.5. Schematic layout of 24 well microtitre plate for chitotriosidase analysis. 
 
Calculating activity: 
For each sample Standard – Substrate blank = fluorescence of 1nmol 4MU. 
Average the test reading for duplicate of samples = T  
Average of Standard = St 
Average of Substrate Blank = SB 
Activity of Chitotriosidase 
  (T – SB)  1.105  1000  
= -------- x ----- x ----  (nmol/hr/ml urine) 
(St – SB)  1.100  5 
[volume correction] [conversion to per ml urine] 
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If the sample has to be diluted multiply the reading by the dilution factor before 
subtracting the blank reading. These sample values are then standardised for 
urine Cr. 
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3.8.2.4 Retinol Binding Protein (RBP) 
 
Principle: 
A double antibody sandwich ELISA (Enzyme-Linked Immunosorbent Assay) 
from Immunology Consultants Laboratory, for quantitative determination of 
RBP in biological samples, was used. In the first incubation step, RBP in 
samples react with the anti-RBP antibodies which have been adsorbed to the 
surface of polystyrene microtitre wells. After removal of unbound sample 
proteins by washing, anti RBP antibodies was conjugated with horseradish 
peroxidise that had been added. These enzyme-labelled antibodies form 
complexes with previously bound sample RBP. After another washing step, the 
enzyme bound to the immunosorbent is assayed by the addition of a 
chromogenic substrate. The quantity of bound enzyme varies directly with the 
concentration of RBP. A dose response curve of absorbance unit (optical density 
at 450nm) versus concentration is generated using values obtained from 
standard. RBP present in the patient samples is determined directly from this 
curve. 
 
Reagents: 
1. Diluent: 
50ml of 5x concentrated phosphate buffered saline (PBS) solution containing 
bovine serum albumin, 0.25% Tween, and 0.1% Proclin300 as a 
preservative. Diluted 1:5 with deionised water, stored at 4-8˚C for up to 1 
week. 
2. Wash solution concentrate: 
50ml of 10x concentrated PBS solution containing 0.5% Tween. Warm 
concentrate to 30-35˚C before dilution. Dilute 1:10 with deionised water, 
stored 4-8˚C for up to 1 week. 
3. Enzyme-Antibody conjugate: 
200μl of 100x concentrated affinity purified anti-Human RBP antibody 
conjugated with horseradish peroxidase in a stabilising buffer. Dilute 100μl 
of 100x concentrated enzyme-antibody conjugate with 10ml of diluent, 
stable for 1 day. 
4. Chromogen-substrate solution: 
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12ml of 3,3’,5,5’-tetramethbenzidine (TMB) and hydrogen peroxide in citric 
acid buffer at pH 3.3 
5. Stop Solution: 
12ml 0.3M sulphuric acid 
6. Anti-Human RBP ELISA microplate: 
96 microwell plate. Each well coated with affinity purified anti-Human RBP 
7. Human RBP calibrator: 
Lyophilized Human RBP. Add 1.0 ml of deionised water to the Human RBP 
calibrator, mix gently until dissolved. Concentration now is at 4.25μg/ml. 
This can be frozen and stored at -20˚C in aliquots. Human RBP standards 
need to be prepared immediately prior to use. 
 
Methodology: 
1. Dilute urine samples 1:20 with diluent. 
2. Prepare standards as follows 
Standard Concentration 
(ng/ml) 
Volume of 
calibrator or 
standard added 
Volume of Diluent 
added 
1 250 50 μl of calibrator 800 μl 
2 125 250 μl of Standard 1 250 μl 
3 62.5 250 μl of Standard 2 250 μl 
4 31.25 250 μl of Standard 3 250 μl 
5 15.625 250 μl of Standard 4 250 μl 
6 7.8125 250 μl of Standard 5 250 μl 
7 3.90625 250 μl of Standard 6 250 
3. Set up RBP ELISA microplate as follows [Diluent (D), Standard (S) and 
urine samples (U)], adding 100ul of diluent, standard or diluted urine sample 
to corresponding well, in duplicate.  
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D D U1 U1 U9 U9 U17 U17 U25 U25 U33 U33 
S1 S1 U2 U2 U10 U10 U18 U18 U26 U26 U34 U34 
S2 S2 U3 U3 U11 U11 U19 U19 U27 U27 U35 U35 
S3 S3 U4 U4 U12 U12 U20 U20 U28 U28 U36 U36 
S4 S4 U5 U5 U13 U13 U21 U21 U29 U29 U37 U37 
S5 S5 U6 U6 U14 U14 U22 U22 U30 U30 U38 U38 
S6 S6 U7 U7 U15 U15 U23 U23 U31 U31 U39 U39 
S7 S7 U8 U8 U16 U16 U24 U24 U32 U32 U40 U40 
 
4. Incubate at room temperature (22˚C) for 60 minutes (± 2 minutes). 
5. Aspirate contents of well and wash with wash buffer four times. 
6. Pipette 100μl of diluted enzyme-antibody conjugate to each well. 
7. Incubate in the dark at room temperature for 10 minutes (± 2 minutes). 
8. Aspirate contents of well and wash with wash buffer four times. 
9. Pipette 100μl of TMB substrate into each well. 
10. Incubate in the dark at room temperature for exactly 10 minutes. 
11. Add 100μl of stop solution into each well. 
12. Determine the absorbance at 450 nm. 
 
Calculating Results: 
The absorbance for each sample is calculated by subtracting the average 
absorbance of the diluents (background value) from the average of duplicate 
samples. 
Absorbance Sample 1 = [Average U1 – Average D] 
Using results from the observed standards, a Standard Curve is constructed. 
Sample values are interpolated from the standard curve and multiplied by 20 to 
correct for dilution of original sample. These sample values are then 
standardised for urine Cr. 
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3.8.2.5 Transforming Growth Factor β1 (TGF-β1) 
 
Principle: 
A quantitative sandwich enzyme immunoassay technique from R&D systems is 
used. A monoclonal antibody specific to TGF-β1 has been pre-coated onto a 
microplate. Standards and samples are pipette into wells and any TGF-β1 
present is bound by the immobilized antibody. After washing away any unbound 
substances, an enzyme-linked polyclonal antibody specific for TGF-β1 is added 
to the wells. Following a wash to remove any unbound antibody-enzyme 
reagent, a substrate solution is added to the wells and colour develops 
proportional to the amount of TGF-β1 bound in the initial step. This colour 
development is stopped and the intensity of the colour is measured. 
 
Reagents: 
1. Calibrator Diluent (RD5-53) concentrate: 
21ml/vial of concentrated buffered protein base with preservatives. Dilute 
1:4 with deionised water. Maybe stored for up to 1 month at 2-8˚C. 
2. Assay Diluent (RD1-21): 
12.5ml/vial of a buffered protein solution with preservatives. Maybe stored 
for up to 1 month at 2-8˚C. 
3. Wash Buffer concentrate: 
50ml/vial of 25x concentrated solution of buffered surfactant with 
preservatives. Warm to room temperature and mix gently with deionised 
water at a dilution of 1:25. Maybe stored for up to 1 month at 2-8˚C. 
4. TGF-β1 conjugate: 
12.5ml/vial of polyclonal antibody against TGF-β1 conjugated to 
horseradish peroxidase with preservatives. Maybe stored for up to 1 month 
at 2-8˚C. 
5. Colour Reagent A: 
12.5ml/vial of stabilised hydrogen peroxide. Maybe stored for up to 1 month 
at 2-8˚C. 
6. Colour Reagent B: 
12.5ml/vial of stabilised chromogen (tetramethylbenzidine). Maybe stored 
for up to 1 month at 2-8˚C. 
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7. Stop Solution: 
23ml/vial of a diluted hydrochloric acid solution. Maybe stored for up to 1 
month at 2-8˚C. 
8. TGF-β1 microplate: 
96 well polystyrene microplate coated with a monoclonal antibody specific 
for TGF-β1.  May be stored for up to 1 month at 2-8˚C. 
9. TGF-β1 standard: 
4.0ng/vial of recombinant human TGF-β1 in a buffered protein base with 
preservatives; lyophilized. Reconstitute with 2.0 ml of diluted calibrator 
diluent RD5-53, giving a concentration of 2000pg/ml. Unused Standard to 
be discarded. 
10. 1N HCl: 
9.8ml of 10.2 N HCL (32%) added to 90.2ml deionised water. 
11. 1.2N NaOH/0.5M HEPES: 
20G of NaOH + 50ml deionised water = 10N NaOH 
12ml of 10N NaOH + 75ml deionised water + 11.9g HEPES making final 
volume to 100ml with deionised water. 
 
Methodology: 
1. Activate latent TGF-β1 in urine samples. To 100μl urine sample add 20μl of 
1N HCL. Incubate 10 minutes at room temperature. Neutralise by adding 
20μl of 1.2N NaOH/0.5M HEPES. 
2. Prepare standards as follows 
Standard Concentration 
(pg/ml) 
Volume of calibrator 
or standard added 
Volume of Diluent 
(RD5-53) added 
1 1000 200μl of 
reconstituted TGF-
β1 standard 
0μl 
2 500 200μl of Standard 1 200μl 
3 250 200μl of Standard 2 200μl 
4 125 200μl of Standard 3 200μl 
5 62.5 200μl of Standard 4 200μl 
6 31.25 200μl of Standard 5 200μl 
7 15.625 200μl of Standard 6 200μl 
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3. Set up TGF-β1 ELISA microplate as follows by  adding 50μl of Assay 
diluents RD1-21 to each well, followed by adding 50μl of diluent, standard 
or urine sample to corresponding well, in duplicate [Diluent (D), Standard 
(S) and urine samples (U)]. 
 
D D U1 U1 U9 U9 U17 U17 U25 U25 U33 U33 
S1 S1 U2 U2 U10 U10 U18 U18 U26 U26 U34 U34 
S2 S2 U3 U3 U11 U11 U19 U19 U27 U27 U35 U35 
S3 S3 U4 U4 U12 U12 U20 U20 U28 U28 U36 U36 
S4 S4 U5 U5 U13 U13 U21 U21 U29 U29 U37 U37 
S5 S5 U6 U6 U14 U14 U22 U22 U30 U30 U38 U38 
S6 S6 U7 U7 U15 U15 U23 U23 U31 U31 U39 U39 
S7 S7 U8 U8 U16 U16 U24 U24 U32 U32 U40 U40 
 
4. Incubate at room temperature (22˚C) for 2 hours. 
5. Aspirate contents of well and wash with wash buffer four times. 
6. Add 100μl of TGF-β1 Conjugate to each well. 
7. Incubate at room temperature for 2 hours. 
8. Aspirate contents of well and wash with wash buffer four times. 
9. Mix Colour Reagents A and B together in equal volumes to make substrate 
solution and use within 15 minutes. 
10. Add 100μl of substrate solution to each well. 
11. Incubate in the dark at room temperature for 30 minutes. 
12. Add 100μl stop solution into each well. 
13. Determine the optical density within 30 minutes at 450 nm, with wavelength 
correction at 540nm or 570nm. 
 
Calculating Results: 
The optical density for each sample is calculated by subtracting the average 
optical density of the diluents (background value) from the average of duplicate 
samples. 
Absorbance Sample 1 = [Average U1 – Average D] 
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Using results from the observed standards, a Standard Curve is constructed. 
Sample values are interpolated from the standard curve and multiplied by 1.4 to 
correct for dilution of original sample (activation step). These sample values are 
then standardised for urine Cr. 
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3.8.2.6 Monocyte Chemoattractant Protein-1 (MCP-1) 
 
Principle: 
A quantitative sandwich enzyme immunoassay technique from R & D systems is 
used. A monoclonal antibody specific to MCP-1 has been pre-coated onto a 
microplate. Standards and samples are pipetted into wells and any MCP-1 
present is bound by the immobilized antibody. After washing away any unbound 
substances, an enzyme-linked polyclonal antibody specific for MCP-1 is added 
to the wells. Following a wash to remove any unbound antibody-enzyme 
reagent, a substrate solution is added to the wells and colour develops 
proportional to the amount of MCP-1 bound in the initial step. This colour 
development is stopped and the intensity of the colour is measured. 
 
Reagents: 
1. Calibrator Diluent (RD5L) concentrate: 
21ml/vial of concentrated buffered protein base with preservatives. Dilute 
1:5 with deionised water. Maybe stored for up to 1 month at 2-8˚C. 
2. Wash Buffer concentrate: 
21ml/vial of 25x concentrated solution of buffered surfactant with 
preservatives. Warm to room temperature and mix gently with deionised 
water at a dilution of 1:25. Maybe stored for up to 1 month at 2-8˚C. 
3. MCP-1 conjugate: 
21ml/vial of polyclonal antibody against MCP-1 conjugated to horseradish 
peroxidase with preservatives. Maybe stored for up to 1 month at 2-8˚C. 
4. Colour Reagent A: 
12.5ml/vial of stabilised hydrogen peroxide. Maybe stored for up to 1 month 
at 2-8˚C. 
5. Colour Reagent B: 
12.5ml/vial of stabilised chromogen (tetramethylbenzidine). Maybe stored 
for up to 1 month at 2-8˚C. 
6. Stop Solution: 
6ml/vial of 2N sulphuric acid. Maybe stored for up to 1 month at 2-8˚C. 
7. MCP-1 microplate: 
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96 well polystyrene microplate coated with a mouse monoclonal antibody 
against human MCP-1. Maybe stored for up to 1 month at 2-8˚C. 
8. MCP-1 standard: 
10ng/vial of recombinant human MCP-1 in a buffered protein base with 
preservatives; lyophilized. Reconstitute with 5.0ml of diluted calibrator 
diluent RD5L, giving a concentration of 2000pg/ml. May be stored in 
aliquots at -20˚C for up to 1 month. 
 
Methodology: 
1. Dilute urine samples 1:2 with diluted calibrator diluent RD5L. 
2. Prepare standards as follows 
 
Standard Concentration 
(pg/ml) 
Volume of calibrator 
or standard added 
Volume of Diluent 
(RD5L) added 
1 1000 500μl of 
reconstituted MCP-1 
standard 
500μl 
2 500 500μl of Standard 1 500μl 
3 250 500μl of Standard 2 500μl 
4 125 500μl of Standard 3 500μl 
5 62.5 500μl of Standard 4 500μl 
6 31.25 500μl of Standard 5 500μl 
7 15.625 500μl of Standard 6 500μl 
 
3. Set up MCP-1 ELISA microplate as follows by adding 200μl of diluent, 
standard or diluted urine sample to corresponding well, in duplicate [Diluent 
(D), Standard (S) and urine samples (U)]. 
 
D D U1 U1 U9 U9 U17 U17 U25 U25 U33 U33 
S1 S1 U2 U2 U10 U10 U18 U18 U26 U26 U34 U34 
S2 S2 U3 U3 U11 U11 U19 U19 U27 U27 U35 U35 
S3 S3 U4 U4 U12 U12 U20 U20 U28 U28 U36 U36 
S4 S4 U5 U5 U13 U13 U21 U21 U29 U29 U37 U37 
S5 S5 U6 U6 U14 U14 U22 U22 U30 U30 U38 U38 
S6 S6 U7 U7 U15 U15 U23 U23 U31 U31 U39 U39 
S7 S7 U8 U8 U16 U16 U24 U24 U32 U32 U40 U40 
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4. Incubate at room temperature (22˚C) for 2 hours. 
5. Aspirate contents of well and wash with wash buffer three times. 
6. Add 200μl of MCP-1 Conjugate to each well. 
7. Incubate at room temperature for 1 hour. 
8. Aspirate contents of well and wash with wash buffer three times. 
9. Mix Colour Reagents A and B together in equal volumes to make Substrate 
solution and use within 15 minutes. 
10. Add 200μl of Substrate solution to each well. 
11. Incubate in the dark at room temperature for 20 minutes. 
12. Add 50μl stop solution into each well. Colour should change from blue to 
yellow. 
13. Determine the optical density at 450 nm, with wavelength correction at 
540nm or 570nm. 
 
Calculating Results: 
The optical density for each sample is calculated by subtracting the average 
optical density of the diluents (background value) from the average of duplicate 
samples. 
Optical Density Sample 1 = [Average U1 – Average D] 
Using results from the observed standards, a Standard Curve is constructed. 
Sample values are interpolated from the standard curve and multiplied by 2 to 
correct for dilution of original sample. These sample values are then 
standardised for urine Cr. 
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3.8.3 Analysing results 
The mean, standard deviation and range for age, height, weight, BSA 
(Monsteller formula
108
) and BMI,  for AFD patients and/or controls were 
calculated and compared with the Mann-Whitney U test. Also the mean, 
standard deviation and range for serum Cr, eGFR, iGFR, left ventricular mass 
index (LVMI)
325
, Mainz Severity Score Index (MSSI)
326
 and number and 
percentage of AFD patients on ERT were calculated for each cohort. 
All activities of urine proteins tested were corrected for urine concentration by 
correcting for urine Cr and compared between AFD patients and controls, based 
on sex and age. The AFD patients were then categorised based on renal 
parameters of microalbuminuria, significant total proteinuria, serum Cr, eGFR 
and iGFR, and the 6 urine proteins tested were compared. Next the AFD patients 
were categorised according to the type of mutation, baseline plasma and 
leucocyte α-gal levels and disease severity based on LVMI and MSSI scores, 
and the 6 urine proteins were compared.  The statistical analysis used was the 
Mann-Whitney U test to compare 2 groups and the Kruskal-Wallis to compare 
more than 2 groups. The Mann Whitney U test and Kruskal-Wallis tests were 
used as they compare non-parametric statistical hypothesis of independent 
samples. 
As there was a significant difference in urine β-Hex and urine MCP-1 activities 
in AFD compared to controls, the corresponding urine protein activities or levels 
within the 95% confidence intervals of the controls were then considered to be 
the “normal” range. AFD patients who had urine protein activities or levels that 
were higher than the presumed normal range were compared with AFD patients 
who had activities in the presumed normal range based on age, sex, urine 
UACR, UPCR, serum Cr, eGFR, iGFR, type of mutation, baseline plasma and 
leucocyte α-Gal activity, MSSI scores and LVMI. 
Multiple regression analysis of urine β-Hex and urine MCP-1 using age, sex and 
type of mutation were analysed. 
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3.9     Results 
 
3.9.1 Demographics 
In all groups, female controls were significantly younger than AFD females, 
except in the TGF-β1 cohort probably due to smaller numbers. There was no 
statistically significant difference in age between the control males and females, 
control males and AFD males or the AFD males and females for all urine protein 
cohorts tested (Table 3.1). AFD males were taller, heavier and had a larger 
surface area than AFD females but there was no significant difference in their 
BMI (Table 3.2). There was no difference in iGFR for AFD males and females 
but AFD males had a significantly higher LVMI and MSSI score compared to 
females in all of the urinary protein cohorts tested (Table 3.3). In the α-Gal, β-
Hex, RBP and MCP-1 cohorts there were significantly more males than females 
treated with ERT (Table 3.3). 
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  Control Male Control Female 
 
AFD Male AFD Female  
Age (years) M SD R M SD R M SD R M SD R * 
α-Gal 40.2 ±11.3 25-60 32.4 ±5.9 25-44 44.9 ±14.4 18-77 44.6 ±16.7 16-79 p = 0.0306 
β-Hex 40.2 ±11.3 25-60 32.7 ±5.8 25-44 44.4 ±14.0 18-77 44.6 ±16.6 16-79 p = 0.0103 
Chitotriosidase 39.0 ±11.9 25-60 33.0 ±7.2 25-44 45.2 ±14.3 26-68 53.2 ±12.2 28-74 p = 0.0011 
RBP 39.6 ±11.0 25-60 33.7 ±5.4 25-44 43.3 ±13.4 20-74 46.0 ±14.8 16-73 p = 0.0054 
TGF-β1 36.0 ±11.2 25-54 35.2 ±6.8 25-44 45.9 ±16.6 18-69 41.2 ±15.8 16-74 ns 
MCP-1 41.4 ±12.0 25-60 33.3 ±5.9 25-44 46.4 ±14.5 18-77 44.8 ±15.9 16-79 p = 0.0325 
 
Table 3.1.  Age differences between the different urine protein cohorts tested. M – Mean, SD – standard deviation, R – Range. * Mann-Whitney U test comparing age between the 
control female and AFD female groups for each cohort. No statistically significant difference in age between control male and AFD male, AFD male and AFD female, and control 
male control female groups in each cohort. 
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 α-Gal β-Hex Chitotriosidase RBP TGF-β1 MCP-1 
 M SD R M SD R M SD R M SD R M SD R M SD R 
Height (m) *   *   *   *   *   *   
AFD M 1.75 ±0.07 1.58-
1.93 
1.76 ±0.07 1.60-
1.93 
1.75 ±0.07 1.58-
1.83 
1.76 ±0.06 1.60-
1.90 
1.77 ±0.09 1.58-
1.93 
1.76 ±0.07 1.64-1.93 
AFD F 1.62 ±0.07 1.50-
1.88 
1.62 ±0.07 1.50-
1.88 
1.60 ±0.06 1.50-
1.73 
1.62 ±0.06 1.50-
1.74 
1.64 ±0.05 1.56-
1.74 
1.62 ±0.06 1.50-1.74 
Weight (kg) *   *   *   *   *   *   
AFD M 76.9 ±15.6 54.0-
124.4 
77.1 ±15.1 54.0-
124.4 
73.2 ±18.6 53.8-
124.4 
75.7 ±15.5 54.0-
124.4 
83.4 ±18.5 55.0-
124.4 
77.2 ±15.0 55.0-124.4 
AFD F 67.0 ±11.9 42.3-
98.0 
66.8 ±11.7 42.3-
98.0 
65.5 ±10.6 45.5-
90.3 
67.1 ±11.9 49.0-
98.0 
67.0 ±11.1 50.2-
98.0 
66.3 ±11.9 42.3-98.0 
BSA (m2) *   *   *   *   *   *   
AFD M 1.93 ±0.21 1.55-
2.45 
1.93 ±0.20 1.59-
2.45 
1.88 ±0.24 1.55-
2.45 
1.92 ±0.21 1.59-
2.45 
2.03 ±0.25 1.55-
2.45 
1.93 ±0.20 1.60-2.45 
AFD F 1.73 ±0.17 1.34-
2.18 
1.73 ±0.17 1.34-
2.18 
1.70 ±0.16 1.39-
2.08 
1.73 ±0.17 1.44-
2.18 
1.74 ±0.15 1.53-
2.18 
1.72 ±0.17 1.34-2.18 
BMI (kg/m2)                   
AFD M 25.1 ±4.6 17.5-
41.1 
24.9 ±4.5 17.5-
41.1 
23.7 ±5.6 18.9-
41.1 
24.5 ±4.6 17.5-
41.1 
26.9 ±5.5 19.7-
41.1 
24.9 ±4.7 18.9-41.1 
AFD F 25.5 ±4.3 18.0-
34.8 
25.4 ±4.2 18.0-
32.9 
25.6 ±2.9 19.4-
30.4 
25.6 ±4.2 18.2-
32.6 
25.1 ±4.2 18.0-
32.4 
25.2 ±4.4 18.0-32.6 
 
Table 3.2. Demographic data for different urine protein cohorts, M – mean, SD – standard deviation, R – range. Mann-Whitney U test statistical analysis used, * p < 
0.05. 
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 α-Gal β-Hex Chito RBP TGF-β1 MCP-1 
 M SD R M SD R M SD R M SD R M SD R M SD R 
Serum Cr (μmol/L) *   *   *   *   *   *   
AFD M 89.0 ±26.1 56-
206 
89.6 ±25.5 57-
206 
86.0 ±17.4 60-
119 
90.2 ±25.9 56-
206 
90.6 ±17.7 57-
119 
86.1 ±16.9 57-
119 
AFD F 66.7 ±14.2 44-
119 
66.8 ±14.4 44-
119 
69.1 ±13.3 53-
106 
66.9 ±14.1 44-
111 
65.5 ±12.1 49-
106 
68.1 ±15.2 49-
119 
eGFR 
(ml/min/1.73m2) 
      *      *      
AFD M 93.9 ±27.5 32.8-
156.0 
92.8 ±26.1 32.8-
143.8 
94.1 ±22.2 56.1-
128.0 
92.4 ±26.6 32.8-
155.9 
89.5 ±25.2 56.1-
140.7 
94.2 ±25.8 56.2-
143.8 
AFD F 94.5 ±23.1 41.8-
155.3 
94.6 ±23.7 41.8-
155.3 
85.8 ±18.4 49.4-
111.7 
93.6 ±23.2 49.4-
143.2 
97.7 ±24.0 49.4-
155.3 
92.9 ±24.0 41.8-
155.3 
iGFR 
(ml/min/1.73m
2
) 
                  
AFD M 82.8 ±24.2 27-
125 
82.5 ±23.4 27-
128 
82.4 ±16.7 63-
116 
80.6 ±21.6 27-
122 
90.2 ±21.4 63-
125 
82.5 ±21.5 42-
125 
AFD F 89.3 ±23.1 41-
133 
90.5 ±22.6 41-
133 
82.90 ±20.6 46-
117 
88.6 ±22.1 45-
133 
96.1 ±22.4 46-
133 
86.5 ±22.7 41-
133 
LVMI (g/m2) *   *   *   *   *   *   
AFD M 128.5 ±40.3 73.3-
277.1 
126.2 ±36.7 76.3-
228.7 
133.0 ±36.4 81.4-
189.2 
126.2 ±38.6 76.3-
228.7 
130.8 ±40.5 76.6-
203.1 
123.8 ±33.2 81.4-
228.7 
AFD F 83.8 ±33.6 47.1-
225.8 
83.3 ±32.6 47.1-
225.8 
103.3 ±32.7 58.1-
159.3 
85.2 ±28.6 47.1-
159.3 
81.4 ±29.3 47.1-
159.3 
79.3 ±32.9 47.1-
225.8 
MSSI *   *   *   *   *   *   
AFD M 23.2 ±9.6 3 - 51 23.1 ±9.4 3 - 51 25.7 ±11.1 8 - 51 23.4 ±9.6 4 - 51 21.3 ±10.0 3-39 24.1 ±10.0 3-51 
AFD F 13.5 ±9.3 1 - 42 13.7 ±9.3 1 - 42 17.9 ±9.8 1 - 40 13.9 ±8.2 1 - 40 11.0 ±6.7 1-24 13.4 ±10.0 1-42 
AFD on ERT no %  no %  no %  no %  no %  no %  
 *   *      *      *   
AFD M 40 87.0  43 87.8  14 93.3  32 91.4  11 73.3  25 80.6  
AFD F 27 48.2  27 48.2  10 66.7  22 57.9  11 45.8  17 39.5  
 
Table 3.3. Demographics based on parameters of organ involvement  data, all statistics based on Mann-Whitney U test; M – mean, SD – standard deviation, R – range, no – 
number of patients on ERT. * p < 0.05. 
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3.9.2 Different urine protein levels tested and compared with renal and other AFD 
parameters 
As expected urine α-Gal levels were significantly lower in AFD than control 
subjects. AFD subjects also had a significantly higher urine β-Hex and MCP-1 
levels compared with controls (Fig 3.6). Urine α-Gal, Chitotriosidase, RBP and 
TGF-β1 activity/levels were not significantly different based on renal parameters 
of microalbuminuria, proteinuria, serum Cr, eGFR or iGFR, but urine β-Hex 
activity was significantly higher in AFD patients with raised UACR and UPCR, 
and urine MCP-1 was higher in AFD patients with raised UACR (Table 3.5). 
Urine α-Gal, β-Hex, RBP, TGF-β1 and MCP-1 activity/levels were not 
significantly different based on type of AFD mutation but urine chitotriosidase 
activity was the only urine protein to be higher in non-missense mutations 
(Table 3.6). As expected urine α-Gal activity was lower in AFD patients with 
lower plasma and/or leucocyte α-Gal activity but urine β-Hex, RBP, 
chitotriosidase, TGF-β1 and MCP-1 activity/levels were not statistically 
different based on the baseline plasma or leucocyte α-Gal activity (Table 3.6). 
Looking at the subgroups, urine β-Hex activity was significantly higher if 
baseline plasma α-Gal activity of < 1 nmol/hr/ml was compared with > 4 
nmol/hr/ml and urine MCP-1 levels were higher if baseline leucocyte α-Gal 
activity of < 5 nmol/hr/ml were compared with >30 nmol/hr/ml (Table 3.6, Fig 
3.7). Urine α-Gal activity was significantly lower and urine β-Hex activity was 
significantly higher in AFD patients with a higher MSSI score and LVMI.  
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Fig 3.6. Summary of Urine Protein levels in AFD vs Control. Statistical analysis used is Mann-Whitney 
U test. 
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    Male Female   Age < 40 years Age ≥ 40 years   
α-Gal Control (n=25) 1151 ± 503.8 1055 ± 644.2 ns 997.7 ± 571.2 1380  ± 480.8 ns 
 (nmol/hr/mmol Cr) AFD (n=102) 124.1 ± 134.8 727.1 ± 731.3 p < 0.0001 382.1 ± 495.8 504.3 ± 697.9 ns 
   p < 0.0001 p = 0.0403   p < 0.0001 p = 0.0006   
β-Hex Control (n=26) 4446 ± 1922 6452 ± 3808 ns 5390 ± 3487 5609 ± 2060 ns 
 (nmol/hr/mmol Cr) AFD (n=105) 11847 ± 9276 8319 ± 5026 p = 0.0224 7753 ± 4055 11441 ± 8824 p = 0.0338 
   p < 0.0001 ns  p = 0.0362 p = 0.0188   
Chitotriosidase Control (n=18) 687.8 ± 495.9 427.8 ± 170.9 ns 454.4 ± 345.5 823.0 ± 411.8 ns 
 (nmol/hr/mmol Cr) AFD (n=30) 630.3 ± 365.0 981.0 ± 1009 ns 773.4 ± 498.9 828.4 ± 878.8 ns 
   ns ns   ns ns   
RBP Control (n=26) 81.31 ± 43.39 121.2 ± 126.8 ns 104.8 ± 107.7 90.56 ± 41.86 ns 
 (μg/mmol Cr) AFD (n=73) 160.7 ± 197.8 103.4 ± 75.4 ns 121.8 ± 70.67 136.8 ± 184 ns 
   ns ns  ns ns   
TGF-β1 Control (n= 12) 0.9719 ± 0.7681 2.606 ± 2.149 p = 0.0303 1.167 ± 0.6249 3.111 ± 1.740 ns 
 (ng/mmol Cr) AFD (n=39) 1.057 ± 0.8389 1.720 ± 1.146 ns 1.561 ± 1.168 1.375 ± 1.006 ns 
   ns ns   ns ns   
MCP-1 Control (n=19) 16.34 ± 6.982 22.90 ± 9.913 ns 17.59 ± 8.251 21.69 ± 9.584 ns 
 (ng/mmol Cr) AFD (n=74) 34.15 ± 20.10 25.12 ± 14.18 p = 0.0486 26.70 ± 17.62 30.16 ± 17.30 ns 
   p = 0.0022 ns   ns ns   
 
Table 3.4. Showing difference between sex and age for various urinary proteins. Statistical test used is Mann-Whitney U test and results are shown as mean and SD. 
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 α-Gal 
(nmol/hr/mmol Cr) 
n = 102 
β-Hex 
 (nmol/hr/mmol 
Cr) 
n = 105 
Chitotriosidase 
 (nmol/hr/mmol 
Cr) 
n = 30 
RBP 
 (μg/mmol Cr) 
n = 73 
TGF-β1 
 (ng/mmol Cr) 
n = 39 
MCP-1 
(ng/mmol Cr) 
n = 74 
Urine Albumin:Cr (mg/mmol/Cr) 
<3.5 425.1 ± 435.2 7731 ± 3913 613.2 ± 413.9 110.3 ± 77.20 1.418 ± 1.115 24.34 ± 13.70 
>3.5 500 ± 842.8 12850 ± 10061 1284 ± 1198 158.1 ± 209.9 1.540 ± 1.047 37.03 ± 20.33 
 Mann-Whitney ns p = 0.0040 ns ns ns p = 0.0036 
Urine Protein:Cr (mg/mmol Cr) 
< 30 410.2 ± 461.6 8577 ± 7142 657.4 ± 417.6 132.6 ± 83.42 1.508 ± 1.119 26.51 ± 15.22 
>30 604.9 ± 979.0 14076 ± 7663 1624.0 ± 1714 189.1 ± 270.8 1.270 ± 1.024 38.00 ± 23.46 
 Mann-Whitney ns p = 0.0002 ns ns ns ns 
Serum Cr (μmol/L) 
< 100 495.5 ± 658.1 9495 ± 7295 866.0 ± 827.1 123.3 ± 79.80 1.506 ± 1.117 29.05 ± 17.22 
≥ 100 198.1 ± 239.7 13268 ± 8574 502.1 ± 231.5 183.6 ± 383.5 1.280 ± 0.926 28.03 ± 20.10 
Mann-Whitney ns ns ns ns ns ns 
eGFR (ml/min/1.73m
2
) 
CKD 1 403.4 ± 523.7 9484 ± 8451 667.8 ± 457.3 129.0 ± 78.25 1.531 ± 1.041 29.64 ± 16.02 
CKD 2 561.9 ± 766.9 10093 ± 6026 1093.0 ± 1131.0 110.3 ± 83.35 1.335 ± 1.187 27.66 ± 17.56 
CKD 3 250.6 ± 291.9 12387 ± 8469 547.5 ± 260.8 230.7 ± 429.5 1.659 ± 1.062 32.44 ± 28.53 
Kruskal-Wallis ns ns ns ns ns ns 
iGFR (ml/min/1.73m
2
) 
CKD 1 384.1 ± 534.9 8352 ± 4949 644.8 ± 502.2 126.6 ±77.10 1.744 ± 1.155 28.81 ± 16.35 
CKD 2 485.1 ± 762.8 10971 ± 9115 733.8 ± 423.2 116.0 ± 83.85 1.128 ± 0.874 29.08 ± 17.76 
CKD3 484.9 ± 498.1 13234 ± 8815 1676.0 ± 2079.0 221.3 ± 399.1 1.768 ± 1.386 27.28 ± 22.69 
Kruskal-Wallis ns ns ns ns ns ns 
 
Table 3.5.Showing urine protein levels compared with renal parameters in AFD patients. Statistical analysis used is Mann-Whitney U-test or Kruskal-Wallis as stated. 
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 α-Gal 
(nmol/hr/mmol Cr) 
n = 102 
β-Hex 
(nmol/hr/mmol Cr) 
n = 105 
Chitotriosidase 
(nmol/hr/mmol Cr) 
n = 30 
RBP  
(μg/mmol Cr) 
n = 73 
TGF-β1 
(ng/mmol Cr) 
n = 39 
MCP-1 
(ng/mmol Cr) 
n = 74 
Type of mutation 
Missense 474.3 ± 660.5 9827 ± 8030 561.2 ± 395.1 112.4 ± 79.22 1.306 ± 0.9694 28.71 ± 18.74 
Non-missense 407.1 ± 531.8 10296 ± 6144 1263 ± 1136 171.0 ± 237.3 2.548 ± 1.263 29.31 ± 14.48 
Mann-Whitney ns ns p = 0.0208 ns ns ns 
Plasma α-Gal (nmol/ml/hr)       
< 1 138 ± 156.9 10575 ± 6058* 697.2 ± 342.0 161.5 ± 224.7 0.924 ± 0.809 30.10 ± 18.06 
 1 – 4 617.2 ± 808.1 8863 ± 5732 647.5 ± 479.6 105.9 ± 79.24 1.750 ± 1.187 25.64 ± 14.53 
≥ 4 836.8 ± 606.9 7307 ± 4849* 2151.0 ± 1693 112.4 ± 69.79 1.312 ± 1.151 19.93 ± 8.910 
Kruskal-Wallis p < 0.0001 ns ns ns ns ns 
Leucocyte α-Gal (nmol/hr/mg Prot)       
< 5 84.02 ± 71.57 11187 ± 6649 447.1 ± 326.7 202.3 ± 263.3 0.803 ± 0.677 33.45 ± 17.08
+ 
5-30 337.5 ± 261.3 13479 ± 14322 520.8 ± 323.0 111.5 ± 66.27 1.714 ± 1.503 35.06 ± 25.83 
≥ 30 956.8 ± 190.5 8599 ± 4537 1540 ± 1360 102.9 ± 77.49 1.484 ± 1.027 21.74 ± 11.28+ 
 Kruskal Wallis p < 0.0001 ns ns ns ns ns 
MSSI       
<20 611.5 ± 752.7 7922 ± 4633 693.0 ± 496.7 122.2 ± 75.05 1.627 ± 1.191 27.63 ± 15.92 
≥ 20 237.4 ± 330.9 12732 ± 9421 862.2 ± 874.7 144.1 ± 203.7 1.069 ± 0.746 31.43 ± 19.60 
Mann-Whitney p = 0.0021 p = 0.0022 ns ns ns
 
ns 
LVMI (g/m
2
)       
Normal 516.3 ± 552.4 8248 ± 5074 752.1 ± 427.2 126.1 ± 80.77 1.594 ± 1.180 25.99 ± 15.13 
Abnormal 388.8 ± 753.7 12612 ±9762 877.5 ± 956.2 144.4 ± 209.2 1.233 ± 0.936 34.79 ± 20.76 
Mann-Whitney p = 0.0362 p = 0.0071 ns ns ns ns 
 
Table 3.6. Showing urine protein levels compared with other disease severity markers. *between cohorts <1 and >4, Mann-Whitney U-test p = 0.0391; 
+
between cohorts <5 
and > 30, Mann-Whitney U test p = 0.0292. 
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Fig 3.7. Graphs showing (A) Urine β-Hex vs Plasma α-Gal levels, (B) Urine β-Hex vs Leucocyte α-
Gal levels, (C) Urine MCP-1 vs α-Gal levels, (B) Urine MCP-1 vs Leucocyte α-Gal levels 
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3.9.3 AFD patients with normal urine β-Hex or MCP-1 activity compared with raised 
urine β-Hex or MCP-1 activity 
 
AFD patients with urine β-Hex activity more than the 95% confidence intervals 
of urine β-Hex activity of controls, were older, had higher UACR, higher urine 
UPCR, higher MSSI scores and higher LVMI compared with AFD patients with 
urine β-Hex activity within the normal range (95% confidence intervals of urine 
β-Hex activity of controls). For AFD patients using the urine MCP-1 levels in 
the same comparison, only a higher LVMI was found in AFD patients with a 
higher urine MCP-1 activity (Table 3.7). 
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  Β-Hex MCP-1 
 Normal or raised urine 
protein activity or level 
M SD R M SD R 
Age (years) Normal 42.5 ±14.9 16 - 73 43.9 ± 15.0 16 – 71 
 Raised 50.3 ±15.6 24 – 79 49.8 ± 15.3 31 - 79 
  p = 0.0397   ns   
Sex Normal 32 M 46 F  20 M 35 F  
 Raised 17 M 10 F  11 M 8 F  
  *ns   *ns   
Urine Albumin:Cr (mg/mmol Cr) Normal 8.0 ±16.5 0.04 – 97.7 9.3 ±27.7 0.04 – 178.1 
 Raised 20.3 ±36.8 0.3 – 178.1 14.0 ±21.6 0.3 – 72.5 
  p = 0.0091   ns   
Urine Protein:Cr (mg/mmol/Cr) Normal 19.5 ±24.3 1.6 – 154.3 19.9 ±26.5 1.6 – 154.3 
 Raised 40.9 ±39.6 6.7 – 182.8 34.2 ±43.3 3.7 – 182.8 
  p < 0.0001   ns   
Serum Cr (μmol/L) Normal 75.4 ±18.1 44 – 121 75.9 ±18.4 49 - 119 
 Raised 83.1 ±33.6 51 – 206 74.1 ±17.8 44 - 116 
  ns   ns   
eGFR (ml/min/1.73m
2
) Normal 94.6 ±24.3 41.8 – 155.3 92.1 ±25.1 41.8 – 155.3 
 Raised 91.4 ±26.5 32.8 – 143.1 97.3 ±23.3 56.3 – 140.7 
  ns   ns   
iGFR (ml/min/1.73m
2
) Normal 88.4 ±21.8 41 – 133 84.4 ±22.6 41 - 133 
 Raised 81.7 ±26.5 27 - 120 85.6 ±20.9 42 - 120 
  ns   ns   
Type of mutation Normal 18 non-missense 37 missense  23 non-missense 55 missense  
 Raised 6 non-missense 13 missense  8 non-missense 19 missense  
  *ns   *ns   
Plasma α-Gal (nmol/ml/hr) Normal 2.3 ±2.0 0.0 – 7.4 2.6 ±2.1 0.0 – 7.4 
 Raised 1.7 ±1.7 0.1 – 5.4 1.6 ±1.6 0.0 – 5.2 
  ns   ns   
Leucocyte α-Gal (nmol//hr/mg Prot) Normal 27.4 ±25.4 0.1 – 88.0 32.4 ±25.7 0.2 – 88.0 
 Raised 18.8 ±21.2 0.4 – 58.0 15.4 ±19.3 0.5 – 60.0 
  ns   ns   
MSSI Normal 16.4 ±9.4 1 – 39 17.2 ±10.8 1 - 40 
 Raised 23.2 ±11.8 5 - 51 20.3 ±12.4 1 - 51 
  p = 0.0123   ns   
LVMI (g/m
2
) Normal 96.0 ±34.1 48.8 – 189.3 90.2 ±31.0 47.1 – 161.8 
 Raised 122.8 ±50.6 47.1 – 228.7 117.8 ±52.3 49.6 – 228.7 
  p = 0.0118   p = 0.0420   
Table 3.7. Comparing urinary β-Hex and MCP-1activity or levels in AFD patients within the normal range (95% confidence interval of corresponding results from controls) 
with AFD patients with raised activity or levels (> 95% confidence interval of controls). Statistical analysis used was Mann-Whitney U-test unless otherwise stated. * Fishers 
exact test  
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3.9.4 Multiple regression analysis 
 
Significant variables in multiple regression analysis for urine β-Hex and urine MCP-1 were age and sex of subjects but not the type of 
mutation (Table 3.8). 
 
Variable p value Significant Correlation Coefficient 
Urine α-Gal    
Age 0.0544 No 0.1710 
Sex <0.0001 Yes 0.4827 
Missense 0.7793 No 0.0488 
Urine β-Hex    
Age 0.0011 Yes 0.2992 
Sex 0.0117 Yes -0.2359 
Missense 0.4289 No -0.0287 
Urine MCP-1    
Age 0.0420 Yes 0.2414 
Sex 0.0317 Yes -0.2583 
Missense 0.6786 No -0.0164 
 
Table 3.8. Multiple regression analysis for urine β-Hex and MCP-1.
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3.10 Discussion 
 
This is the largest study looking at urine α-Gal activity in urine. Urine α-Gal activity is 
significantly lower in AFD patients than controls (Fig 3.6) as expected and confirms 
Kitigawa et al’s findings. Urine α-Gal activity is also lower in AFD males compared 
with AFD females. Lower baseline plasma and leucocyte α-Gal activity was also 
significantly associated with urine α-Gal activity. Multiple regression analysis showed 
that sex was a significant variable but not age and type of mutation for urine α-Gal 
activity. Lower urine α-Gal activity was associated with more significant end organ 
damage reflected by an increased LVMI and higher MSSI scores but not by renal 
parameters of eGFR, iGFR, microalbuminuria or proteinuria which are reflection of 
glomerular function rather than renal tubular function. 
 
Two other lysosomal enzymes β-Hex and Chitotriosidase were analysed in the urine of 
AFD patients. Urine β-Hex activity was significantly higher in AFD male patients 
compared with male controls and AFD females. Also urine β-Hex activity was higher in 
AFD males at a younger age (<40) and at an older age (>40) when compared with 
controls. Multiple regression analysis showed age and sex were important variables for 
urine β-Hex activity in AFD patients but the type of mutation was not a significant 
variable.  But urine β-hex levels were significantly higher in AFD patients with a lower 
baseline plasma α-Gal levels. These results were not reflected in urine chitotriosidase 
activity where there is no difference comparing AFD patients with controls eventhough 
plasma chitotriosidase activity is reported to be higher in AFD males
216
. Of note urine 
chitotriosidase activity was significantly higher in patients with non-missense 
mutations. Looking at other measures of end organ involvement, urine β-hex is 
significantly higher in AFD patients with raised UACR and UPCR but not different 
based a staging of CKD with eGFR or iGFR. Urine β-hex activity was also higher in 
AFD patients with higher MSSI scores and raised LVMI. This suggests that urine β-hex 
activity is increased in AFD patients with evidence of cardiac, renal and systemic organ 
involvement. We then used 95% confidence interval values of urine β-hex in controls to 
be the normal range and presumed that >95% confidence interval value of urine β-hex 
activity in controls as being abnormally raised activity. AFD patients with an abnormal 
urine β-hex activity were older, had increased microalbuminuria and proteinuria, higher 
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MSSI scores and raised LVMI. This further suggests that urine β-hex activity appears to 
be raised in AFD patients with significant end organ damage. 
This increase in urine β-hex activity maybe a reflection of reduced tubular reabsorption 
or increased tubular secretion due to damage to renal tubular cells or interstitial damage 
or increased lysosomal activity in renal cells, but the absence of concurrent increased 
chitotriosidase activity suggests that increased lysosomal activity is less likely. Sample 
size for urine chitotriosidase cohort were smaller (controls = 18, AFD = 30) compared 
to the urine β-hex cohort (controls = 26, AFD = 102) therefore significant differences 
may be difficult to elicit. Also because of glomerular filtration of the smaller protein 
chitotriosidase compared to β-hex which is not filtered due to its larger molecular mass, 
could mean that the proportion of activity of urine chitotriosidase could predominantly 
be from filtered chitotriosidase rather than chitotriosidase from tubular damage or 
increased lysosomal activity. Therefore if there was increased urine chitotriosidase from 
renal tubular damage or lysosomal activity this may not significantly increase the 
overall total urine chitotriosidase activity. Previously it had been shown that plasma 
chitotriosidase activity was elevated in male AFD hemizygotes and this reduced with 
ERT
216, 217
. Since chitotriosidase would be freely filtered due to its small molecular 
weight (39-50kDa) it would be expected that urine chitotriosidase activity of male AFD 
hemizygotes should be similarly be increased compared to females as plasma 
chitotriosidase activity, though we could not show this in our data. 
  
In our study we have shown that urine RBP levels are not elevated in AFD patients. 
RBP which is freely filtered at the glomerulus and reabsorbed at the proximal tubules 
has been shown to be a marker of renal tubular dysfunction. Considering that urine β-
hex activity is increased and urine RBP levels are normal, more likely that tubular 
reabsorption function in our group of patients is preserved but there is increased 
lysosomal enzymuria excretion from renal tubules (indicated by raised urine β-hex 
activity). The reasons for preserved tubular reabsorptive function but not glomerular 
function could be because firstly recombinant α-Gal is filtered despite having a 
molecular weight of 110kDa and via megalin receptors accumulate in the proximal 
tubules
156
 and secondly the proximal tubular cells have a relatively fast turnover
327
. 
Combination of these 2 factors could mean that tubular cells are less susceptible or 
regenerate faster than glomerular cells and therefore maintain function. Analysing our 
data further (not shown) AFD patients not on ERT (3 AFD males and 16 AFD females) 
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did not have significantly different mean RBP levels compared to controls (12 males 
and 12 females; note the small numbers) possibly indicating that tubular reabsorptive 
function is preserved in AFD.  
 
TGFβ-1, a mediator of renal scarring is not increased in urine of AFD patients. MCP-1 a 
chemokine important in the inflammatory process is raised in AFD patients compared to 
controls. Urine MCP-1 levels are significantly higher in AFD males compared with 
controls or AFD females, but not affected by age. It is higher in AFD patients with 
microalbuminuria but not associated with other markers of end organ damage and 
appears to be higher in AFD patients with lower leucocyte α-Gal levels. Again we used 
the 95% confidence intervals of urine MCP-1 levels of controls as the normal range and 
presumed that >95% confidence interval value of urine MCP-1 levels of controls as 
being abnormal. Only AFD patients with an abnormal LVMI had a significantly higher 
urine MCP-1 level. Multiple regression analysis also showed that age and sex were 
significant variables for urine MCP-1 levels in AFD. This may indicate that the 
biological pathway for renal fibrosis and damage may be via MCP-1 and not TGF-β1. 
Again we would be cautious in saying that TGFβ-1 is not a mediator for renal scarring 
in AFD since the sample size was again small (AFD = 39, controls =12).  
 
Proposed mechanisms of renal injury in AFD are 
1) The development of microvascular disease due to the deposition on GB3 in 
arterial vessel walls which then result in subsequent vascular compromise. This 
was proposed by Gubler et al
115
 due to the ischaemic changes of 
glomerulosclerosis, often with wrinkled and partially collapsed glomerular 
basement membranes, tubular atrophy, interstitial fibrosis and vascular 
thickening occurring in older patients found on renal biopsies. 
2) The toxic accumulation of GB3 in podocytes
135
; podocytes are postmitotic and 
fail to proliferate under most pathological conditions and are generally not 
replaced
328
. 
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Podocytes lost 
 
 
Denuded GBM contacts parietal epithelial cells 
 
 
Forms a synechia 
 
 
Activation and proliferation of cells (Mesangial) 
Entry of immune cells (macrophages) 
Accumulation of extracellular matrix protein 
 
 
Matrix expansion and subsequent collapse of capillary loop appears as a 
focus of solidification (Segmental glomerulosclerosis) 
 
3) Deposition of GB3 within tubular epithelial cells may lead to focal tubular 
atrophy and interstitial fibrosis 
 
It is well documented that glomerular function is affected in AFD due to significant 
microalbuminuria, proteinuria and reduced eGFR and iGFR. There has been no 
quantitative study on assessment of renal tubular function to date. From our study, a 
cross sectional investigation of AFD patients, we have shown that urine β-hex activity is 
increased with normal urine RBP levels, suggesting an increased renal tubular secretion 
without significant renal tubular reabsorptive dysfunction. This does not correlate with 
renal pathological findings that GB3 deposition and renal atrophy and scarring is 
present in most regions of the kidney. The well known difficulty with diagnosing and 
quantifying disease severity in AFD is due to the heterogeneity of the disease especially 
in females. 
Current guidance for the use of ERT suggests that ERT should be initiated in AFD 
patients with impaired GFR and/or significant proteinuria implying glomerular 
dysfunction. Renal biopsies have been advocated in AFD patients with 
microalbuminuria but no other evidence of end organ damage prior to making a 
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decision on initiating on ERT. But it has been shown that even in individuals with 
normal renal function and no proteinuria, renal pathological findings of AFD are 
present
115, 138, 145
. The benefits of invasive tissue diagnosis from renal biopsies and 
prediction of progression have to be weighed with the risks of complications from the 
procedure. We would suggest that renal biopsies be reserved for patients where a second 
renal pathology is possible resulting in different therapeutic options (e.g. an 
immunological process) or in females with the α-Gal A mutation with minimal 
microalbuminuria, proteinuria or impaired GFR where renal disease could be due to 
AFD or other coexisting comorbidities (diabetes or hypertension). 
Renal tubular dysfunction can lead to a variety of complications due to renal tubular 
acidosis. This may result in bone disorders (rickets, osteomalacia, osteopenia, and 
osteoporosis), Fanconi syndrome, renal stone disease and electrolyte disturbances. 
Currently there is no published literature demonstrating AFD patients with Fanconi 
syndrome, glycosuria, aminoaciduria, hyperuricosuria, hyperphosphaturia or metabolic 
acidosis. This makes renal tubular acidosis less likely in AFD. But studies have shown 
evidence of osteopenia and osteoporosis in AFD patients
329, 330
 and proposed 
mechanisms of this maybe due to vitamin D deficiency, secondary 
hyperparathyroidisim, associated depression, carbamazepine use, reduced physical 
activity and GB3 deposition in bone macrophages
330
. Another potential mechanism of 
these bone disorders in AFD could be due to potential renal tubular acidosis form renal 
tubular dysfunction. We propose that a further study into screen AFD patients for renal 
tubular acidosis, vitamin D deficiency and hyperparathyroidism should be undertaken. 
 
 
3.11 Limitations 
 
Sample size was a major limitation in our study, with the largest cohort being 105 
samples and smallest 30 samples. Also some of the patients were already on ERT but 
ideally the study should have been carried out on patients before the initiation of ERT 
and followed up prospectively, over a long period of time, ideally years rather than 
months. As AFD is a rare disease, patients in our unit travelling nationally and at most 
for 6 monthly follow up, it was difficult for a larger population size to be studied. 
Even though in our study population there was a statistically younger control female 
cohort compared to AFD females, when older AFD females were removed from the 
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AFD cohort (ensuring no significant difference in age of the AFD females versus 
control females) the statistical significance of the data presented was not altered (data 
not shown). Therefore, to have a larger number, the data presented were from the 
original study population. 
 
 
3.12 Conclusions 
 
Currently predicting the progression of renal disease in AFD is difficult and the timing 
of the initiation of ERT to prevent end stage renal disease is challenging. Once 
significant proteinuria  (>1G/24 hours) or glomerulosclerosis (>50%) has developed the 
therapeutic benefit of ERT is reduced
10
. A non-invasive biomarker in AFD, such a 
plasma chitotriosidase in Gaucher’s disease, would be ideal for diagnosis, management 
and monitoring. We suggest that urine β-hex can be used with or without 
microalbuminuria as another marker for early evidence of renal damage in AFD. 
Unexpectedly urinary markers of renal fibrosis or scarring do not appear to be elevated 
in AFD (maybe due to small numbers or technical reasons) but an increased 
inflammatory process maybe present as evidence by raised urine MCP-1 levels. 
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Chapter 4. Assessment of autonomic function in AFD 
 
4.1 Introduction 
4.2 Rationale for study 
4.3 Aims 
4.4 Hypothesis 
4.5 Materials and methods 
4.6 Results 
4.7 Discussion 
4.8 Limitations 
4.9 Conclusions
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4.1 Introduction 
 
The autonomic nervous system (ANS) or visceral nervous system is the part of 
the nervous system that controls visceral functions and acts as a control system 
below the conscious level. It affects heart rate, blood pressure, gut motility and 
digestion, respiratory rate, salivation, perspiration, pupillary diameter, 
micturition and sexual arousal. Most of the ANS actions are involuntary and is 
divided into the parasympathetic and the sympathetic nervous systems. A variety 
of conditions can affect the ANS and is summarised in Table 4.1. Due to this 
variety of conditions, autonomic dysfunction may present in any age group or 
may have a significant family history if genetic in origin. Due to the varied 
functions of the ANS, symptoms of dysfunction are varied and are summarised 
in Table 4.2. 
 
System Disease / Disorder 
Primary Acute/ subacute dysautonomias – pure pandysautonomia, pandysautonomia with 
neurological features, pure cholinergic dysautonomia 
Chronic autonomic failure syndromes – pure autonomic failure, multiple system 
atrophy (Shy-Drager syndrome), autonomic failure with parkinson’s disease 
Secondary Congenital – nerve growth factor deficiency 
Hereditary – autosomal dominant trait, familial amyloid neuropathy, autosomal 
recessive trait, familial dysautonomia: Riley-Day syndrome, dopamine β-hydroxylase 
deficiency 
Metabolic diseases – diabetes mellitus, chronic renal failure, chronic liver disease, 
alcohol induced 
Inflammatory – Guillain-Barŕe syndrome, transverse myelitis 
Infections – bacterial (tetanus), parasitic (Chagas’ disease), viral (HIV) 
Neoplasia – brain tumours especially of the third ventricle or posterior fossa, 
paraneoplastic, systemic amyloidosis 
Surgery – vagotomy and drainage procedures 
Trauma – cervical and high thoracic spinal cord transection 
Drugs, chemical toxins By causing a neuropathy or direct effects; see Table 4.3 
 
Table 4.1. Summary of the causes of autonomic dysfunction. Adapted from Mathias CJ. Disorders of the 
autonomic nervous system. In: Bradley WG, Daroff RB, Fenichel GM, Marsden CD. Neurology in 
clinical practice, 3
rd
 ed. Boston: Butterworth-Heinemann, 2000:2131-65. 
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System Symptoms 
Cardiovascular Orthostatic Hypotension  
- Cerebral hypoperfusion – dizziness, visual disturbance, syncope, cognitive deficits 
- Muscle hypoperfusion - paracervical and suboccipital ache, lower back/buttock ache 
Renal Hypoperfusion 
- Oliguria 
Spinal Cord hypoperfusion 
Non-specific  
- Weakness 
- Lethargy 
- Fatigue 
Falls 
Lability of blood pressure 
Tachycardia 
Supine Hypertension 
Paroxsymal hypertension 
Bradycardia 
Sudomotor Hypo- or anhidrosis 
Hyperhidrosis 
Gustatory sweating 
Hypothermia 
Hyperpyrexia 
Gastrointestinal Xerostomia 
Dysphagia 
Gastric stasis 
Dumping syndromes 
Constipation 
Diarrhoea 
Urinary Nocturia 
Frequency 
Urgency, retention 
Incontinence 
Sexual Erectile failure 
Ejaculatory failure 
Retrograde ejaculation 
Priapism 
Eye Pupillary abnormalities 
Ptosis 
Alachryma 
Abnormal lacrimation with food ingestion 
 
Table 4.2. Summary of symptoms of autonomic nervous system dysfunction
331
. 
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4.2 Rationale for study 
 
Currently there is documented evidence for involvement of the central and peripheral 
nervous system in AFD. Patients suffer with symptoms of acroparaethesia, fever pain 
attacks, transient ischaemic attacks or strokes, altered sweating, postural hypotension 
and headaches. Extensive GB3 deposition are found in neurons of autonomic and dorsal 
root ganglia
332-334
, with clinical evidence of impairment of autonomic function
335
, also 
present in heterozygotes
336
. Small calibre myelinated and unmyelinated nerve fibres are 
more severely affected than thick myelinated nerve fibres
333, 337-340
. GB3 deposits have 
been found in perineurial cells, endothelial and periepithelial cells of small epineurial or 
endoneurial vessels in nerve axons and Schwann cells
339, 341-343
. GB3 deposition has also 
been found in sweat gland cells
339, 340
. To our knowledge there is only two published 
articles showing abnormal cardiac autonomic function (heart rate variability) in 
males
344, 345
 which improved significantly over a 26 week period with ERT
345
 but also 2 
studies showing normal cardiac autonomic
346, 347
 function. Sweat function also 
improved with ERT
20
 though baseline skin moisture may not
348
. 
 
 
4.3 Aims 
 
i) To investigate cardiac autonomic dysfunction in AFD subjects. 
ii) To investigate plasma catecholamine levels in AFD subjects. 
iii) To investigate autonomic symptoms and neuropathic pain in AFD subjects. 
 
 
4.4 Hypothesis 
 
AFD patients have significant autonomic symptoms, neuropathic pain, evidence 
of cardiac autonomic involvement and abnormal plasma catecholamine 
response. 
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4.5 Materials and methods 
 
I recruited patients from the lysosomal storage disorders unit at the Royal Free Hospital, 
UK from November 2006 until February 2009. Study was approved by the NHS 
Research Ethics Committee (REC reference 07/Q0501/81). Patients recruited had to 
give informed and signed consent and have a documented mutation in the α-Gal A gene. 
I performed the autonomic function tests, at the Pickering Unit, St Mary’s Hospital, UK 
with the exception of the quantitative sudomotor axon-reflex test (QSART) which I 
carried out at the Royal Free Hospital. Subjects were also asked to complete the Leeds 
Assessment of Neuropathic Symptoms and Signs (LANSS) and Composite Autonomic 
Symptom Scale (COMPASS) questionnaires. 
 
4.5.1 Cardiac autonomic function screening tests 
 
These tests were carried out by me, at the Pickering Unit, St Mary’s Hospital. Prior to 
conducting autonomic function screening tests, subjects were asked to refrain from 
caffeine, nicotine and alcohol for at least 3 hours before, and avoid drugs with 
adrenergic and anticholinergic properties (Table 4.3) for at least 48 hours before. 
Subjects with cardiac pacemakers and/or defibrillators, known to have autonomic 
dysfunction due to another disorder or disease process other than AFD, had proliferative 
diabetic retinopathy or if they were unable to avoid drugs as listed in Table 4.3, were 
excluded from this study. 
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Medication Effect 
Decreasing sympathetic activity Centrally acting – clonidine, methyldopa, moxonidine, 
reserpine, barbiturates, anaesthetics 
Peripherally acting – sympathetic nerve endings (guanethidine, 
bethanidine), α adrenoceptor blockade (phenoxybenzamine), β 
adrenoceptor blockade (propanolol) 
Increasing sympathetic activity Amphetamines, releasing noradrenaline (tyramine), uptake 
blockers (imipramine), monoamine oxidase inhibitors 
(tranylcypromine), β adrenoceptor stimulants (isoprenaline) 
Decreasing parasympathetic activity Antidepressants (imipramine), tranquilisers (phenothiazines), 
antidysrhytmics (disopyramide), anticholinergics (atropine, 
probanthine, benztropine), toxins (botulinum) 
Increasing parasympathetic activity Cholinomimetics (carbachol, bethanechol, pilocarpine, 
mushroom poisoning), anticholinesterases, reversible 
carbamate inhibitors (pyridostigmine, neostigmine), 
organophosphorous inhibitors (parathion, sarin) 
Miscellaneous Alcohol, thiamine (Vitamin B1) deficiency 
Vincristine, perhexiline maleate 
Thallium, mercury, arsenic 
 
Table 4.3. Drugs affecting autonomic function screening tests. Adapted from Mathias CJ. Disorders of the 
autonomic nervous system. In: Bradley WG, Daroff RB, Fenichel GM, Marsden CD. Neurology in 
clinical practice, 3
rd
 ed. Boston: Butterworth-Heinemann, 2000:2131-65. 
 
Subjects were monitored with continuous electrocardiogram (ECG), blood pressure 
(BP) and heart rate (HR) measurements with an automated sphygmomanometer and 
finometer (used to measure beat to beat finger arterial pressure). ECG monitoring 
provided continuous HR monitoring, the finometer a continuous beat to beat variation in 
BP and the automated sphygmomanometer HR and BP measurements at regular 
intervals. These measurements were carried out with the following sequence of 
positions or activities: 
1. The subject was supine for 15 minutes with BP measurements every 3 minutes. 
2. The subject was then tilted to 60° for 10 minutes (using an automated tilt table) 
with BP measurements every 3 minutes. 
3. At the end of initial supine and end of tilt positions plasma samples for 
adrenaline and noradrenaline were taken via venepuncture. 
4. The subject was then returned to a supine position. In the supine position the 
following tests were carried out. 
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 Isometric exercise: 
The subject was asked to squeeze the pump of a manual sphygmomanometer 
and sustain this at 30-40% of maximum hand grip for 3 minutes. The BP was 
measured with the sustained hand grip after 2.5 to 3 minutes from the start of 
the exercise. This exercise was stopped after the BP was measured. 
 Mental arithmetic exercise: 
The subject was asked to subtract 7 from 400 continuously. The BP was 
measured 1.5 to 2 minutes after the start of the mental exercise. The exercise 
was stopped after the BP had been measured. 
 Cold pressor exercise: 
An ice pack was placed on the subject’s hand for 90 seconds, and the BP 
measured at 1 minute from the start of the exercise. 
 Deep breathing exercise/ respiratory sinus arrhythmia: 
The subject was asked to do deep breathing at a rate of 6 breaths per minute 
(5 seconds inspiration and 5 seconds expiration), for a total of 1 minute, with 
continuous ECG monitor. The mean of difference between maximum and 
minimum HR for 6 measured cycles were calculated in beats per minute 
(bpm). 
 Hyperventilation exercise: 
The subject was asked to perform rapid shallow breathing for 1 minute with 
the BP and HR measured 30 seconds after the start of the exercise. 
 Valsalva manoeuvre and HR response: 
The subject was asked to blow into a mouthpiece connected to modified 
sphygomanometer and hold the expiratory pressure of 40mmHg for 10 
seconds with continuous ECG monitoring. This was repeated three times 
with 1 minute intervals. The average of 3 valsalva ratios (ratio of the 
maximum rise in HR to the maximum fall in HR) was calculated. 
 
Venous blood samples that were collected into heparinised tubes for plasma adrenaline 
and noradrenaline levels, were added with 1,2-di (2-aminoethoxy) ethan-NNN'n'-
tetraacetic acid (EGTA) and glutathione to prevent oxidation. Samples were kept on ice 
until centrifuged and the plasma then kept at -20 °C until assayed. Plasma 
concentrations of plasma noradrenaline (norepinephrine), and adrenaline (epinephrine) 
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were measured by high performance liquid chromatography with an electrochemical 
detector
349
. The intra-assay and interassay coefficients of variation were 3.1% and 4.6% 
(respectively) for noradrenaline and 4.6% and 5.1% for adrenaline. 
 
Normal autonomic screening tests responses are summarised in Table 4.4. 
 
Test System tested Normal Response 
Head Tilt (BP) Sympathetic < 20mmHg systolic drop at 3 minutes 
< 10mmHg diastolic drop at 3 minutes 
Head Tilt (HR) Sympathetic HR rise of ≥ 5 bpm 
Isometric, Mental 
Arithmetic, Cold Pressor 
Parasympathetic and 
sympathetic 
≥ 10mmHg systolic rise AND 
≥ 5 mmHg diastolic rise AND 
≥ 3bpm HR rise 
Respiratory sinus 
Arrhythmia 
Parasympathetic > 10 bpm HR rise – modest response 6-10 bpm 
HR rise and minimal response 1-5 bpm HR rise 
Hyperventilation Parasympathetic ≥ 10 bpm HR rise 
Valsalva Parasympathetic Valsalva ratio > 1.0 
Table 4.4. Summary of normal cardiac autonomic responses. 
 
4.5.2 Quantitative sudomotor axon-reflex test (QSART)
350, 351
.  
 
The QSART involved using a Q-SWEAT
TM
 machine from WR Medical Electronics 
Co., Stilwater, Minnesota (Fig 4.1). The Q-SWEAT device accurately measures sweat 
production from a small area of skin, by evaporating sweat into dry air and measuring 
the increase in the fractional relative humidity of the air returning from the skin. The 
device was switched on for 15 – 20 minutes to warm up prior to use. Subjects were 
seated quietly for 15 – 20 minutes prior to test to acclimatise to the room temperature 
and humidity. The left medial forearm (75% of the distance from the ulnar epicondyle 
to the piciform bone), was used as the skin surface area for the test. The medial forearm 
was chosen as sweat production here is not affected by age
352
. An alcoholic wipe was 
used to clean the skin and dried for 1 minute. The recording capsule was attached to the 
skin area that had been cleaned. The recording capsule is made up of a 
multicompartmental sweat cell. The outer compartment is loaded with 10% 
acetylcholine solution. The Q-SWEAT device uses a desiccant pack (#5190; WR 
Medical Electronics Co., Stillwater, Minnesota) as its dry air source. Room air is drawn 
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in through an intake pump and channelled through a serpentine of drierite (W.A. 
Hammond Co., Xenia, Ohio). This air is then passed through a set of sensors 
(Honeywell International, Inc., Morristown, New Jersey), which controls the flow rate. 
The sensors evaluate the temperature and percent relative humidity. Finally the dried air 
is delivered to the multicompartmental sweat cell. The test was started when a steady 
baseline sweat production rate had been achieved. A constant current of 2mA is applied 
for 5 minutes through the outer compartment containing the 10% acetylcholine solution. 
The sweat produced in the inner compartment evaporates and was measured by the Q-
SWEAT device. The sweat response was recorded during the electrical stimulus and for 
5 minutes after. The production of sweat in the inner compartment is based on the 
neural pathway consisting of an axon reflex mediated by the post-ganglionic 
sympathetic sudomotor axon (Fig 4.2). Baseline sweat rate, latency (time from electrical 
stimulus till noticeable sweat rate change occurred) and total sweat volume (in 10 
minutes from start of electrical stimulus) was calculated by Test-works software (WRE 
Medical electronics co., Stilwater, Minnesota). Total sweat volume was corrected for 
surface area of multicompartmental sweat cell. 
 
Fig 4.1.  Q-SWEAT
 TM
 machine from WR Medical Electronics Co., Stilwater, Minnesota. 
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Fig 4.2. (A) Diagram of the sudomotor axon reflex and (B) schematic picture of a normal sweat response. 
From Clinical autonomic disorders: Evaluation and management; Edited by Philip A.Low, Chapter 14, 
Laboratory evaluation of autonomic failure, p172. 
 
4.5.3 Questionnaires 
 
Subjects were asked to complete the following 2 questionnaires to assess autonomic 
symptoms and neuropathic pain. 
1. Composite autonomic symptom scale. 
2. Leeds assessment of neuropathic symptoms and signs. 
 
4.5.3.1 Composite autonomic symptom scale (COMPASS)
353
,  (Fig 4.3). 
This questionnaire has 73 items subdivided into 9 domains, concerning different 
aspects of autonomic symptoms and is item-weighted, with higher scores 
indicating more or worse symptoms. Three different population groups; 41 
healthy controls (mean age 46.6 years), 33 patients with non-autonomic 
peripheral neuropathy (mean age 59.5 years) and 39 patients with autonomic 
failure (mean age 61.1 years) were tested in developing this questionnaire. Mean 
scores were 9.8 (±9), 25.9 (±17.9) and 52.3 (±24.2) respectively. This 
questionnaire was validated by correlating COMPASS scores with the scores of 
the composite autonomic scoring scale
354
 derived from the autonomic reflex 
screen. 
A B 
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18. In the past year, have you ever felt faint, dizzy, or "goofy" or had difficulty thinking soon after standing up from a 
sitting or lying down position?   1. Yes   2. No 
If you marked YES go to question 19.    If you marked No go to question 37. 
19. When standing up, how frequently do you get these feelings or symptoms? 
1. Rarely 
2. Occasionally 
3. Frequently 
4. Almost always 
20. How would you rate the severity of these feelings or symptoms? 
1. Mild 
2. Moderate 
3. Severe 
21. For how long have you been experiencing these feelings or symptoms? 
1. Less than 3 months 
2. 3 to 6 months 
3. 7 to 12 months 
4. 13 months to 5 years 
5. More than 5 years 
6. As long as I can remember 
22. In the past year, how often have you ended up fainting soon after standing up from a sitting or lying down? 
0. Never 
1. Once 
2. Twice 
3. Three times 
4. Four times 
5. Five or more times 
23. How cautious are you about standing up from a sitting or lying down position? 
1. Not cautious at all 
2. Somewhat cautious 
3. Extremely cautious 
24. What part of the day are these feelings worse? (Check only one) 
1. Early morning 
2. Rest of morning 
3. Afternoon 
4. Evening 
5. At night, when I get up after I've been asleep 
6. No particular time is worse 
7. Other time, please specify______________________________ 
25. In the past year, have these feelings or symptoms that you have experienced: 
1. Gotten much worse 
2. Gotten somewhat worse 
3. Stayed about the same 
4. Gotten somewhat better 
5. Gotten much better 
6. Completely gone 
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Please rate the average severity you have experienced in the past year for each of the following symptoms. 
 None Mild Moderate Severe 
26. Rapid or increased heart rate? (palpitations)     
27. Sickness to your stomach (nausea) or vomiting?     
28. A spinning or swimming sensation?      
30. Blurred vision?      
29. Dizziness?     
31. Feeling of weakness?      
32. Feeling shaky or shaking sensation?      
33. Feeling anxious or nervous?      
34. Turning pale?      
35. Clammy feeling to your skin?      
36. Do you have any biological (blood, natural) relatives among your parents, grandparents, brothers, sisters, or 
children who have frequent dizziness after standing from a sitting or lying down position? 
                                                             1. Yes   2. No  
If Yes, please list their names and relationship to you. 
Name    Relationship 
 
In the past year, have you ever felt faint, dizzy, or "goofy" or had difficulty thinking: 
37. soon after a meal?       1. Yes   2. No 
38. after standing for a long time?      1. Yes   2. No 
39. during or soon after physical activity or exercise?    1. Yes   2. No 
40. during or soon after being in a hot bath, shower, tub, or sauna?  1. Yes   2. No 
41. Have you ever felt dizzy or faint or actually fainted when you saw blood or had a blood sample taken? 
        1. Yes   2. No 
In the past year, have you fainted: 
42. while passing urine?       1. Yes   2. No 
43. while coughing?       1. Yes   2. No 
44. while pressing on side of neck?      1. Yes   2. No 
45. before a public speech?       1. Yes   2. No 
46. any other time?       1. Yes   2. No 
If you checked "Yes" to any of these questions on fainting, please describe circumstances. 
 
47. In the past year, have you ever completely lost consciousness after a spell of dizziness?  
        1. Yes   2. No 
48. In the past year, have you had any seizures or convulsions?  1. Yes  2. No 
If Yes please describe circumstances below 
 
In the past 5 years how would rate the amount of trouble, if any, you have had: 
 None Some A lot Constant 
49. with paralysis in parts of your face?     
50. with feelings of complete weakness all over your body?     
51. with attacks of uncontrollable movements of your arms or legs?     
52. with attacks in which you couldn't control your speech?     
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53. Have you ever in your adult life had a spell of dizziness?  1. Yes   2. No 
54. In the past year, have you ever noticed colour changes in your skin, such as red, white, or purple? 
        1. Yes   2. No 
If Yes, go to question 55.    If No, go to question 65. 
What colour changes have occurred? 
55. My skin turns red      1. Yes   2. No 
56. My skin turns white      1. Yes   2. No 
57. My skin turns purple      1. Yes   2. No 
58. Other, please Specify_______________________________________________________________ 
What parts of your body are affected by these colour changes? 
59. My hands       1. Yes   2. No 
60. My feet       1. Yes   2. No 
61. Other parts, please specify___________________________________________________________ 
62. Entire body       1. Yes   2. No 
63. For how long have you been experiencing these changes in skin colour? 
1. Less than 3 months 
2. 3 to 6 months 
3. 7 to 12 months 
4. 13 months to 5 years 
5. More than 5 years 
6. As long as I can remember 
64. Are these changes in your skin colour: 
1. Getting much worse 
2. Getting somewhat worse 
3. Staying about the same 
4. Getting somewhat better 
5. Getting much better 
6. Completely gone 
65. In the past year, after a long hot bath or shower, have you ever noticed the pads on the ends of your fingers 
wrinkle up?       1. Yes   2. No 
66. In the past 5 years, what changes, if any, have occurred in your general body sweating? 
1. I sweat much more than I used to 
2. I sweat somewhat more than I used to 
3. I haven't noticed any changes in my sweating 
4. I sweat somewhat less than I used to 
5. I sweat much less than I used to 
67. In the past 5 years, what changes, if any, have occurred in the amount your feet sweat? 
1. They sweat much more than they used to 
2. They sweat somewhat more than they used to 
3. I haven't noticed any changes 
4. They sweat somewhat less than they used to 
5. They sweat much less than they used to 
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68. In the past 5 years, what changes, if any, have occurred in facial sweating after eating spicy foods? 
1. I sweat much more than I used to 
2. I sweat somewhat more than I used to 
3. I haven't noticed any changes in my sweating 
4. I sweat somewhat less than I used to 
5. I sweat much less than I used to 
6. I avoid eating spicy foods because I sweat so much 
7. I avoid eating spicy foods for other reasons 
In the past 5 years, what changes, if any, have occurred in your ability to tolerate heat during a hot day, strenuous 
work or exercise, hot bath or shower, hot tub, or sauna?   
69. I now get more overheated     1. Yes   2. No 
70. I now get dizzy       1. Yes   2. No 
71. I now get short of breath      1. Yes   2. No 
72. Other changes, please specify________________________________________________________ 
73. No change       1. Yes   2. No 
74. Do your eyes feel excessively dry?     1. Yes   2. No 
75. Does your mouth feel excessively dry?    1. Yes   2. No 
76. Do you have excessive amounts of saliva formation?   1. Yes   2. No 
77. What is the longest period of time that you have had any one of these symptoms: dry eyes, dry mouth, or 
increased saliva production? 
0. I have not had any of these symptoms 
1. Less than 3 months 
2. 3 to 6 months 
3. 7 to 12 months 
4. 13 months to 5 years 
5. More than 5 years 
6. As long as I can remember 
78. For the symptom of dry eyes, dry mouth, or increased saliva production that you have had for the longest period 
of time, is this symptom: 
0. I have not had any of these symptoms 
1. Getting much worse 
2. Getting somewhat worse 
3. Staying about the same 
4. Getting somewhat better 
5. Getting much better 
6. Completely gone 
79. What weight changes, if any, have you had over the past year? 1. I have lost about ________ pounds 
                      2. My weight has not changed 
                 3. I have gained about ________ pounds 
80. In the past year, have you noticed any changes in how quickly you get full when eating a meal? 
1. I get full a lot more quickly now than I used to 
2. I get full more quickly now than I used to 
3. I haven't noticed any change 
4. I get full less quickly now than I used to 
5. I get full a lot less quickly now than I used to 
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81. In the past year, have you felt excessively full or persistently full (bloated feeling) after a meal? 
1. Never    2. Sometimes    3. A lot of the time 
82. In the past year, have you felt like you had a persistent upset stomach (nausea)? 
1. Never    2. Sometimes    3. A lot of the time 
83. In the past year, have you vomited after a meal? 
1. Never    2. Sometimes    3. A lot of the time 
84. In the past year, have you had a cramping or colicky abdominal pain? 
1. Never    2. Sometimes   3. A lot of the time 
If Never, go to the question 87. Else, go to question 85. 
85. Are these pains usually after a meal?    1. Yes   2. No 
86. How long have you had these cramping or colicky abdominal pains? 
1. Less than 3 months 
2. 3 to 6 months 
3. 7 to 12 months 
4. 13 months to 5 years 
5. More than 5 years 
6. As long as I can remember 
87. In the past year, have you had any bouts of diarrhea?   1. Yes   2. No 
If Yes, go to question 88.   If No, go to question 94. 
88. How frequently does this occur? 
1. Rarely 
2. Occasionally 
3. Frequently, _____times per month 
4. Constantly 
89. How severe are these bouts of diarrhea? 
1. Mild    2. Moderate    3. Severe 
90. What part of the day do they seem to be worse? 
1. First thing in the morning 
2. Rest of the morning 
3. Afternoon 
4. Evening 
5. During the night 
6. No particular time 
91. Do these bouts of diarrhea usually occur after a meal?   1. Yes   2. No 
92. Are these bouts of diarrhea accompanied by a lot of rectal gas (flatus)? 
1. Never  2. Occasionally  3. Frequently   4. Always 
93. Are your bouts with diarrhea getting: 
1. Much worse 
2. Somewhat worse 
3. Staying the same 
4. Somewhat better 
5. Much better 
6. Completely gone 
94. In the past year, have you been constipated?    1. Yes   2. No 
If Yes, go to question 95.   If No, go to question 98. 
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95. How frequently are you constipated? 
1. Rarely 
2. Occasionally 
3. Frequently, _____times per month 
4. Constantly 
96. How severe are these episodes of constipation? 
1. Mild    2. Moderate    3. Severe 
97.Is your constipation getting: 
1. Much worse 
2. Somewhat worse 
3. Staying the same 
4. Somewhat better 
5. Much better 
6. Completely gone 
98.Overall, are your abdominal symptoms of vomiting, diarrhea, constipation, or weight loss getting: 
0. I have not had these symptoms 
1. Much worse 
2. Somewhat worse 
3. Staying the same 
4. Somewhat better 
5. Much better 
6. Completely gone 
99.Which one of the following symptoms have been most troublesome for you? (Check only one.) 
0. None 
1. Vomiting 
2. Diarrhea 
3. Constipation 
4. Weight loss 
100.How long have you had this most troublesome symptom? 
0. I do not have any of these symptoms 
1. Less than 3 months 
2. 3 to 6 months 
3. 7 to 12 months 
4. 13 months to 5 years 
5. More than 5 years 
6. As long as I can remember 
101. Is this most troublesome symptom getting: 
0. I do not have any of these symptoms 
1. Much worse 
2. Somewhat worse 
3. Staying the same 
4. Somewhat better 
5. Much better 
6. Completely gone 
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102. In the past 5 years, how would you rate the amount of trouble, if any, you have had with difficulty in 
swallowing? 
1. No trouble 
2. Some trouble 
3. A lot of trouble 
4. Constant trouble 
103. In the past 5 years, how would you rate the amount of trouble, if any, you have had with everything you eat 
tasting the same? 
1. No trouble 
2. Some trouble 
3. A lot of trouble 
4. Constant trouble 
Have you ever in your adult life: 
104. been nauseated or vomited?     1. Yes   2. No 
105. had a bout of diarrhea?      1. Yes   2. No 
106. lost your appetite for at least part of a day?    1. Yes   2. No 
107. felt discomfort or pain in the pit of your stomach?   1. Yes   2. No 
108. In the past year, have you ever leaked urine or lost control of your bladder function? 
1. Never 
2. Occasionally 
3. Frequently, _____times per month 
4. Constantly 
109. In the past year, have you had difficulty passing urine? 
1. Never 
2. Occasionally 
3. Frequently, _____times per month 
4. Constantly 
110. In the past year, have you had trouble completely emptying your bladder? 
1. Never 
2. Occasionally 
3. Frequently, _____times per month 
4. Constantly 
111. How would you describe your current sexual desire? 
1. Completely absent 
2. Greatly reduced 
3. Somewhat reduced 
4. About the same or more than in the past 
If Male, go to question 112  If Female, go to question 124 
112. Are you able to have a full erection? 
1. Never, under any circumstances 
2. Much less frequently than in past 
3. Somewhat less frequently than in past 
4. The same, or more frequently, than in past 
Which of the following statements apply to your situation? 
113. My ability to have intercourse has not changed   1. Yes   2. No 
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114. I have erections but am unable to have intercourse   1. Yes   2. No 
115. I can have intercourse only some of the time    1. Yes   2. No 
116. My erections are definitely impaired    1. Yes   2. No 
117. I am able to have intercourse, but am unable to ejaculate  1. Yes   2. No 
118. I have "dry orgasms" and afterward my urine looks milky  1. Yes   2. No 
119. I have been unable to have erections or they have been impaired since I started taking a 
medication_____________ 
120. Other situation, please describe_______________________ 
121. None of the above apply 
122. How long have you had difficulty with erectile function? 0. I do not have this difficulty 
           1. Less than 3 months 
         2. 3 to 6 months 
         3. 7 to 12 months 
          4. 13 months to 5 years 
         5. More than 5 years 
         6. As long as I can remember 
123. Is this difficulty getting:  0. I have not had difficulty 
      1. Much worse 
     2. Somewhat worse 
     3. Staying the same 
     4. Somewhat better 
     5. Much better 
     6. Completely gone 
124. In the past year, without sunglasses or tinted glasses, has bright light bothered your eyes? 
1. Never 2. Occasionally 3. Frequently  4. Constantly 
125. How severe is this sensitivity to bright light? 
1. Mild    2. Moderate    3. Severe 
126 In the past year, have you had trouble focusing your eyes? 
1. Never 2. Occasionally 3. Frequently  4. Constantly 
127 How severe is this focusing problem? 
1. Mild    2. Moderate    3. Severe 
128 In the past year, have you had blurred vision? 
1. Never 2. Occasionally 3. Frequently  4. Constantly  
129 How severe is this blurred vision? 
1. Mild    2. Moderate    3. Severe 
130 In the past year, have you had difficulty seeing at night? 
1. Never 2. Occasionally 3. Frequently  4. Constantly 
131 How severe is this night vision problem? 
1. Mild    2. Moderate    3. Severe 
132 In the past year, has the same degree of light seemed: 
1. Excessively dimmer 2. Much dimmer  3. About the same 4. Much brighter 5. Excessively 
brighter 
133. Which one of the following eye symptoms is the most troublesome for You? (Check only one) 
0. None  1. Trouble Focusing  2. Blurred Vision  3. Difficulty seeing at night 
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134 How long have your had this most troublesome eye symptom? 
0.I don't have any of these symptoms 
1. Less than 3 months 
2. 3 to 6 months 
3. 7 to 12 months 
4. 13 months to 5 years 
5. More than 5 years 
6. As long as I can remember 
135 Is this most troublesome symptom with your eyes getting: 
0. I don't have any of these symptoms 
1. Much worse 
2. Somewhat worse 
3. Staying the same 
4. Somewhat better 
5. Much better 
6. Completely gone 
136. In the past year, have you ever noticed or been told that while sleeping you stop breathing for several seconds?
      1. Yes   2. No 
137. In the past year, have you ever noticed or been told that while sleeping you snore loudly? 
      1. Yes   2. No 
Have you ever been told you have or been diagnosed as having: 
138. Narcolepsy?      1. Yes   2. No  3. Don’t know 
139. Obstructive sleep apnoea?    1. Yes   2. No  3. Don’t know  
140. Abnormal or disordered sleep patterns?   1. Yes   2. No  3. Don’t know 
141 Currently, how refreshing and restorative is your sleep? 
1. Not at all restorative - derive no benefit 
2. Some slight restorative value 
3. Restorative, but not adequate 
4. Relatively satisfactory 
5. Very satisfactory - feel completely refreshed 
142 Compared with a year ago, how would you rate your own sleep over the last month? 
1. Last month was much worse than a year ago 
2. Last month was slightly worse than a year ago 
3. Last month was about the same as a year ago 
4. Last month was slightly better than a year ago 
5. Last month was much better than a year ago 
143. Have you ever in your adult life had difficulty getting to sleep or staying asleep once you were asleep?  
      1. Yes   2. No 
144. In the past year, have you ever noticed or been told that during the day you sometimes breathe very loudly( e.g., 
croup)?     1. Yes   2. No 
Fig 4.3 Composite Autonomic symptom Scale 
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4.5.3.2 Leeds assessment of neuropathic symptoms and signs (LANSS)
355
, (Table 4.5).  
This is a pain scale used to identify patients in whom neuropathic mechanisms 
dominate their pain experience. Developed based on 60 patients with nociceptive 
and neuropathic pain and validated in a further 40 patients. It is a seven-item 
instrument which includes 5 self report questions and two sensory tests (with the 
physician present). A cut-off point of 12 is sensitive (83%) and specific (87%) 
for differentiating between neuropathic and non-neuropathic pain. It assesses 
five types of pain (thermal, dysesthesia, paroxysmal, evoked and autonomic 
dysfunction).  
 
Question Answer Score 
1) In the area where you have pain, do you also have 
‘pins and needles’, tingling or prickling sensations? 
Yes 
 
No 
5 
 
0 
2) Does the painful area change colour (look mottled 
or more red) when the pain is particularly bad? 
Yes 
 
No 
 
5 
 
0 
3) Does your pain make the affected skin abnormally 
sensitive to touch?  
(Getting unpleasant sensations or pain when lightly 
stroking the skin might describe this.) 
Yes 
 
No 
3 
 
0 
4) Does your pain come on suddenly and in bursts for 
no apparent reason when you are completely still? 
(Words like ‘electric shocks’, jumping and bursting 
might describe this.) 
Yes 
 
No 
2 
 
0 
5) In the area where you have pain, does your skin feel 
unusually hot like a burning pain? 
Yes 
 
No 
 
1 
 
0 
6) Gently rub the painful area with your index finger 
and then rub a non-painful area (for example, an area 
of skin further away or on the opposite side from the 
painful area). 
How does this rubbing feel in the painful area? 
I feel discomfort (like 
pins and needles, tingling 
or burning) different from 
the normal area. 
No difference 
 
5 
 
 
 
0 
7) Gently press on the painful area with your finger tip 
then gently press in the same way onto a non-painful 
area (the same non-painful area that you chose in the 
last question). 
How does this feel in the painful area? 
I feel numbness or 
tenderness in the painful 
area different from the 
normal area. 
No difference 
 
3 
 
 
 
0 
  
             Total 
 
Table 4.5 Leeds assessment of neuropathic symptoms and signs questionnaire. 
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4.5.4 Analysing results 
 
All demographic data were expressed as mean and standard deviation. Statistical 
analysis used was Wilcoxon matched-pairs rank test unless otherwise stated. 
Cardiac autonomic tests were expressed as mean and standard deviation in 
tables; mean, minimum and maximum values graphically and/or expressed as 
percentage of the AFD subjects with abnormal tests over total AFD subjects 
tested. Plasma catecholamines were expressed as mean and standard deviation 
and subdivided based on supine or tilted position, sex or type of mutation. 
QSART data was compared to normative data from Sletten et al 2010
356
 and 
COMPASS scores were compared to normative data from Suarez et al
353
 as no 
controls were recruited for this study. Statistical analysis used to compare study 
population with normative data was the 1 sample t-test. 
 
 
4.6 Results 
 
4.6.1 Cardiac autonomic function tests 
 
Demographics (Table 4.6). 
No control group was recruited. 24 AFD subjects were recruited; 9 males and 15 
females with a mean age of 42.8 ± 15.9 years, majority were on ERT (79.2%) 
and had a missense mutation (75.0%).  
 
 n = 24 
Age (years) 42.8 ± 15.9 
Sex 9 males, 15 females 
ERT, n (%) 19 (79.2%) 
Missense mutations, n (%) 18 (75.0%) 
MSSI 16.5 ± 8.8 
iGFR (ml/min/1.73m2) 82.7 ± 24.9 
UACR (mg/mmol Cr) 12.6 ± 23.4 
UPCR (mg/mmol Cr) 26.6 ± 36.1 
LVMI (g/m2) 97.4 ± 34.4 
 
Table 4.6.  Demographic data for cardiac autonomic tests. 
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Head tilt (Fig 4.4 – 4.6, Table 4.7) 
Mean systolic, diastolic and mean arterial pressure (MAP) rose in AFD subjects 
from 0 to 9 minutes with an appropriate rise in HR. Systolic BP drop of ≥ 
20mmHg was present in 1 male and 1 female at 1 minute, 1 female at 3 minutes 
and 1 female at 6 minutes. Diastolic BP drop of ≥ 10mmHg was present in 1 
female at 1 minute. HR fall or a rise of < 5 bpm was present in 1 male and 5 
females at 1 minute, 1 male and 4 females at 3 minutes, 1 male and 2 females at 
6 minutes and 2 females at 9 minutes. 
 
Isometric, mental arithmetic and cold pressor test (Fig 4.7, Table 4.8) 
Mean increase in systolic and diastolic BP in all AFD subjects was present in all 
3 pressor tests but HR only rose for isometric exercise and not the mental 
arithmetic or cold pressor tests (mean change in HR was 6.2 ± 11, 0.2 ± 6.7 and 
1.4 ± 9.7 bpm respectively). When analysed according to sex of subjects, there 
was no significant rise in HR in males and females for the mental arithmetic and 
cold pressor tests. Reviewing each subject individually, in the isometric exercise 
trial patient 23 had poor response in systolic BP, diastolic BP and HR response, 
in the mental arithmetic exercise, trial patients 15, 18 and 35 had a poor 
responses, and in the cold pressor exercise trial patient 17 had a poor response. 
 
Respiratory sinus arrhythmia (Fig 4.8, Table 4.9) 
The mean change in HR for all subjects, males and females were 20.8 ± 8.7, 
26.1 ± 7.3 and 17.2 ± 7.9 bpm respectively. Of the 22 AFD subjects who 
completed this test, only 2 females had an abnormal HR response to deep 
breathing; trial number 14 had a minimal HR rise of 4bpm and trial number 1 
had a modest HR rise of 7bpm. 
 
Hyperventilation (Fig  4.9,Table 4.10) 
The mean change in HR for all subjects, male and females were 14.2 ± 12.1, 
19.8 ± 13.8 and 10.1 ± 9.2 bpm respectively. Of the 21 AFD subjects who 
completed this test, 2 males and 8 females had HR rises of < 10 bpm (range from 
-1 to 6 bpm change in HR).  
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Valsalva manoeuvre (Fig 4.10, Table 4.11) 
The mean HR at rest was 66.5 ± 10.7 bpm rising to 88.9 ± 14.1 bpm in phase II 
with an appropriate fall to 57.0 ± 9.7 bpm in phase IV. The mean Valsalva ratio 
was 3.4 ± 2.9. Individually reviewing results showed that 1 male and 2 females 
had valsalva ratios of < 1.0 (abnormal).  
 
Summary of cardiac autonomic tests (Table 4.12) 
0 to 15% of AFD patients had an abnormality in 1 of the sympathetic cardiac 
autonomic tests, 9.1 to 47.6% of AFD patients had an abnormality in of the 
parasympathetic cardiac autonomic tests and 16.7 to 23.8% of AFD patients had 
an abnormality in 1 of the sympathetic and parasympathetic cardiac autonomic 
tests. 
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 0 min 1 min 3 min 6 min 9 min 0 vs 3 min 
All (n=21)       
Systolic (mmHg) 106.8 ± 11.9 108.4 ± 16.1 109.6 ± 11.4 112.8 ± 14.1 111.8 ± 14.5 ns 
Diastolic (mmHg) 58.8 ± 8.1 64.0 ± 8.5 66.1 ± 7.3 66.5 ± 11.7 65.5 ±8.8 p = 0.0005 
MAP (mmHg) 76.2 ± 8.9 82.2 ± 10.8 85.0 ± 8.6 84.8 ± 12.6 85.5 ± 9.2 p = 0.0004 
HR (bpm) 66.9 ±10.5 76.3 ± 11.9 76.7 ± 10.4 77.7 ± 10.8 77.5 ± 9.5 P = 0.0001 
Males (n=9)       
Systolic (mmHg) 113.3 ± 10.3 111.9 ± 18.6 114.1 ± 14.4 116.3 ± 18.2 116.4 ± 16.9 ns 
Diastolic (mmHg) 60.3 ± 9.1 66.4 ± 10.5 68.9 ± 9.0 69.0 ± 12.3 67.9 ± 11.4 p = 0.0091 
MAP (mmHg) 79.7 ± 9.6 85.6 ± 14.4 90.7 ± 9.6 88.2 ± 13.2 89.2 ± 9.6 p = 0.0091 
HR (bpm) 64.8 ± 8.2 76.3 ± 9.3 77.9 ± 9.0 77.9 ± 7.9 77.7 ± 8.7 p = 0.0039 
Females (n=12)       
Systolic (mmHg) 101.8 ± 10.8 105.8 ± 14.2 106.3 ± 7.5 110.1 ± 10.1 108.3 ±12.0 ns 
Diastolic (mmHg) 57.8 ± 7.6 62.2 ± 6.6 64.1 ± 5.3 64.7 ± 11.3 63.8 ± 6.2 p = 0.0262 
MAP (mmHg) 73.6 ± 7.7 79.9 ± 6.7 80.7 ± 4.7 82.2 ± 12.1 82.8 ± 8.1 p = 0.0161 
HR (bpm) 68.4 ± 12.1 76.4 ± 13.9 75.8 ± 11.7 77.5 ± 12.9 77.3 ± 10.5 p = 0.0058 
Table 4.7. Mean and SD of systolic, diastolic, MAP and HR of AFD patients for head tilt test. Statistical analysis used is Wilcoxon matched-pairs rank test.
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Fig 4.4. Head tilt test in all AFD patients; (A) Mean, minimum and maximum of the systolic, diastolic and mean arterial BP, and HR at 0, 1, 3, 6 and 9 minutes, (B) 
Percentage of AFD patients with abnormal responses at 1, 3, 6 and 9 minutes. 
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Blood Pressure and Heart Rate Change Tilt Table test  (Males)
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Fig 4.5. Head tilt test in male AFD patients; (A) Mean, minimum and maximum of the systolic, diastolic and mean arterial BP, and HR at 0, 1, 3, 6 and 9 minutes, (B) 
Percentage of AFD patients with abnormal responses at 1, 3, 6 and 9 minutes. 
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Blood Pressure and Heart Rate Change Tilt Table test  (Females)
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Fig 4.6. Head tilt test in female AFD patients; (A) Mean, minimum and maximum of the systolic, diastolic and mean arterial BP, and HR at 0, 1, 3, 6 and 9 minutes, (B) 
Percentage of AFD patients with abnormal responses at 1, 3, 6 and 9 minutes. 
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 Isometric Exercise Mental Arithmetic Cold Pressor 
 Pre test Post test Change Pre vs Post 
test 
Pre test Post test Change Pre vs Post 
test 
Pre test Post test Change Pre vs Post 
test 
All N = 20 N = 20 N = 17 
Systolic 
(mmHg) 
108.2 ± 
12.1 
133.9 
±23.8 
25.8 ± 15.6 p < 0.0001 110.6 ± 
15.2 
122.7 
±18.9 
12.1 ± 10.5 p = 0.0003 112.5 ± 
17.9 
136.3 ± 
22.5 
23.8 ± 14.0 p = 0.0003 
Diastolic 
(mmHg) 
59.0 ± 9.0 75.5 ± 12.6 16.5 ± 10.5 p = 0.0001 63.0 ± 8.6 68.0 ± 11.0 5.0 ± 4.6 p = 0.0012 60.2 ± 9.9 75.9 ± 13.7 15.8 ± 9.9 p = 0.0005 
MAP 
(mmHg) 
78.3 ± 9.6 101.1 ± 
17.8 
22.8 ± 12.5 p < 0.0001 82.6 ± 9.6 89.0 ± 14.3 6.5 ± 7.4 p = 0.0017 79.5 ± 11.2 100.8 ± 
16.3 
21.3 ± 12.7 p = 0.0005 
HR 
(bpm) 
64.6 ±10.9 70.9 ± 13.7 6.2 ± 11.1 p = 0.0083 70.0 ± 10.7 70.2 ± 8.9 0.2 ± 6.7 ns 67.7 ±10.9 69.1 ± 13.7 1.4 ± 9.7 ns 
Males N = 9 N = 9 N= 7 
Systolic 
(mmHg) 
112.0 ± 
13.44 
150.0 ± 
22.1 
38.0 ± 13.5 p = 0.0039 118.6 ± 
12.9 
132.1 ± 
16.6 
13.6 ±15.2 ns 126.0 ± 
13.9 
148.4 ± 
21.7 
22.4 ± 18.3 p = 0.0223 
Diastolic 
(mmHg) 
60.9 ± 10.0 84.7 ± 10.1 23.8 ± 8.9 p = 0.0039 67.1 ± 7.9 74.3 ± 9.8 7.2 ± 4.4 p = 0.0138 64.9 ± 11.7 78.9 ± 16.5 14.0 ± 11.0 p = 0.0313 
MAP 
(mmHg) 
81.6 ± 7.6 113.9 ± 
15.2 
32.2 ± 10.8 p = 0.0090 87.7 ± 6.6 95.8 ± 12.1 8.1 ± 6.9 p = 0.0091 88.7 ± 8.0 106.6 ± 
18.3 
17.9 ± 14.5 p = 0.0343 
HR 
(bpm) 
65.3 ± 7.8 74.8 ±13.9 9.4 ± 16.1 Ns 70.8 ± 7.9 71.3 ± 6.3 0.6 ± 9.1 ns 71.1 ± 7.6 66.9 ± 12.5 -4.3 ± 
11.38 
ns 
Females N = 11 N = 11 N = 10 
Systolic 
(mmHg) 
105.0 ± 
10.5 
120.7 ± 
16.3 
15.7± 8.3 p = 0.0038 104.0 ± 
14.2 
114.9 
±17.6 
10.9 ± 4.7 p = 0.0038 103.0 ± 
14.1 
127.8 ± 
19.8 
24.8 ± 11.2 p = 0.0059 
Diastolic 
(mmHg) 
57.5 ± 8.4 68.0 ± 9.1 10.6 ± 7.6 p = 0.0058 59.6 ±7.9 62.7 ± 9.2 3.1 ± 4.1 p = 0.0492 56.9 ± 7.3 73.9 ± 11.9 17.0 ± 9.5 p = 0.0020 
MAP 
(mmHg) 
75.6 ± 10.6 90.6 ± 12.1 14.9 ±7.4 p = 0.0038 78.3 ± 9.9 83.5 ± 14.1 5.1 ±7.8 ns 73.1 ± 8.2 96.8 ± 14.3 23.7 ± 11.3 p = 0.0059 
HR (bpm) 64.1 ± 13.3 67.6 ± 13.3 3.5 ± 3.1 P = 0.0122 69.3 ± 13.0 69.2 ± 10.9 -0.1 ± 4.5 ns 65.3 ± 12.5 70.6 ± 15.0 5.3 ± 6.4 ns 
 
Table 4.8. Summary of AFD patients systolic, diastolic, mean arterial BP and HR for isometric, mental arithmetic and cold pressor tests. Results are mean and SD. Statistical 
analysis used is the Wilcoxon matched-rank pairs test.
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Fig 4.7. Isometric exercise, mental arithmetic and cold pressor tests in AFD patients. Mean, minimum and 
maximum of the systolic, diastolic and mean arterial BP, and HR; pre and post test. 
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Fig 4.8. Respiratory sinus arrhythmia test with mean and SD of minimum and maximum HR in all male 
and female AFD patients. 
 
 
 Minimum HR Maximum HR Difference Pre vs Post test 
All (n = 22) 54.7 ± 8.2 75.5 ± 12.8 20.8 ± 8.7 p < 0.0001 
Male (n = 9) 55.2 ± 8.0 81.3 ± 9.6 26.1 ± 7.3 p = 0.0091 
Female (n=13) 54.3 ± 8.7 71.5 ± 13.4 17.2 ± 7.9 p = 0.0017 
 
Table 4.9. Summary of respiratory sinus arrhythmia data showing mean and SD. Statistical analysis used 
is the Wilcoxon matched-pairs rank test.   
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Fig 4.9. Hyperventilation test with mean, minimum and maximum HR pre and post test in all, male and 
female AFD patients. 
 
 
 Pre test Post test Change Pre vs Post test 
All HR (n = 21) 66.1 ± 10.3 80.3 ± 15.7 14.2 ± 12.1 p < 0.0001 
Male HR (n = 9) 66.1 ± 7.7 85.9 ± 12.0 19.8 ± 13.8 p = 0.0078 
Female HR (n = 12) 66.0 ± 12.2 76.1 ± 17.3 10.1 ± 9.2 p = 0.0025 
 
Table 4.10. Summary of data from hyperventilation test showing mean and SD of HR pre and 30 seconds 
after start of the test. Statistical analysis used is the Wilcoxon matched-pairs rank test.   
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Fig 4.10. Graph of all AFD patients HR during Valsalva manoeuvre. 
 
 
 Rest Phase II Phase IV Valsalva Ratio 
All HR (n = 19) 66.5 ± 10.7 88.9 ± 14.1 57.0 ± 9.7 3.4 ± 2.9 
Male HR (n = 9) 68.1 ± 9.3 94.4 ± 11.5 56.3 ± 10.2 3.1 ± 2.2 
Female HR (n = 10 ) 65.0 ± 12.2 83.9 ± 14.8 57.6 ± 9.9 3.6 ± 3.5 
 
Table 4.11. Summary of data from valsalva manoeuvre test showing mean and SD of HR during the rest 
phase, phase II and phase IV and the valsalva ratio.  
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Type of Test Name Number Definition of abnormal test Abnormal 
test 
Trial number % 
abnormal 
Sympathetic 
 
Head Tilt N = 21 Systolic  BP drop > 20mmHg at 3 minutes 1 Female 11 4.8 
Sympathetic 
 
Head Tilt N = 21 Diastolic BP drop > 10mmHg at 3 minutes None none 0 
Parasympathetic and 
sympathetic 
Head Tilt N = 21 HR drop or < 5 bpm rise at 3 minutes 1 Male 
4 Females 
13, 14, 19, 22, 23 23.8 
Sympathetic Isometric Exercise N = 20 < 10 mmHg rise in sys, < 5mmHg rise in dias and 
<3bpm rise in HR 
1 Female 23 5 
Sympathetic Mental Arithmetic N = 20 < 10 mmHg rise in sys, < 5mmHg rise in dias and 
<3bpm rise in HR 
1 Male 
2 Females 
15, 18, 35 15 
Sympathetic Cold Pressor N = 17 < 10 mmHg rise in sys, < 5mmHg rise in dias and 
<3bpm rise in HR 
1 Male 17 5.9 
Parasympathetic  Respiratory Sinus 
Arrhythmia 
N = 22 Minimal < 5 bpm HR rise 
Modest 6-10 bpm HR rise 
2 Females   1, 14 9.1 
Parasympathetic Hyperventilation N = 21 < 10 bpm rise in HR 2 Males 
8 Females 
1, 4, 8, 11, 13, 14, 19, 22, 
23, 49 
47.6 
Parasympathetic and 
sympathetic 
Valsalva Manoeuvre N = 18 Valsalva ratio < 1.0 1 Male 
2 Females 
9, 22, 23 16.7 
 
Table 4.12. Summary of cardiac autonomic tests abnormalities in AFD patients.
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4.6.2 Plasma catecholamines (Fig 4.11 - 4.12, Table 4.13) 
 
No control group was recruited. 20 AFD subjects were recruited; 9 males and 11 
females with a mean age of 40.9 ± 15.4 years, majority were on ERT (81.0%) 
and had a missense mutation (66.7%). Mean plasma noradrenaline level was 
236.6pg/ml in a supine position with a significant rise to 306.9pg/ml in a tilted 
position. Mean plasma adrenaline level rose from 39.9pg/ml in a supine position 
to 54.2pg/ml in a tilted position. There was no difference in plasma 
noradrenaline or adrenaline levels in AFD subjects when subdivided by sex or 
type of mutation (Fig  4.12). 
 
 
 n = 20 
Age (years) 40.9 ± 15.4 
Sex 9 males, 11 females 
ERT, n (%) 17 (81.0%) 
Missense mutation, n (%) 14 (66.7%) 
Plasma Noradrenaline [supine] (pg/ml) 236.6 ± 58.1 
Plasma Noradrenaline [tilted], (pg/ml) 306.9 ± 71.1 
Plasma Adrenaline [supine], (pg/ml) 39.9 ± 20.5 
Plasma Adrenaline [tilted], (pg/ml) 54.2 ± 31.6 
MSSI 17.5 ± 9.0 
iGFR (ml/min/1.73m2) 80.5 ± 25.4 
UACR (mg/mmol Cr) 14.2 ± 25.3 
UPCR (mg/mmol Cr) 28.9 ± 38.2 
LVMI (g/m2) 99.4 ± 35.1 
 
Table 4.13. Demographics of AFD patients tested for plasma catecholamine levels. Mean and SD of 
results are shown. 
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Fig 4.11. Plasma noradrenaline and adrenaline levels in supine and tilted positions for AFD patients. Statistical analysis used was Wilcoxon matched-pairs rank test. 
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Fig 4.12. Plasma catecholamine levels in AFD categorised by (A) sex and (B) mutation type. 
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4.6.3 QSART (Fig 4.13, Table 4.14 – 4.15) 
 
No control group was recruited. 20 AFD subjects were recruited; 8 males and 12 
females with a mean age of 41.7 ± 15.9 years, majority were on ERT (75.0%) 
and had a missense mutation (80.0%). Mean baseline sweat rate was 54.8 ± 12.8 
nL/min and mean total sweat volume was 0.69 ± 0.53 μL/cm2. Comparing our 
AFD population with controls from Sletten et al
356
 there was no significant 
difference in median total sweat volume in males and females or median latency 
in males (Table 4.15). Comparing total sweat volumes in AFD subjects showed 
no significant difference when subdivided for age, sex of type of mutation (Fig 
4.13).  
 
 n = 20 
Age (years) 41.7 ± 15.9 
Sex 8 males, 12 females 
ERT, n (%) 15 (75.0%) 
Missense mutation, n (%) 16 (80.0%) 
Baseline Sweat (nL/min) 54.8 ± 12.8 
Latency (min) 1.7 ± 0.6 
Total Sweat volume (μL/cm2) 0.69 ± 0.53 
MSSI 15.2 ± 8.7 
iGFR (ml/min/1.73m2) 84.6 ± 24.2 
UACR (mg/mmol Cr) 12.0 ± 24.8 
UPCR (mg/mmol Cr) 25.1 ± 38.0 
LVMI (g/m2) 93.2 ± 30.9 
Table 4.14. Showing demographic data for AFD population tested with Q Sweat machine. 
 
  Control M 
(n=44) 
Control F 
(n=50) 
AFD M (n=8) AFD F (n=12) 
Total sweat 
volume (μl/cm2) 
Median 1.3 0.5 0.90 0.47 
 Min 0.3 0.1 0.11 0.18 
 Max 3.9 2.4 1.70 1.27 
Latency (mins) Median 1.7 2.0* 1.8 1.7* 
 Min 1.0 0.2 0.6 1.1 
 Max 3.0 3.5 2.8 2.6 
Table 4.15. Summary of Q-Sweat data in AFD patients comparing with normative data from Sletten et al 
2010
356
. *No significant difference using 1 sample t-test except for median latency between AFD females 
compared with control females. 
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Fig 4.13. Total sweat volume in AFD patients comparing sex, type of mutation and age. Statistical 
analysis used was the Mann Whitney U-test. 
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4.6.4 LANSS and COMPASS scores (Fig 4.14 – 4.16, Table 4.16 – 4.17) 
 
No control group was recruited. 37 AFD subjects were recruited; 16 males and 
21 females with a mean age of 47.3 ± 15.0 years, majority were on ERT (65.7%) 
and had a missense mutation (78.4%). 
Mean LANSS score was 6.4 ± 8.0 and 11 out of 37 (29.7%) has LANSS score ≥ 
12 indicating significant neuropathic pain
355
. No significant difference in 
LANSS scores in AFD patients differentiated for age, sex, type of AFD mutation 
or treated with ERT. Multiple regression analysis for LANSS scores showed no 
significant correlation (Data not shown). 
Mean COMPASS score was 34.5 ± 25.3 for AFD subjects which is significantly 
higher than controls (NML) and peripheral neuropathy (PN) groups and 
significantly lower than neurogenic autonomic failure (NAF) groups from 
Suarez et al
353
 who had mean levels of 9.8 ± 9, 25.9 ± 17.9 and 52.3 ± 24.2 
respectively (Fig 4.15). The most common COMPASS subscores for AFD 
subjects was pupillomotor, gastroparesis and sleep subscores and least common 
was reflex syncope. In AFD subjects all COMPASS subscores were higher than 
controls except for the reflex syncope subscore. When AFD subjects were 
compared to PN and NAF groups there was no difference in subscores for 
urinary and vasomotor. In the pupillomotor subscore AFD subjects had a 
significantly higher mean score than PN and NAF groups. Also AFD subjects 
had a significantly lower mean score for male sexual dysfunction when 
compared to PN and NAF groups. For orthostatic intolerance and secretomotor 
subscores AFD subjects had similar mean scores to PN group but lower than 
NAF group but for gastrointestinal symptoms (gastroparesis, diarrhoea and 
constipation) and sleep subscores had significantly higher means to PN group 
but similar to the NAF group (Table 4.17). 
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 n = 37 
Age (years) 47.3 ± 15.0 
Sex 16 males 
21 females 
ERT, n (%) 23 (65.7%) 
Missense mutation, n(%) 29 (78.4%) 
COMPASS score 34.5 ± 25.3 
LANSS score 6.4 ± 8.0 
LANSS score ≥ 12 6 males, 5 females (no significant difference, Fisher’s exact test) 
4 not on ERT, 7 on ERT (no significant difference, Fisher’s exact test) 
MSSI 16.6 ± 9.8 
iGFR (ml/min/1.73m2) 84.0 ± 25.4 
UACR (mg/mmol Cr) 11.2 ± 19.2 
UPCR (mg/mmol Cr) 26.1 ± 28.7 
LVMI (g/m2) 101.3 ± 45.9 
 
Table 4.16 Demographic data on AFD population studied for COMPASS and LANSS questionnaires, 
means ± SD unless otherwise stated. 
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Fig 4.14. LANSS scores of AFD patients categorised according to sex, age, type of mutation and whether 
on ERT.  
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Fig 4.15. Comparison of mean total COMPASS scores of AFD patients in current study to population 
from Suarez et al 1999
353
. Statistical analysis used was the 1 sample t-test. 
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Fig 4.16. Comparison of mean COMPASS subscores of AFD patients in current study to population from 
Suarez et al 1999
353
.
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Domain Maximum 
Score 
Control (C), n=41 Peripheral neuropathy (PN), n = 
33 
Neurogenic autonomic 
failure (NAF), n=39 
AFD, n=37 AFD 
vs C 
AFD 
vs PN 
AFD vs 
NAF 
  Mean % > 0 Range Mean % > 0 Range Mean % > 0 Range Mean 
(Median) 
% > 0 Range    
Orthostatic 
intolerance 
40 3.6 34.2 0–17.5  8.4 51.5 0-32.5 21.6 89.7 0–37.5 9.5 
(10.0) 
59.5 0-33 p = 
0.0008 
ns p < 
0.0001 
Secretomotor 20 0.9 31.7 0-6.2 3.7 75.8 0-12.3 6.5 94.9 0-16.9 3.2 
(2.0) 
64.9 0-12 p = 
0.0003 
ns p < 
0.0001 
Male sexual 
dysfunction 
30 0.6 21.7 0-8.6 5.8 75.0 0-12.9 9.5 71.4 0-19.3 3.3 
(0.0) 
37.5 0-12 P = 
0.0343 
p = 
0.0407 
p < 
0.0001 
Urinary 20 0.8 31.7 0-4 1.3 45.5 0-8 2.9 69.2 0-14 2.6 
(0.0) 
48.6 0-18 p = 
0.0130 
ns ns 
Gastroparesis 10 0.5 22.0 0-5.7 0.7 36.4 0-4.3 2.4 59.0 0-10 2.8 
(2.0) 
81.1 0-10 p < 
0.0001 
p < 
0.001 
ns 
Diarrhoea 20 1.5 29.3 0-8 2.8 33.3 0-16 4.2 46.2 0-16 5.2 
(6.0) 
62.2 0-17 p < 
0.0001 
p = 
0.0049 
ns 
Constipation 10 0.6 34.2 0-7.1 1.1 42.4 0-7.1 2.5 66.7 0-10 2.3 
(0.0) 
48.6 0-8.0 p = 
0.0006 
p = 
0.0113 
ns 
Pupillomotor 5 0.4 36.6 0-1.8 0.7 60.6 0-4.1 1.6 82.1 0-4.5 2.1 
(2.0) 
86.5 0-5.0 p < 
0.0001 
p < 
0.0001 
p = 
0.0237 
Vasomotor 10 0.4 7.3 0-6.3 2.3 39.4 0-7.5 2.2 38.5 0-8.1 2.4 
(2.0) 
75.7 0-11 p < 
0.0001 
ns ns 
Reflex syncope 20 0 0 0-0 0.2 6.1 0-4.0 0.9 23.1 0-4.0 0.1 
(0.0) 
2.7 0-4.0 ns ns p < 
0.0001 
Sleep 15 0.8 34.2 0-6 1.8 57.6 0-8.3 2.4 56.4 0-12 2.9 
(2.0) 
81.1 0-8.0 p < 
0.0001 
p = 
0.0032 
ns 
Male 
Female 
200 
170 
         32.9 
35.8 
93.8 
95.2 
0-83 
0-105 
   
Table 4.17. Summary of Compass total and subscores in AFD patients compared with Suarez et al 1999 study population353. Statistical analysis used was the 1 sample t-test. 
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4.7 Discussion 
 
The result of this study has demonstrated there is some evidence of cardiac autonomic 
dysfunction in AFD patients on formal cardiac autonomic screening tests, but screening 
tests for sympathetic or parasympathetic function are not consistently abnormal in the 
individual patients. No AFD patients in this study consistently had abnormal 
sympathetic nervous system tests (head tilt, isometric exercise, mental arithmetic and 
cold pressor tests). Only 2 female patients, both already on ERT (9.5% of test group) 
had abnormalities in parasympathetic screening tests (respiratory sinus arrhythmia and 
hyperventilation tests). This supports the studies by Morgan et al
347
 and Biegstraaten et 
al
346
 who concluded that autonomic control of the cardiovascular system is normal. 
More recently Hilz et al assessed reduced baroreflex sensitivity in response in 
sympathetic
357
 and parasympathetic
358
 challenge  in untreated AFD males which 
normalised with ERT (18 to 23 months)
357, 358
. This suggested possible subclinical 
autonomic dysfunction in AFD males (asymptomatic from autonomic symptoms). 
Postganglionic nerve fibres of the sympathetic reflex arc mostly secrete adrenaline and 
noradrenaline as its neurotransmitters. Plasma noradrenaline and adrenaline 
concentrations maybe a reﬂection of sympathetic vasoconstrictor activity and be an 
indirect measure of activation of sympathetic efferents however, many factors inﬂuence 
noradrenaline and adrenaline concentrations in plasma. In the head up tilt the plasma 
noradrenaline and adrenaline concentrations increased which may reflect the ability in 
AFD patients to increase sympathetic nerve activity suggesting normal sympathetic 
neuroendocrine function.  
Nearly a third (29.7%) of our cohort of AFD patients had significant neuropathic pain, 
reflected by a LANSS score of ≥ 12. Eventhough there was no significant difference in 
LANSS scores when analysed based on sex, age, type of mutation and treated with 
ERT, there was a tendency for the mean LANSS scores to be higher in males, older 
AFD patients, AFD patients with a non-missense mutation and AFD patients on ERT. 
To delineate this possible difference a much larger cohort of AFD patients would be 
needed. COMPASS scores in AFD were significantly higher than COMPASS scores 
from the control cohort described by Suarez et al
353
 and significantly higher than the 
cohort with peripheral neuropathy but lower than the cohort with neurogenic autonomic 
failure. Higher mean COMPASS scores in AFD patients compared to controls were also 
shown by Biegstraaten et al
346
 especially in the orthostatic intolerance, vasomotor 
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impairment and gastroparesis subgroups. In our cohort all subgroups had a significantly 
higher COMPASS score, except for the reflex syncope subgroup, than controls. Also 
COMPASS subscores in AFD patients for orthostatic intolerance and secretomotor 
subscores were similar to peripheral neuropathy patients and gastroparesis, diarrhoea 
and constipation subscores were similar to the neurogenic autonomic failure patients. 
This reflects a varied distribution of autonomic symptoms in AFD (COMPASS score 
range of 0 to 150). 
In this cohort of AFD patients there was no significant difference in total sweat volumes 
measured with QSART. Characteristic cytoplasmic inclusions have been observed in 
the eccrine sweat glands which may be responsible for reduced sweating
359, 360
. 
Previously one symptomatic AFD female had been shown to have anhidrosis but 
preserved basal activity and responsiveness of skin sympathetic activity
361
. This 
suggests that sweat function maybe affected due to sweat gland involvement rather than 
autonomic nervous system involvement. Schiffmann et al showed there was an acute 
improvement in sweat function 24-72 hours after ERT infusion
20
, demonstrating 
abnormal sweat function of AFD patients was partly due to a functional defect at the 
sweat gland level rather than a gross structural abnormality or autonomic neuropathy. In 
our study, we were unable to demonstrate abnormal sweat function in our cohort as 
majority (75%) of our cohort were already on treatment with ERT. We can say that the 
prevalence of abnormal total sweat volumes in this cohort of AFD patients was not 
significantly different to previous documented control population. Our results of no 
conclusive autonomic dysfunction in AFD patients, fits with Moller et al’s conclusions 
that reduced sweat output is not because of dysfunction of the autonomic innervations 
(preserved sympathetic responses) but in addition they showed a reduced skin flare 
response
362
 and together with loss of C-fibers in skin biopsies
340
, suggested that C-fiber 
dysfunction may contribute to sweat dysfunction in AFD patients. 
Overall AFD patients have significant symptoms of neuropathic pain and symptoms of 
autonomic dysfunction but not at the same level as patients with autonomic failure. 
Clinical testing does not show consistent abnormality in the sympathetic or 
parasympathetic systems in males or females but this disease is heterogeneous with 
significant variability that mild symptoms or signs may not be clinically evident on 
clinical testing. This is further compounded by small study populations due to this 
disease being rare. Also symptoms of autonomic dysfunction could be related to the end 
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organ damaged, rather than the autonomic reflex itself as suggested by sweat function in 
AFD patients.    
 
 
4.8 Limitations 
This study did not have a control group though data was compared to control data from 
other large published series. Again AFD numbers were small (n=20 for cardiac 
autonomic screening tests), but this would be difficult to circumvent in view of low 
prevalence of AFD. 
 
4.9 Conclusions 
This cohort of AFD patients had minimal parasympathetic autonomic cardiac 
abnormalities, normal adrenaline and noradrenaline production with head tilt, normal 
sweat production but significant symptoms of autonomic dysfunction (based on 
COMPASS) and neuropathic pain (LANSS). There is currently no definite clinical 
evidence of autonomic dysfunction but subclinical autonomic dysfunction would need 
further investigation. 
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Chapter 5. Final Discussion and Conclusion 
 
AFD is a multisystem genetic disorder with varied phenotypic manifestations. Being an 
orphan disease with large heterogeneity, recognition and diagnosis of AFD has been 
difficult. An increasing awareness of AFD and the disease burden imposed on patients 
together with the availability of therapeutic interventions to prevent or reduce disease 
progression and improve symptoms, has led to increased availability of therapy to AFD 
sufferers.  
 
Due to the slow progression of end stage cardiac or renal disease, usually more apparent 
from the third decade of life onwards, timing of the initiation of expensive therapies and 
efficacies of these available therapies need to be justified. Progression of the disease 
process has been shown to continue even with ERT, once significant damage has 
occurred to end organs. There may be a point of no return when disease burden or 
damage is irreversible. ERT is expensive and invasive therapy and in the current 
economic climate, there needs to be evidence the use of ERT would benefit the patient 
and be cost effective. This thesis examined some possible early markers of organ 
dysfunction in AFD. 
 
Renal involvement in the form of proteinuria was one of the first symptoms described 
by William Anderson. Our first study has shown that standard clinical practices of 
measuring or monitoring renal function in AFD may result in over estimation of GFR. 
The most commonly used measure of GFR has been the use of serum Cr. It is well 
known that serum Cr has large variability due to sex, age, muscle mass, ethnicity and 
laboratory techniques, to name a few. Over the years formulae have been developed to 
better estimate GFR still using serum Cr, but most of these formulae have usually been 
validated in Caucasian diabetic populations with CKD stage 3 to 5. Our aims were to 
document the most appropriate method of measuring GFR in AFD in a clinical setting, 
and in one of the largest cohorts of AFD, we have shown that the MDRD or CKD-EPI 
equations had the best eGFR compared to a clinical gold standard method. These 
equations gave the least bias and had the least number of “missed” or “over-treated” 
patients when looking at CKD Stage 1 to 3. In terms of decision on initiating ERT may 
have to be decided on a more invasive or expensive clinical test but regular monitoring 
of renal function can be done via these equations. Initiating ERT in a patient should be 
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decided with the best information available as these would mean the patient would be 
committed to a lifelong expensive and invasive therapy. We also were able demonstrate 
that a significant proportion of eGFR investigations over or underestimated GFR 
especially related to sex of the patient. CG, the Mayo quadratic equation and 24 hour 
urine Cr clearances significantly overestimated GFR but not the MDRD or CKD-EPI 
when looking at all AFD patients with CKD stages 1 to 3, but further analysis shows 
that the MDRD and CKD-EPI overestimates GFR in AFD males with CKD 1 to 3 and 
the MDRD underestimated GFR in AFD females with CKD stages 1 to 3. Based on 
these findings we conclude that the CKD-EPI is the best method for estimating GFR 
and AFD clinicians should employ this method in monitoring renal function in AFD 
patients.  
 
In the second part of our study we aimed to investigate urine α-Gal activity in AFD 
patients and healthy controls and we clearly showed that AFD males and females had 
significantly lower α-Gal activity in urine compared to controls. Next we showed that 
only the lysosomal enzyme β-hex and not chitotriosidase was raised in urine of AFD 
patients. Despite measures of glomerular function being the common assessment for 
renal involvement in AFD, histological studies have shown evidence of tubular atrophy 
and scarring in the kidney. We have shown in our study that urine β-hex is significantly 
elevated in AFD patients suggesting proximal tubular dysfunction. As urine RBP levels 
were not raised but urine β-hex activity was, this suggested a normal reabsorptive 
proximal tubular function. Increased urine β-hex activity is a reflection of renal tubular 
damage, and we recommend that urine β-hex be incorporated as part of the renal 
assessment in AFD. The reason for this recommendation is because we know that 
patients with greater proteinuria or poorer renal function despite ERT, their GFR 
deteriorates at a increased rate compared to patients with lower proteinuria or better 
renal function at baseline
10, 11, 363
. To determine earlier renal dysfunction, be it 
glomerular or tubular dysfunction we need a better array of available investigations, to 
detect earlier end organ damage. We have shown urine β-hex is increased in AFD 
patients and associated with end organ damage or disease burden. On the other hand we 
have not shown longitudinal data on whether urine β-hex activity would improve or 
normalise on ERT, and whether this would reflect clinical improvement and 
improvement in mortality and morbidity. Analysing urine β-hex activity is a fairly 
simple fluoremetric method similar to the analysis of α-Gal activity. This method 
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should already be available in most units managing AFD patients. Urine of AFD 
patients are already analysed as part of their routine investigations. Availability of 
equipment, method of analysis  and urine samples would mean it could be fairly straight 
forward for most units managing AFD patients to analyse urine β-hex in all their 
patients retrospectively and prospectively. This longitudinal data may help determine 
the efficacy of managing AFD patients with ERT, or future therapies such as substrate 
reduction therapy or chaperone therapy. Urine MCP-1 a marker of renal inflammation is 
also raised in AFD but we would suggest further investigation in its use in AFD 
patients, in view of small number of urine samples we analysed.  
 
Finally the third part of our study was to investigate autonomic dysfunction, plasma 
catecholamine levels and symptoms of autonomic dysfunction and neuropathic pain in 
AFD patients. We have shown that there is no significant evidence of cardiac autonomic 
system dysfunction on screening tests but AFD patients do suffer from significant 
neuropathic pain based on the LANSS questionnaire and have significant autonomic 
symptoms reflected by high COMPASS scores. 
 
In summary we have shown that the CKD-EPI equation is the best method currently for 
estimating GFR with serum Cr, urine β-hexosaminidase shows evidence of renal tubular 
dysfunction in AFD patients and should be used to determine renal dysfunction in AFD 
patients and eventhough AFD patients have symptoms of autonomic dysfunction, this is 
not evident of screening tests. 
 
This study did have its limitations and the most striking is the small number of patients 
recruited with great phenotypic heterogeneity. This resulted in a difficult analysis, in 
trying to tease out correlations with end organ damage with genotype and phenotype of 
AFD patients. Another problem encountered was the wide spread of AFD patients 
attending our unit from the United Kingdom. Recruiting for autonomic function 
screening tests, which could take an extra half a day as patients had to be taken to a 
different site (St Mary’s Hospital, Paddington, London) resulted in a poor uptake for 
recruitment and follow up data. Another difficulty was the long term follow up of 
patients. Many of the patients recruited in the study were on ERT or were to be started 
on ERT. We do not know if disease markers assessed would change with time as part of 
the natural history or improve/stabilise with the use of ERT. To improve on these 
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limitations, collaborations with other AFD units to obtain urine samples and analyse a 
cross-section and with follow up samples would improve the significance of these tests 
as markers of disease severity and progression. Also follow up samples on a 6 monthly 
basis over a 10 year period would probably give us a more robust analysis. 
 
Looking back at the study there are a few ways to take these experiments and research 
forward. More novel biomarkers in CKD have been proposed and these in the future 
should be investigated in AFD to help us in the decision making of initiating and 
monitoring efficacy of therapy. Two examples are Cystatin C and Neutrophil gelatinase 
associated lipocalin (NGAL). Cystatin C is a sensitive biomarker of kidney function in 
mild to moderate kidney disease
364
 and can predict progression of CKD
365
. In AFD, it 
has been shown that Cystatin C is a more reliable and sensitive marker of renal function 
than serum Cr or the MDRD equation
105, 366, 367
. NGAL was initially identified as an 
early biomarker of acute kidney injury
368-370
 but recent evidence suggests it may be 
involved as a mediator of CKD and urinary NGAL has been shown to be higher in 
patients with adult polycystic kidney disease who progressed more rapidly to end stage 
renal failure
371
. Also cross sectional studies have shown higher urine and serum NGAL 
in CKD due to a variety of primary causes
372-375
. 
 
Another suggestion for the future is based on a more international level of cooperation. 
Currently there are two large international databases in AFD, the Fabry Outcome 
Survey and the Fabry Registry. These international databases hope to show longitudinal 
data with respect to natural history and outcomes in AFD patients with or without 
treatment. Similar to this an international collaboration of stored samples (e.g. serum, 
urine) in AFD patients could potentially be a large research source as more novel 
markers on disease or organ progression are developed in the future. This may have 
more ethical and financial considerations but is not unfeasible. 
 
The most robust level of evidence for disease progression and effect of therapies in this 
orphan disease would be to have large prospective randomised trials looking at early 
biomarkers of end organ damage with the end point being the emergence of 
conventional features of AFD. Early biomarkers could be in the form a specific 
biochemical assays such as urine β-hexosaminidase as demonstrated in this thesis. 
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We analysed a variety of urine proteins in this thesis. A further potential tool or 
assessment in AFD patient is the use of mass-spectrometry based profiling of urinary 
proteins. Increased levels or activity of urine proteins in differing combination related to 
type of genetic mutations, sex or the use of ERT could help determine the 
pathophysiology in relation to the AFD kidney or other end organ damage, and may be 
able to distinguish whether treatment strategies are beneficial or not and even possibly 
when to initiate therapy. 
 
The link between the genetic abnormality in AFD to organ damage, which then 
manifests as patient symptoms and signs, is still not clearly understood.  Hopefully the 
identification of measurable biomarkers can help to determine the best way in managing 
the disease burden for these patients. 
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